#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Functional Connectivity of the Raphe Nuclei: Link to Tobacco Withdrawal in Smokers
#Text=Abstract
#Text=Background
#Text=Although nicotine alters serotonergic neurochemistry, clinical trials of serotonergic medications for smoking cessation have provided mixed results.
1-1	0-10	Functional	_	
1-2	11-23	Connectivity	_	
1-3	24-26	of	_	
1-4	27-30	the	_	
1-5	31-36	Raphe	_	
1-6	37-43	Nuclei	_	
1-7	43-44	:	_	
1-8	45-49	Link	_	
1-9	50-52	to	_	
1-10	53-60	Tobacco	_	
1-11	61-71	Withdrawal	_	
1-12	72-74	in	_	
1-13	75-82	Smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
1-14	83-91	Abstract	_	
1-15	92-102	Background	_	
1-16	103-111	Although	_	
1-17	112-120	nicotine	_	
1-18	121-127	alters	_	
1-19	128-140	serotonergic	_	
1-20	141-155	neurochemistry	_	
1-21	155-156	,	_	
1-22	157-165	clinical	_	
1-23	166-172	trials	_	
1-24	173-175	of	_	
1-25	176-188	serotonergic	_	
1-26	189-200	medications	_	
1-27	201-204	for	_	
1-28	205-212	smoking	_	
1-29	213-222	cessation	_	
1-30	223-227	have	_	
1-31	228-236	provided	_	
1-32	237-242	mixed	_	
1-33	243-250	results	_	
1-34	250-251	.	_	

#Text=Understanding the role of serotonergic dysfunction in tobacco use disorder may advance development of novel pharmacotherapies.
2-1	252-265	Understanding	_	
2-2	266-269	the	_	
2-3	270-274	role	_	
2-4	275-277	of	_	
2-5	278-290	serotonergic	_	
2-6	291-302	dysfunction	_	
2-7	303-305	in	_	
2-8	306-313	tobacco	_	
2-9	314-317	use	_	
2-10	318-326	disorder	_	
2-11	327-330	may	_	
2-12	331-338	advance	_	
2-13	339-350	development	_	
2-14	351-353	of	_	
2-15	354-359	novel	_	
2-16	360-377	pharmacotherapies	_	
2-17	377-378	.	_	

#Text=Methods
#Text=Functional magnetic resonance imaging was used to measure resting-state functional connectivity of the raphe nuclei as an indicator of serotonergic function.
3-1	379-386	Methods	_	
3-2	387-397	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
3-3	398-406	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
3-4	407-416	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
3-5	417-424	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
3-6	425-428	was	_	
3-7	429-433	used	_	
3-8	434-436	to	_	
3-9	437-444	measure	_	
3-10	445-458	resting-state	_	
3-11	459-469	functional	_	
3-12	470-482	connectivity	_	
3-13	483-485	of	_	
3-14	486-489	the	_	
3-15	490-495	raphe	_	
3-16	496-502	nuclei	_	
3-17	503-505	as	_	
3-18	506-508	an	_	
3-19	509-518	indicator	_	
3-20	519-521	of	_	
3-21	522-534	serotonergic	_	
3-22	535-543	function	_	
3-23	543-544	.	_	

#Text=Connectivity of the dorsal and median raphe nuclei was compared between 18 young smokers (briefly abstinent, ~40 minutes post-smoking) and 19 young nonsmokers (16–21 years old); connectivity was also examined in a separate sample of overnight-abstinent smokers (18–25 years old), before and after smoking the first cigarette of the day.
4-1	545-557	Connectivity	_	
4-2	558-560	of	_	
4-3	561-564	the	_	
4-4	565-571	dorsal	_	
4-5	572-575	and	_	
4-6	576-582	median	_	
4-7	583-588	raphe	_	
4-8	589-595	nuclei	_	
4-9	596-599	was	_	
4-10	600-608	compared	_	
4-11	609-616	between	_	
4-12	617-619	18	_	
4-13	620-625	young	_	
4-14	626-633	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
4-15	634-635	(	_	
4-16	635-642	briefly	_	
4-17	643-652	abstinent	_	
4-18	652-653	,	_	
4-19	654-655	~	_	
4-20	655-657	40	_	
4-21	658-665	minutes	_	
4-22	666-678	post-smoking	_	
4-23	678-679	)	_	
4-24	680-683	and	_	
4-25	684-686	19	_	
4-26	687-692	young	_	
4-27	693-703	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
4-28	704-705	(	_	
4-29	705-707	16	_	
4-30	707-708	–	_	
4-31	708-710	21	_	
4-32	711-716	years	_	
4-33	717-720	old	_	
4-34	720-721	)	_	
4-35	721-722	;	_	
4-36	723-735	connectivity	_	
4-37	736-739	was	_	
4-38	740-744	also	_	
4-39	745-753	examined	_	
4-40	754-756	in	_	
4-41	757-758	a	_	
4-42	759-767	separate	_	
4-43	768-774	sample	_	
4-44	775-777	of	_	
4-45	778-797	overnight-abstinent	_	
4-46	798-805	smokers	_	
4-47	806-807	(	_	
4-48	807-809	18	_	
4-49	809-810	–	_	
4-50	810-812	25	_	
4-51	813-818	years	_	
4-52	819-822	old	_	
4-53	822-823	)	_	
4-54	823-824	,	_	
4-55	825-831	before	_	
4-56	832-835	and	_	
4-57	836-841	after	_	
4-58	842-849	smoking	_	
4-59	850-853	the	_	
4-60	854-859	first	_	
4-61	860-869	cigarette	_	
4-62	870-872	of	_	
4-63	873-876	the	_	
4-64	877-880	day	_	
4-65	880-881	.	_	

#Text=Relationships between connectivity of the raphe nuclei with psychological withdrawal and craving were tested in smokers.
5-1	882-895	Relationships	_	
5-2	896-903	between	_	
5-3	904-916	connectivity	_	
5-4	917-919	of	_	
5-5	920-923	the	_	
5-6	924-929	raphe	_	
5-7	930-936	nuclei	_	
5-8	937-941	with	_	
5-9	942-955	psychological	_	
5-10	956-966	withdrawal	_	
5-11	967-970	and	_	
5-12	971-978	craving	_	
5-13	979-983	were	_	
5-14	984-990	tested	_	
5-15	991-993	in	_	
5-16	994-1001	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
5-17	1001-1002	.	_	

#Text=Results
#Text=Connectivity of the median raphe nucleus with the right hippocampal complex was weaker in smokers than in nonsmokers and was negatively correlated with psychological withdrawal in smokers.
6-1	1003-1010	Results	_	
6-2	1011-1023	Connectivity	_	
6-3	1024-1026	of	_	
6-4	1027-1030	the	_	
6-5	1031-1037	median	_	
6-6	1038-1043	raphe	_	
6-7	1044-1051	nucleus	_	
6-8	1052-1056	with	_	
6-9	1057-1060	the	_	
6-10	1061-1066	right	_	
6-11	1067-1078	hippocampal	_	
6-12	1079-1086	complex	_	
6-13	1087-1090	was	_	
6-14	1091-1097	weaker	_	
6-15	1098-1100	in	_	
6-16	1101-1108	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
6-17	1109-1113	than	_	
6-18	1114-1116	in	_	
6-19	1117-1127	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
6-20	1128-1131	and	_	
6-21	1132-1135	was	_	
6-22	1136-1146	negatively	_	
6-23	1147-1157	correlated	_	
6-24	1158-1162	with	_	
6-25	1163-1176	psychological	_	
6-26	1177-1187	withdrawal	_	
6-27	1188-1190	in	_	
6-28	1191-1198	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
6-29	1198-1199	.	_	

#Text=In overnight-abstinent smokers, smoking increased connectivity of the median raphe nucleus with the right hippocampal complex, and the increase was positively correlated with the decrease in psychological withdrawal.
7-1	1200-1202	In	_	
7-2	1203-1222	overnight-abstinent	_	
7-3	1223-1230	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
7-4	1230-1231	,	_	
7-5	1232-1239	smoking	_	
7-6	1240-1249	increased	_	
7-7	1250-1262	connectivity	_	
7-8	1263-1265	of	_	
7-9	1266-1269	the	_	
7-10	1270-1276	median	_	
7-11	1277-1282	raphe	_	
7-12	1283-1290	nucleus	_	
7-13	1291-1295	with	_	
7-14	1296-1299	the	_	
7-15	1300-1305	right	_	
7-16	1306-1317	hippocampal	_	
7-17	1318-1325	complex	_	
7-18	1325-1326	,	_	
7-19	1327-1330	and	_	
7-20	1331-1334	the	_	
7-21	1335-1343	increase	_	
7-22	1344-1347	was	_	
7-23	1348-1358	positively	_	
7-24	1359-1369	correlated	_	
7-25	1370-1374	with	_	
7-26	1375-1378	the	_	
7-27	1379-1387	decrease	_	
7-28	1388-1390	in	_	
7-29	1391-1404	psychological	_	
7-30	1405-1415	withdrawal	_	
7-31	1415-1416	.	_	

#Text=Conclusions
#Text=Relief of withdrawal due to smoking is potentially linked to the serotonergic pathway that includes the median raphe nucleus and hippocampal complex.
8-1	1417-1428	Conclusions	_	
8-2	1429-1435	Relief	_	
8-3	1436-1438	of	_	
8-4	1439-1449	withdrawal	_	
8-5	1450-1453	due	_	
8-6	1454-1456	to	_	
8-7	1457-1464	smoking	_	
8-8	1465-1467	is	_	
8-9	1468-1479	potentially	_	
8-10	1480-1486	linked	_	
8-11	1487-1489	to	_	
8-12	1490-1493	the	_	
8-13	1494-1506	serotonergic	_	
8-14	1507-1514	pathway	_	
8-15	1515-1519	that	_	
8-16	1520-1528	includes	_	
8-17	1529-1532	the	_	
8-18	1533-1539	median	_	
8-19	1540-1545	raphe	_	
8-20	1546-1553	nucleus	_	
8-21	1554-1557	and	_	
8-22	1558-1569	hippocampal	_	
8-23	1570-1577	complex	_	
8-24	1577-1578	.	_	

#Text=These results suggest that serotonergic medications may be especially beneficial for smokers who endorse strong psychological withdrawal during abstinence from smoking.
9-1	1579-1584	These	_	
9-2	1585-1592	results	_	
9-3	1593-1600	suggest	_	
9-4	1601-1605	that	_	
9-5	1606-1618	serotonergic	_	
9-6	1619-1630	medications	_	
9-7	1631-1634	may	_	
9-8	1635-1637	be	_	
9-9	1638-1648	especially	_	
9-10	1649-1659	beneficial	_	
9-11	1660-1663	for	_	
9-12	1664-1671	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
9-13	1672-1675	who	_	
9-14	1676-1683	endorse	_	
9-15	1684-1690	strong	_	
9-16	1691-1704	psychological	_	
9-17	1705-1715	withdrawal	_	
9-18	1716-1722	during	_	
9-19	1723-1733	abstinence	_	
9-20	1734-1738	from	_	
9-21	1739-1746	smoking	_	
9-22	1746-1747	.	_	

#Text=Significance Statement
#Text=This study extends previous observations that smokers have lower serotonin concentrations in the median raphe nucleus and hippocampal complex than nonsmokers to show smoking-related differences in serotonergic function and links to affective aspects of tobacco withdrawal in young smokers.
10-1	1748-1760	Significance	_	
10-2	1761-1770	Statement	_	
10-3	1771-1775	This	_	
10-4	1776-1781	study	_	
10-5	1782-1789	extends	_	
10-6	1790-1798	previous	_	
10-7	1799-1811	observations	_	
10-8	1812-1816	that	_	
10-9	1817-1824	smokers	_	
10-10	1825-1829	have	_	
10-11	1830-1835	lower	_	
10-12	1836-1845	serotonin	_	
10-13	1846-1860	concentrations	_	
10-14	1861-1863	in	_	
10-15	1864-1867	the	_	
10-16	1868-1874	median	_	
10-17	1875-1880	raphe	_	
10-18	1881-1888	nucleus	_	
10-19	1889-1892	and	_	
10-20	1893-1904	hippocampal	_	
10-21	1905-1912	complex	_	
10-22	1913-1917	than	_	
10-23	1918-1928	nonsmokers	_	
10-24	1929-1931	to	_	
10-25	1932-1936	show	_	
10-26	1937-1952	smoking-related	_	
10-27	1953-1964	differences	_	
10-28	1965-1967	in	_	
10-29	1968-1980	serotonergic	_	
10-30	1981-1989	function	_	
10-31	1990-1993	and	_	
10-32	1994-1999	links	_	
10-33	2000-2002	to	_	
10-34	2003-2012	affective	_	
10-35	2013-2020	aspects	_	
10-36	2021-2023	of	_	
10-37	2024-2031	tobacco	_	
10-38	2032-2042	withdrawal	_	
10-39	2043-2045	in	_	
10-40	2046-2051	young	_	
10-41	2052-2059	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
10-42	2059-2060	.	_	

#Text=Smokers exhibited weaker functional connectivity between these 2 serotonin-rich regions than nonsmokers, and this weakness was associated with psychological withdrawal.
11-1	2061-2068	Smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
11-2	2069-2078	exhibited	_	
11-3	2079-2085	weaker	_	
11-4	2086-2096	functional	_	
11-5	2097-2109	connectivity	_	
11-6	2110-2117	between	_	
11-7	2118-2123	these	_	
11-8	2124-2125	2	_	
11-9	2126-2140	serotonin-rich	_	
11-10	2141-2148	regions	_	
11-11	2149-2153	than	_	
11-12	2154-2164	nonsmokers	_	
11-13	2164-2165	,	_	
11-14	2166-2169	and	_	
11-15	2170-2174	this	_	
11-16	2175-2183	weakness	_	
11-17	2184-2187	was	_	
11-18	2188-2198	associated	_	
11-19	2199-2203	with	_	
11-20	2204-2217	psychological	_	
11-21	2218-2228	withdrawal	_	
11-22	2228-2229	.	_	

#Text=Acute smoking increased connectivity, and this effect was associated with reductions in psychological withdrawal.
12-1	2230-2235	Acute	_	
12-2	2236-2243	smoking	_	
12-3	2244-2253	increased	_	
12-4	2254-2266	connectivity	_	
12-5	2266-2267	,	_	
12-6	2268-2271	and	_	
12-7	2272-2276	this	_	
12-8	2277-2283	effect	_	
12-9	2284-2287	was	_	
12-10	2288-2298	associated	_	
12-11	2299-2303	with	_	
12-12	2304-2314	reductions	_	
12-13	2315-2317	in	_	
12-14	2318-2331	psychological	_	
12-15	2332-2342	withdrawal	_	
12-16	2342-2343	.	_	

#Text=Although selective serotonin reuptake inhibitors have produced mixed results in clinical trials for smoking cessation, the present findings motivate further research into the use of serotonergic pharmacotherapies for smoking cessation, indicating that they may be especially beneficial to smokers who endorse high levels of psychological withdrawal.
13-1	2344-2352	Although	_	
13-2	2353-2362	selective	_	
13-3	2363-2372	serotonin	_	
13-4	2373-2381	reuptake	_	
13-5	2382-2392	inhibitors	_	
13-6	2393-2397	have	_	
13-7	2398-2406	produced	_	
13-8	2407-2412	mixed	_	
13-9	2413-2420	results	_	
13-10	2421-2423	in	_	
13-11	2424-2432	clinical	_	
13-12	2433-2439	trials	_	
13-13	2440-2443	for	_	
13-14	2444-2451	smoking	_	
13-15	2452-2461	cessation	_	
13-16	2461-2462	,	_	
13-17	2463-2466	the	_	
13-18	2467-2474	present	_	
13-19	2475-2483	findings	_	
13-20	2484-2492	motivate	_	
13-21	2493-2500	further	_	
13-22	2501-2509	research	_	
13-23	2510-2514	into	_	
13-24	2515-2518	the	_	
13-25	2519-2522	use	_	
13-26	2523-2525	of	_	
13-27	2526-2538	serotonergic	_	
13-28	2539-2556	pharmacotherapies	_	
13-29	2557-2560	for	_	
13-30	2561-2568	smoking	_	
13-31	2569-2578	cessation	_	
13-32	2578-2579	,	_	
13-33	2580-2590	indicating	_	
13-34	2591-2595	that	_	
13-35	2596-2600	they	_	
13-36	2601-2604	may	_	
13-37	2605-2607	be	_	
13-38	2608-2618	especially	_	
13-39	2619-2629	beneficial	_	
13-40	2630-2632	to	_	
13-41	2633-2640	smokers	_	
13-42	2641-2644	who	_	
13-43	2645-2652	endorse	_	
13-44	2653-2657	high	_	
13-45	2658-2664	levels	_	
13-46	2665-2667	of	_	
13-47	2668-2681	psychological	_	
13-48	2682-2692	withdrawal	_	
13-49	2692-2693	.	_	

#Text=Introduction
#Text=Nicotine, the primary addictive constituent of tobacco smoke, affects the serotonergic system.
14-1	2694-2706	Introduction	_	
14-2	2707-2715	Nicotine	_	
14-3	2715-2716	,	_	
14-4	2717-2720	the	_	
14-5	2721-2728	primary	_	
14-6	2729-2738	addictive	_	
14-7	2739-2750	constituent	_	
14-8	2751-2753	of	_	
14-9	2754-2761	tobacco	_	
14-10	2762-2767	smoke	_	
14-11	2767-2768	,	_	
14-12	2769-2776	affects	_	
14-13	2777-2780	the	_	
14-14	2781-2793	serotonergic	_	
14-15	2794-2800	system	_	
14-16	2800-2801	.	_	

#Text=In rodents, injections of nicotine into the dorsal raphe nucleus, hippocampus, and prefrontal cortex promote serotonin release in these regions, but chronic nicotine administration decreases serotonin concentrations in the hippocampus.
15-1	2802-2804	In	_	
15-2	2805-2812	rodents	_	
15-3	2812-2813	,	_	
15-4	2814-2824	injections	_	
15-5	2825-2827	of	_	
15-6	2828-2836	nicotine	_	
15-7	2837-2841	into	_	
15-8	2842-2845	the	_	
15-9	2846-2852	dorsal	_	
15-10	2853-2858	raphe	_	
15-11	2859-2866	nucleus	_	
15-12	2866-2867	,	_	
15-13	2868-2879	hippocampus	_	
15-14	2879-2880	,	_	
15-15	2881-2884	and	_	
15-16	2885-2895	prefrontal	_	
15-17	2896-2902	cortex	_	
15-18	2903-2910	promote	_	
15-19	2911-2920	serotonin	_	
15-20	2921-2928	release	_	
15-21	2929-2931	in	_	
15-22	2932-2937	these	_	
15-23	2938-2945	regions	_	
15-24	2945-2946	,	_	
15-25	2947-2950	but	_	
15-26	2951-2958	chronic	_	
15-27	2959-2967	nicotine	_	
15-28	2968-2982	administration	_	
15-29	2983-2992	decreases	_	
15-30	2993-3002	serotonin	_	
15-31	3003-3017	concentrations	_	
15-32	3018-3020	in	_	
15-33	3021-3024	the	_	
15-34	3025-3036	hippocampus	_	
15-35	3036-3037	.	_	

#Text=Compared to nonsmokers, smokers have lower levels of serotonin and its metabolite 5-hydroxyindoleocetic acid (5-HIAA) in the raphe nuclei and hippocampal complex at postmortem assessment, possibly in part because smokers have higher densities of 5-HT1A autoreceptors in the median raphe nucleus.
16-1	3038-3046	Compared	_	
16-2	3047-3049	to	_	
16-3	3050-3060	nonsmokers	_	
16-4	3060-3061	,	_	
16-5	3062-3069	smokers	_	
16-6	3070-3074	have	_	
16-7	3075-3080	lower	_	
16-8	3081-3087	levels	_	
16-9	3088-3090	of	_	
16-10	3091-3100	serotonin	_	
16-11	3101-3104	and	_	
16-12	3105-3108	its	_	
16-13	3109-3119	metabolite	_	
16-14	3120-3121	5	_	
16-15	3121-3122	-	_	
16-16	3122-3141	hydroxyindoleocetic	_	
16-17	3142-3146	acid	_	
16-18	3147-3148	(	_	
16-19	3148-3149	5	_	
16-20	3149-3150	-	_	
16-21	3150-3154	HIAA	_	
16-22	3154-3155	)	_	
16-23	3156-3158	in	_	
16-24	3159-3162	the	_	
16-25	3163-3168	raphe	_	
16-26	3169-3175	nuclei	_	
16-27	3176-3179	and	_	
16-28	3180-3191	hippocampal	_	
16-29	3192-3199	complex	_	
16-30	3200-3202	at	_	
16-31	3203-3213	postmortem	_	
16-32	3214-3224	assessment	_	
16-33	3224-3225	,	_	
16-34	3226-3234	possibly	_	
16-35	3235-3237	in	_	
16-36	3238-3242	part	_	
16-37	3243-3250	because	_	
16-38	3251-3258	smokers	_	
16-39	3259-3263	have	_	
16-40	3264-3270	higher	_	
16-41	3271-3280	densities	_	
16-42	3281-3283	of	_	
16-43	3284-3285	5	_	
16-44	3285-3286	-	_	
16-45	3286-3290	HT1A	_	
16-46	3291-3304	autoreceptors	_	
16-47	3305-3307	in	_	
16-48	3308-3311	the	_	
16-49	3312-3318	median	_	
16-50	3319-3324	raphe	_	
16-51	3325-3332	nucleus	_	
16-52	3332-3333	.	_	

#Text=Activation of these receptors inhibits the firing of serotonergic neurons in the raphe nuclei, inhibiting serotonin release in the cerebral cortex.
17-1	3334-3344	Activation	_	
17-2	3345-3347	of	_	
17-3	3348-3353	these	_	
17-4	3354-3363	receptors	_	
17-5	3364-3372	inhibits	_	
17-6	3373-3376	the	_	
17-7	3377-3383	firing	_	
17-8	3384-3386	of	_	
17-9	3387-3399	serotonergic	_	
17-10	3400-3407	neurons	_	
17-11	3408-3410	in	_	
17-12	3411-3414	the	_	
17-13	3415-3420	raphe	_	
17-14	3421-3427	nuclei	_	
17-15	3427-3428	,	_	
17-16	3429-3439	inhibiting	_	
17-17	3440-3449	serotonin	_	
17-18	3450-3457	release	_	
17-19	3458-3460	in	_	
17-20	3461-3464	the	_	
17-21	3465-3473	cerebral	_	
17-22	3474-3480	cortex	_	
17-23	3480-3481	.	_	

#Text=The raphe nuclei provide serotonergic innervation throughout the brain, including the hippocampal complex.
18-1	3482-3485	The	_	
18-2	3486-3491	raphe	_	
18-3	3492-3498	nuclei	_	
18-4	3499-3506	provide	_	
18-5	3507-3519	serotonergic	_	
18-6	3520-3531	innervation	_	
18-7	3532-3542	throughout	_	
18-8	3543-3546	the	_	
18-9	3547-3552	brain	_	
18-10	3552-3553	,	_	
18-11	3554-3563	including	_	
18-12	3564-3567	the	_	
18-13	3568-3579	hippocampal	_	
18-14	3580-3587	complex	_	
18-15	3587-3588	.	_	

#Text=The hippocampal complex has the highest 5-HT1A receptor availability in the brain, as indicated by positron emission tomography, and the density of 5-HT1A receptors in this region is negatively correlated with levels of 5-HIAA in the raphe nuclei in humans.
19-1	3589-3592	The	_	
19-2	3593-3604	hippocampal	_	
19-3	3605-3612	complex	_	
19-4	3613-3616	has	_	
19-5	3617-3620	the	_	
19-6	3621-3628	highest	_	
19-7	3629-3630	5	_	
19-8	3630-3631	-	_	
19-9	3631-3635	HT1A	_	
19-10	3636-3644	receptor	_	
19-11	3645-3657	availability	_	
19-12	3658-3660	in	_	
19-13	3661-3664	the	_	
19-14	3665-3670	brain	_	
19-15	3670-3671	,	_	
19-16	3672-3674	as	_	
19-17	3675-3684	indicated	_	
19-18	3685-3687	by	_	
19-19	3688-3696	positron	_	
19-20	3697-3705	emission	_	
19-21	3706-3716	tomography	_	
19-22	3716-3717	,	_	
19-23	3718-3721	and	_	
19-24	3722-3725	the	_	
19-25	3726-3733	density	_	
19-26	3734-3736	of	_	
19-27	3737-3738	5	_	
19-28	3738-3739	-	_	
19-29	3739-3743	HT1A	_	
19-30	3744-3753	receptors	_	
19-31	3754-3756	in	_	
19-32	3757-3761	this	_	
19-33	3762-3768	region	_	
19-34	3769-3771	is	_	
19-35	3772-3782	negatively	_	
19-36	3783-3793	correlated	_	
19-37	3794-3798	with	_	
19-38	3799-3805	levels	_	
19-39	3806-3808	of	_	
19-40	3809-3810	5	_	
19-41	3810-3811	-	_	
19-42	3811-3815	HIAA	_	
19-43	3816-3818	in	_	
19-44	3819-3822	the	_	
19-45	3823-3828	raphe	_	
19-46	3829-3835	nuclei	_	
19-47	3836-3838	in	_	
19-48	3839-3845	humans	_	
19-49	3845-3846	.	_	

#Text=Therefore, smoking-induced changes in serotonin may alter the functioning of the raphe nuclei and hippocampal complex.
20-1	3847-3856	Therefore	_	
20-2	3856-3857	,	_	
20-3	3858-3873	smoking-induced	_	
20-4	3874-3881	changes	_	
20-5	3882-3884	in	_	
20-6	3885-3894	serotonin	_	
20-7	3895-3898	may	_	
20-8	3899-3904	alter	_	
20-9	3905-3908	the	_	
20-10	3909-3920	functioning	_	
20-11	3921-3923	of	_	
20-12	3924-3927	the	_	
20-13	3928-3933	raphe	_	
20-14	3934-3940	nuclei	_	
20-15	3941-3944	and	_	
20-16	3945-3956	hippocampal	_	
20-17	3957-3964	complex	_	
20-18	3964-3965	.	_	

#Text=Given the role of serotonergic dysfunction in affective disorders, affective symptoms linked to tobacco withdrawal may be related to serotonin function.
21-1	3966-3971	Given	_	
21-2	3972-3975	the	_	
21-3	3976-3980	role	_	
21-4	3981-3983	of	_	
21-5	3984-3996	serotonergic	_	
21-6	3997-4008	dysfunction	_	
21-7	4009-4011	in	_	
21-8	4012-4021	affective	_	
21-9	4022-4031	disorders	_	
21-10	4031-4032	,	_	
21-11	4033-4042	affective	_	
21-12	4043-4051	symptoms	_	
21-13	4052-4058	linked	_	
21-14	4059-4061	to	_	
21-15	4062-4069	tobacco	_	
21-16	4070-4080	withdrawal	_	
21-17	4081-4084	may	_	
21-18	4085-4087	be	_	
21-19	4088-4095	related	_	
21-20	4096-4098	to	_	
21-21	4099-4108	serotonin	_	
21-22	4109-4117	function	_	
21-23	4117-4118	.	_	

#Text=Brief abstinence from smoking increases negative affect, anxiety, and psychological withdrawal, and rapid abstinence-induced increases in negative affect and anxiety predict relapse during a quit attempt.
22-1	4119-4124	Brief	_	
22-2	4125-4135	abstinence	_	
22-3	4136-4140	from	_	
22-4	4141-4148	smoking	_	
22-5	4149-4158	increases	_	
22-6	4159-4167	negative	_	
22-7	4168-4174	affect	_	
22-8	4174-4175	,	_	
22-9	4176-4183	anxiety	_	
22-10	4183-4184	,	_	
22-11	4185-4188	and	_	
22-12	4189-4202	psychological	_	
22-13	4203-4213	withdrawal	_	
22-14	4213-4214	,	_	
22-15	4215-4218	and	_	
22-16	4219-4224	rapid	_	
22-17	4225-4243	abstinence-induced	_	
22-18	4244-4253	increases	_	
22-19	4254-4256	in	_	
22-20	4257-4265	negative	_	
22-21	4266-4272	affect	_	
22-22	4273-4276	and	_	
22-23	4277-4284	anxiety	_	
22-24	4285-4292	predict	_	
22-25	4293-4300	relapse	_	
22-26	4301-4307	during	_	
22-27	4308-4309	a	_	
22-28	4310-4314	quit	_	
22-29	4315-4322	attempt	_	
22-30	4322-4323	.	_	

#Text=Nicotine injection into the dorsal raphe nucleus produces anxiolytic effects in rodents; the serotonin system may therefore be a reasonable therapeutic target for symptoms of Tobacco Use Disorder, especially those related to affect.
23-1	4324-4332	Nicotine	_	
23-2	4333-4342	injection	_	
23-3	4343-4347	into	_	
23-4	4348-4351	the	_	
23-5	4352-4358	dorsal	_	
23-6	4359-4364	raphe	_	
23-7	4365-4372	nucleus	_	
23-8	4373-4381	produces	_	
23-9	4382-4392	anxiolytic	_	
23-10	4393-4400	effects	_	
23-11	4401-4403	in	_	
23-12	4404-4411	rodents	_	
23-13	4411-4412	;	_	
23-14	4413-4416	the	_	
23-15	4417-4426	serotonin	_	
23-16	4427-4433	system	_	
23-17	4434-4437	may	_	
23-18	4438-4447	therefore	_	
23-19	4448-4450	be	_	
23-20	4451-4452	a	_	
23-21	4453-4463	reasonable	_	
23-22	4464-4475	therapeutic	_	
23-23	4476-4482	target	_	
23-24	4483-4486	for	_	
23-25	4487-4495	symptoms	_	
23-26	4496-4498	of	_	
23-27	4499-4506	Tobacco	_	
23-28	4507-4510	Use	_	
23-29	4511-4519	Disorder	_	
23-30	4519-4520	,	_	
23-31	4521-4531	especially	_	
23-32	4532-4537	those	_	
23-33	4538-4545	related	_	
23-34	4546-4548	to	_	
23-35	4549-4555	affect	_	
23-36	4555-4556	.	_	

#Text=Trials of selective serotonin reuptake inhibitors (SSRIs) as medications for smoking cessation have provided mixed results, in part because SSRIs indiscriminately affect serotonergic transmission, promoting serotonin binding at various receptor subtypes.
24-1	4557-4563	Trials	_	
24-2	4564-4566	of	_	
24-3	4567-4576	selective	_	
24-4	4577-4586	serotonin	_	
24-5	4587-4595	reuptake	_	
24-6	4596-4606	inhibitors	_	
24-7	4607-4608	(	_	
24-8	4608-4613	SSRIs	_	
24-9	4613-4614	)	_	
24-10	4615-4617	as	_	
24-11	4618-4629	medications	_	
24-12	4630-4633	for	_	
24-13	4634-4641	smoking	_	
24-14	4642-4651	cessation	_	
24-15	4652-4656	have	_	
24-16	4657-4665	provided	_	
24-17	4666-4671	mixed	_	
24-18	4672-4679	results	_	
24-19	4679-4680	,	_	
24-20	4681-4683	in	_	
24-21	4684-4688	part	_	
24-22	4689-4696	because	_	
24-23	4697-4702	SSRIs	_	
24-24	4703-4719	indiscriminately	_	
24-25	4720-4726	affect	_	
24-26	4727-4739	serotonergic	_	
24-27	4740-4752	transmission	_	
24-28	4752-4753	,	_	
24-29	4754-4763	promoting	_	
24-30	4764-4773	serotonin	_	
24-31	4774-4781	binding	_	
24-32	4782-4784	at	_	
24-33	4785-4792	various	_	
24-34	4793-4801	receptor	_	
24-35	4802-4810	subtypes	_	
24-36	4810-4811	.	_	

#Text=Medications with more selective actions may be more effective for smoking cessation.
25-1	4812-4823	Medications	_	
25-2	4824-4828	with	_	
25-3	4829-4833	more	_	
25-4	4834-4843	selective	_	
25-5	4844-4851	actions	_	
25-6	4852-4855	may	_	
25-7	4856-4858	be	_	
25-8	4859-4863	more	_	
25-9	4864-4873	effective	_	
25-10	4874-4877	for	_	
25-11	4878-4885	smoking	_	
25-12	4886-4895	cessation	_	
25-13	4895-4896	.	_	

#Text=For example, lorcaserin, a 5-HT2C receptor agonist, decreased nicotine self-administration in rodents and facilitated smoking cessation in humans during a 12-week randomized clinical trial.
26-1	4897-4900	For	_	
26-2	4901-4908	example	_	
26-3	4908-4909	,	_	
26-4	4910-4920	lorcaserin	_	
26-5	4920-4921	,	_	
26-6	4922-4923	a	_	
26-7	4924-4925	5	_	
26-8	4925-4926	-	_	
26-9	4926-4930	HT2C	_	
26-10	4931-4939	receptor	_	
26-11	4940-4947	agonist	_	
26-12	4947-4948	,	_	
26-13	4949-4958	decreased	_	
26-14	4959-4967	nicotine	_	
26-15	4968-4987	self-administration	_	
26-16	4988-4990	in	_	
26-17	4991-4998	rodents	_	
26-18	4999-5002	and	_	
26-19	5003-5014	facilitated	_	
26-20	5015-5022	smoking	_	
26-21	5023-5032	cessation	_	
26-22	5033-5035	in	_	
26-23	5036-5042	humans	_	
26-24	5043-5049	during	_	
26-25	5050-5051	a	_	
26-26	5052-5054	12	_	
26-27	5054-5055	-	_	
26-28	5055-5059	week	_	
26-29	5060-5070	randomized	_	
26-30	5071-5079	clinical	_	
26-31	5080-5085	trial	_	
26-32	5085-5086	.	_	

#Text=It is important to consider young smokers in smoking cessation efforts, because those who stop smoking before the age of 25 avoid most of the long-term negative consequences of smoking.
27-1	5087-5089	It	_	
27-2	5090-5092	is	_	
27-3	5093-5102	important	_	
27-4	5103-5105	to	_	
27-5	5106-5114	consider	_	
27-6	5115-5120	young	_	
27-7	5121-5128	smokers	_	
27-8	5129-5131	in	_	
27-9	5132-5139	smoking	_	
27-10	5140-5149	cessation	_	
27-11	5150-5157	efforts	_	
27-12	5157-5158	,	_	
27-13	5159-5166	because	_	
27-14	5167-5172	those	_	
27-15	5173-5176	who	_	
27-16	5177-5181	stop	_	
27-17	5182-5189	smoking	_	
27-18	5190-5196	before	_	
27-19	5197-5200	the	_	
27-20	5201-5204	age	_	
27-21	5205-5207	of	_	
27-22	5208-5210	25	_	
27-23	5211-5216	avoid	_	
27-24	5217-5221	most	_	
27-25	5222-5224	of	_	
27-26	5225-5228	the	_	
27-27	5229-5238	long-term	_	
27-28	5239-5247	negative	_	
27-29	5248-5260	consequences	_	
27-30	5261-5263	of	_	
27-31	5264-5271	smoking	_	
27-32	5271-5272	.	_	

#Text=Compared to older smokers, younger smokers smoke fewer cigarettes per day and are less nicotine-dependent.
28-1	5273-5281	Compared	_	
28-2	5282-5284	to	_	
28-3	5285-5290	older	_	
28-4	5291-5298	smokers	_	
28-5	5298-5299	,	_	
28-6	5300-5307	younger	_	
28-7	5308-5315	smokers	_	
28-8	5316-5321	smoke	_	
28-9	5322-5327	fewer	_	
28-10	5328-5338	cigarettes	_	
28-11	5339-5342	per	_	
28-12	5343-5346	day	_	
28-13	5347-5350	and	_	
28-14	5351-5354	are	_	
28-15	5355-5359	less	_	
28-16	5360-5378	nicotine-dependent	_	
28-17	5378-5379	.	_	

#Text=Targeting young smokers may therefore result in higher sustained cessation rates than targeting older smokers.
29-1	5380-5389	Targeting	_	
29-2	5390-5395	young	_	
29-3	5396-5403	smokers	_	
29-4	5404-5407	may	_	
29-5	5408-5417	therefore	_	
29-6	5418-5424	result	_	
29-7	5425-5427	in	_	
29-8	5428-5434	higher	_	
29-9	5435-5444	sustained	_	
29-10	5445-5454	cessation	_	
29-11	5455-5460	rates	_	
29-12	5461-5465	than	_	
29-13	5466-5475	targeting	_	
29-14	5476-5481	older	_	
29-15	5482-5489	smokers	_	
29-16	5489-5490	.	_	

#Text=No study has examined the relationship between serotoninergic function and features of Tobacco Use Disorder in smokers of any age.
30-1	5491-5493	No	_	
30-2	5494-5499	study	_	
30-3	5500-5503	has	_	
30-4	5504-5512	examined	_	
30-5	5513-5516	the	_	
30-6	5517-5529	relationship	_	
30-7	5530-5537	between	_	
30-8	5538-5552	serotoninergic	_	
30-9	5553-5561	function	_	
30-10	5562-5565	and	_	
30-11	5566-5574	features	_	
30-12	5575-5577	of	_	
30-13	5578-5585	Tobacco	_	
30-14	5586-5589	Use	_	
30-15	5590-5598	Disorder	_	
30-16	5599-5601	in	_	
30-17	5602-5609	smokers	_	
30-18	5610-5612	of	_	
30-19	5613-5616	any	_	
30-20	5617-5620	age	_	
30-21	5620-5621	.	_	

#Text=Although the raphe nuclei are relatively small and are not visible on a T1-weighted image acquired with MRI at 3 Tesla, one fMRI study localized the dorsal and median raphe nuclei by examining serotonin transporter (SERT) availability using positron emission tomography (PET).
31-1	5622-5630	Although	_	
31-2	5631-5634	the	_	
31-3	5635-5640	raphe	_	
31-4	5641-5647	nuclei	_	
31-5	5648-5651	are	_	
31-6	5652-5662	relatively	_	
31-7	5663-5668	small	_	
31-8	5669-5672	and	_	
31-9	5673-5676	are	_	
31-10	5677-5680	not	_	
31-11	5681-5688	visible	_	
31-12	5689-5691	on	_	
31-13	5692-5693	a	_	
31-14	5694-5696	T1	_	
31-15	5696-5697	-	_	
31-16	5697-5705	weighted	_	
31-17	5706-5711	image	_	
31-18	5712-5720	acquired	_	
31-19	5721-5725	with	_	
31-20	5726-5729	MRI	_	
31-21	5730-5732	at	_	
31-22	5733-5734	3	_	
31-23	5735-5740	Tesla	_	
31-24	5740-5741	,	_	
31-25	5742-5745	one	_	
31-26	5746-5750	fMRI	_	
31-27	5751-5756	study	_	
31-28	5757-5766	localized	_	
31-29	5767-5770	the	_	
31-30	5771-5777	dorsal	_	
31-31	5778-5781	and	_	
31-32	5782-5788	median	_	
31-33	5789-5794	raphe	_	
31-34	5795-5801	nuclei	_	
31-35	5802-5804	by	_	
31-36	5805-5814	examining	_	
31-37	5815-5824	serotonin	_	
31-38	5825-5836	transporter	_	
31-39	5837-5838	(	_	
31-40	5838-5842	SERT	_	
31-41	5842-5843	)	_	
31-42	5844-5856	availability	_	
31-43	5857-5862	using	_	
31-44	5863-5871	positron	_	
31-45	5872-5880	emission	_	
31-46	5881-5891	tomography	_	
31-47	5892-5893	(	_	
31-48	5893-5896	PET	_	
31-49	5896-5897	)	_	
31-50	5897-5898	.	_	

#Text=In that study, the dorsal and median raphe nuclei exhibited resting-state functional connectivity with the hippocampal complex, thalamus, striatum, insula, anterior and posterior cingulate cortices, and cerebellum; the median (but not the dorsal) raphe nucleus also exhibited connectivity with the precuneus and cuneus.
32-1	5899-5901	In	_	
32-2	5902-5906	that	_	
32-3	5907-5912	study	_	
32-4	5912-5913	,	_	
32-5	5914-5917	the	_	
32-6	5918-5924	dorsal	_	
32-7	5925-5928	and	_	
32-8	5929-5935	median	_	
32-9	5936-5941	raphe	_	
32-10	5942-5948	nuclei	_	
32-11	5949-5958	exhibited	_	
32-12	5959-5972	resting-state	_	
32-13	5973-5983	functional	_	
32-14	5984-5996	connectivity	_	
32-15	5997-6001	with	_	
32-16	6002-6005	the	_	
32-17	6006-6017	hippocampal	_	
32-18	6018-6025	complex	_	
32-19	6025-6026	,	_	
32-20	6027-6035	thalamus	_	
32-21	6035-6036	,	_	
32-22	6037-6045	striatum	_	
32-23	6045-6046	,	_	
32-24	6047-6053	insula	_	
32-25	6053-6054	,	_	
32-26	6055-6063	anterior	_	
32-27	6064-6067	and	_	
32-28	6068-6077	posterior	_	
32-29	6078-6087	cingulate	_	
32-30	6088-6096	cortices	_	
32-31	6096-6097	,	_	
32-32	6098-6101	and	_	
32-33	6102-6112	cerebellum	_	
32-34	6112-6113	;	_	
32-35	6114-6117	the	_	
32-36	6118-6124	median	_	
32-37	6125-6126	(	_	
32-38	6126-6129	but	_	
32-39	6130-6133	not	_	
32-40	6134-6137	the	_	
32-41	6138-6144	dorsal	_	
32-42	6144-6145	)	_	
32-43	6146-6151	raphe	_	
32-44	6152-6159	nucleus	_	
32-45	6160-6164	also	_	
32-46	6165-6174	exhibited	_	
32-47	6175-6187	connectivity	_	
32-48	6188-6192	with	_	
32-49	6193-6196	the	_	
32-50	6197-6206	precuneus	_	
32-51	6207-6210	and	_	
32-52	6211-6217	cuneus	_	
32-53	6217-6218	.	_	

#Text=Resting-state functional connectivity was positively associated with SERT availability in these regions.
33-1	6219-6232	Resting-state	_	
33-2	6233-6243	functional	_	
33-3	6244-6256	connectivity	_	
33-4	6257-6260	was	_	
33-5	6261-6271	positively	_	
33-6	6272-6282	associated	_	
33-7	6283-6287	with	_	
33-8	6288-6292	SERT	_	
33-9	6293-6305	availability	_	
33-10	6306-6308	in	_	
33-11	6309-6314	these	_	
33-12	6315-6322	regions	_	
33-13	6322-6323	.	_	

#Text=We performed a seed-based analysis to assess the effects of smoking on resting-state functional connectivity of the dorsal and median raphe nuclei with the hippocampal complex as an indicator of serotonergic function.
34-1	6324-6326	We	_	
34-2	6327-6336	performed	_	
34-3	6337-6338	a	_	
34-4	6339-6349	seed-based	_	
34-5	6350-6358	analysis	_	
34-6	6359-6361	to	_	
34-7	6362-6368	assess	_	
34-8	6369-6372	the	_	
34-9	6373-6380	effects	_	
34-10	6381-6383	of	_	
34-11	6384-6391	smoking	_	
34-12	6392-6394	on	_	
34-13	6395-6408	resting-state	_	
34-14	6409-6419	functional	_	
34-15	6420-6432	connectivity	_	
34-16	6433-6435	of	_	
34-17	6436-6439	the	_	
34-18	6440-6446	dorsal	_	
34-19	6447-6450	and	_	
34-20	6451-6457	median	_	
34-21	6458-6463	raphe	_	
34-22	6464-6470	nuclei	_	
34-23	6471-6475	with	_	
34-24	6476-6479	the	_	
34-25	6480-6491	hippocampal	_	
34-26	6492-6499	complex	_	
34-27	6500-6502	as	_	
34-28	6503-6505	an	_	
34-29	6506-6515	indicator	_	
34-30	6516-6518	of	_	
34-31	6519-6531	serotonergic	_	
34-32	6532-6540	function	_	
34-33	6540-6541	.	_	

#Text=This investigation had 3 aims, addressed in 2 fMRI studies: (1) to compare connectivity of the raphe nuclei with the hippocampal complex in smokers vs nonsmokers; (2) to test the effects of acute smoking on connectivity of the raphe nuclei with the hippocampal complex; and (3) to examine the relationship of this connectivity with psychological withdrawal and craving for cigarettes.
35-1	6542-6546	This	_	
35-2	6547-6560	investigation	_	
35-3	6561-6564	had	_	
35-4	6565-6566	3	_	
35-5	6567-6571	aims	_	
35-6	6571-6572	,	_	
35-7	6573-6582	addressed	_	
35-8	6583-6585	in	_	
35-9	6586-6587	2	_	
35-10	6588-6592	fMRI	_	
35-11	6593-6600	studies	_	
35-12	6600-6601	:	_	
35-13	6602-6603	(	_	
35-14	6603-6604	1	_	
35-15	6604-6605	)	_	
35-16	6606-6608	to	_	
35-17	6609-6616	compare	_	
35-18	6617-6629	connectivity	_	
35-19	6630-6632	of	_	
35-20	6633-6636	the	_	
35-21	6637-6642	raphe	_	
35-22	6643-6649	nuclei	_	
35-23	6650-6654	with	_	
35-24	6655-6658	the	_	
35-25	6659-6670	hippocampal	_	
35-26	6671-6678	complex	_	
35-27	6679-6681	in	_	
35-28	6682-6689	smokers	_	
35-29	6690-6692	vs	_	
35-30	6693-6703	nonsmokers	_	
35-31	6703-6704	;	_	
35-32	6705-6706	(	_	
35-33	6706-6707	2	_	
35-34	6707-6708	)	_	
35-35	6709-6711	to	_	
35-36	6712-6716	test	_	
35-37	6717-6720	the	_	
35-38	6721-6728	effects	_	
35-39	6729-6731	of	_	
35-40	6732-6737	acute	_	
35-41	6738-6745	smoking	_	
35-42	6746-6748	on	_	
35-43	6749-6761	connectivity	_	
35-44	6762-6764	of	_	
35-45	6765-6768	the	_	
35-46	6769-6774	raphe	_	
35-47	6775-6781	nuclei	_	
35-48	6782-6786	with	_	
35-49	6787-6790	the	_	
35-50	6791-6802	hippocampal	_	
35-51	6803-6810	complex	_	
35-52	6810-6811	;	_	
35-53	6812-6815	and	_	
35-54	6816-6817	(	_	
35-55	6817-6818	3	_	
35-56	6818-6819	)	_	
35-57	6820-6822	to	_	
35-58	6823-6830	examine	_	
35-59	6831-6834	the	_	
35-60	6835-6847	relationship	_	
35-61	6848-6850	of	_	
35-62	6851-6855	this	_	
35-63	6856-6868	connectivity	_	
35-64	6869-6873	with	_	
35-65	6874-6887	psychological	_	
35-66	6888-6898	withdrawal	_	
35-67	6899-6902	and	_	
35-68	6903-6910	craving	_	
35-69	6911-6914	for	_	
35-70	6915-6925	cigarettes	_	
35-71	6925-6926	.	_	

#Text=The hypotheses tested were that connectivity of the raphe nuclei with the hippocampal complex would be: (1) weaker in smokers than in nonsmokers; (2) negatively correlated with psychological withdrawal and craving; and (3) increased by smoking after overnight abstinence in association with decreases in psychological withdrawal and craving.
36-1	6927-6930	The	_	
36-2	6931-6941	hypotheses	_	
36-3	6942-6948	tested	_	
36-4	6949-6953	were	_	
36-5	6954-6958	that	_	
36-6	6959-6971	connectivity	_	
36-7	6972-6974	of	_	
36-8	6975-6978	the	_	
36-9	6979-6984	raphe	_	
36-10	6985-6991	nuclei	_	
36-11	6992-6996	with	_	
36-12	6997-7000	the	_	
36-13	7001-7012	hippocampal	_	
36-14	7013-7020	complex	_	
36-15	7021-7026	would	_	
36-16	7027-7029	be	_	
36-17	7029-7030	:	_	
36-18	7031-7032	(	_	
36-19	7032-7033	1	_	
36-20	7033-7034	)	_	
36-21	7035-7041	weaker	_	
36-22	7042-7044	in	_	
36-23	7045-7052	smokers	_	
36-24	7053-7057	than	_	
36-25	7058-7060	in	_	
36-26	7061-7071	nonsmokers	_	
36-27	7071-7072	;	_	
36-28	7073-7074	(	_	
36-29	7074-7075	2	_	
36-30	7075-7076	)	_	
36-31	7077-7087	negatively	_	
36-32	7088-7098	correlated	_	
36-33	7099-7103	with	_	
36-34	7104-7117	psychological	_	
36-35	7118-7128	withdrawal	_	
36-36	7129-7132	and	_	
36-37	7133-7140	craving	_	
36-38	7140-7141	;	_	
36-39	7142-7145	and	_	
36-40	7146-7147	(	_	
36-41	7147-7148	3	_	
36-42	7148-7149	)	_	
36-43	7150-7159	increased	_	
36-44	7160-7162	by	_	
36-45	7163-7170	smoking	_	
36-46	7171-7176	after	_	
36-47	7177-7186	overnight	_	
36-48	7187-7197	abstinence	_	
36-49	7198-7200	in	_	
36-50	7201-7212	association	_	
36-51	7213-7217	with	_	
36-52	7218-7227	decreases	_	
36-53	7228-7230	in	_	
36-54	7231-7244	psychological	_	
36-55	7245-7255	withdrawal	_	
36-56	7256-7259	and	_	
36-57	7260-7267	craving	_	
36-58	7267-7268	.	_	

#Text=Methods
#Text=Participants and Procedures
#Text=Study 1: Smokers vs Nonsmokers
#Text=Study 1 employed a between-subjects design.
37-1	7269-7276	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
37-2	7277-7289	Participants	_	
37-3	7290-7293	and	_	
37-4	7294-7304	Procedures	_	
37-5	7305-7310	Study	_	
37-6	7311-7312	1	_	
37-7	7312-7313	:	_	
37-8	7314-7321	Smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
37-9	7322-7324	vs	_	
37-10	7325-7335	Nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
37-11	7336-7341	Study	_	
37-12	7342-7343	1	_	
37-13	7344-7352	employed	_	
37-14	7353-7354	a	_	
37-15	7355-7371	between-subjects	_	
37-16	7372-7378	design	_	
37-17	7378-7379	.	_	

#Text=Thirty-seven participants (18 smokers, 19 nonsmokers, all 16–21 years of age) were recruited through online advertisements.
38-1	7380-7392	Thirty-seven	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-2	7393-7405	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-3	7406-7407	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-4	7407-7409	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-5	7410-7417	smokers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[3]	
38-6	7417-7418	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-7	7419-7421	19	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-8	7422-7432	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
38-9	7432-7433	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-10	7434-7437	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-11	7438-7440	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-12	7440-7441	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-13	7441-7443	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-14	7444-7449	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-15	7450-7452	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-16	7453-7456	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-17	7456-7457	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-18	7458-7462	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-19	7463-7472	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-20	7473-7480	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-21	7481-7487	online	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-22	7488-7502	advertisements	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
38-23	7502-7503	.	_	

#Text=At an intake session, participants gave written informed consent after receiving a detailed explanation of the study (approved by the UCLA Institutional Review Board; IRB# 10-000259).
39-1	7504-7506	At	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-2	7507-7509	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-3	7510-7516	intake	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-4	7517-7524	session	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-5	7524-7525	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-6	7526-7538	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-7	7539-7543	gave	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-8	7544-7551	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-9	7552-7560	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-10	7561-7568	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-11	7569-7574	after	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-12	7575-7584	receiving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-13	7585-7586	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-14	7587-7595	detailed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-15	7596-7607	explanation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-16	7608-7610	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-17	7611-7614	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-18	7615-7620	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-19	7621-7622	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-20	7622-7630	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-21	7631-7633	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-22	7634-7637	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-23	7638-7642	UCLA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-24	7643-7656	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-25	7657-7663	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-26	7664-7669	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-27	7669-7670	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-28	7671-7674	IRB	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-29	7674-7675	#	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-30	7676-7678	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-31	7678-7679	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-32	7679-7685	000259	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-33	7685-7686	)	_	
39-34	7686-7687	.	_	

#Text=Exclusion criteria were: positive urine test for illicit drugs (including marijuana), using an Instant-View immunoassay urine test (ALFA Scientific Designs, Inc.), self-report of marijuana use >8 times per month and alcohol use >5 days per month, any Axis I psychiatric disorder, including current drug abuse or dependence (other than nicotine dependence for those in the smoking group), history of neurological injury or disease or pregnancy, and contraindication for MRI scanning (e.g., metal material such as implants inside the body).
40-1	7688-7697	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-2	7698-7706	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-3	7707-7711	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-4	7711-7712	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-5	7713-7721	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-6	7722-7727	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-7	7728-7732	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-8	7733-7736	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-9	7737-7744	illicit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-10	7745-7750	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-11	7751-7752	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-12	7752-7761	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-13	7762-7771	marijuana	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-14	7771-7772	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-15	7772-7773	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-16	7774-7779	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-17	7780-7782	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-18	7783-7795	Instant-View	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-19	7796-7807	immunoassay	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-20	7808-7813	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-21	7814-7818	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-22	7819-7820	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-23	7820-7824	ALFA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-24	7825-7835	Scientific	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-25	7836-7843	Designs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-26	7843-7844	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-27	7845-7848	Inc	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-28	7848-7849	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-29	7849-7850	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-30	7850-7851	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-31	7852-7863	self-report	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-32	7864-7866	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-33	7867-7876	marijuana	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-34	7877-7880	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-35	7881-7882	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-36	7882-7883	8	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-37	7884-7889	times	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-38	7890-7893	per	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-39	7894-7899	month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-40	7900-7903	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-41	7904-7911	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-42	7912-7915	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-43	7916-7917	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-44	7917-7918	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-45	7919-7923	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-46	7924-7927	per	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-47	7928-7933	month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-48	7933-7934	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-49	7935-7938	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-50	7939-7943	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-51	7944-7945	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-52	7946-7957	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-53	7958-7966	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-54	7966-7967	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-55	7968-7977	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-56	7978-7985	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-57	7986-7990	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-58	7991-7996	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-59	7997-7999	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-60	8000-8010	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-61	8011-8012	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-62	8012-8017	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-63	8018-8022	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-64	8023-8031	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-65	8032-8042	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-66	8043-8046	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-67	8047-8052	those	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-68	8053-8055	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-69	8056-8059	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-70	8060-8067	smoking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-71	8068-8073	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-72	8073-8074	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-73	8074-8075	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-74	8076-8083	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-75	8084-8086	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-76	8087-8099	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-77	8100-8106	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-78	8107-8109	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-79	8110-8117	disease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-80	8118-8120	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-81	8121-8130	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-82	8130-8131	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-83	8132-8135	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-84	8136-8152	contraindication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-85	8153-8156	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-86	8157-8160	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-87	8161-8169	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-88	8170-8171	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-89	8171-8174	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-90	8174-8175	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-91	8175-8176	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-92	8177-8182	metal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-93	8183-8191	material	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-94	8192-8196	such	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-95	8197-8199	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-96	8200-8208	implants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-97	8209-8215	inside	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-98	8216-8219	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-99	8220-8224	body	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-100	8224-8225	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
40-101	8225-8226	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=Eighteen participants were classified as smokers based on endorsement of daily smoking for at least 6 months and having CO concentrations of >5 ppm in expired air (Smokerlyzer, Bedfont Scientific).
41-1	8227-8235	Eighteen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-2	8236-8248	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-3	8249-8253	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-4	8254-8264	classified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-5	8265-8267	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-6	8268-8275	smokers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[8]	
41-7	8276-8281	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-8	8282-8284	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-9	8285-8296	endorsement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-10	8297-8299	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-11	8300-8305	daily	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-12	8306-8313	smoking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-13	8314-8317	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-14	8318-8320	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-15	8321-8326	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-16	8327-8328	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-17	8329-8335	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-18	8336-8339	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-19	8340-8346	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-20	8347-8349	CO	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-21	8350-8364	concentrations	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-22	8365-8367	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-23	8368-8369	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-24	8369-8370	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-25	8371-8374	ppm	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-26	8375-8377	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-27	8378-8385	expired	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-28	8386-8389	air	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-29	8390-8391	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-30	8391-8402	Smokerlyzer	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-31	8402-8403	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-32	8404-8411	Bedfont	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-33	8412-8422	Scientific	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-34	8422-8423	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
41-35	8423-8424	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	

#Text=All smokers completed the Fagerström Test for Nicotine Dependence (FTND) at the intake session.
42-1	8425-8428	All	_	
42-2	8429-8436	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
42-3	8437-8446	completed	_	
42-4	8447-8450	the	_	
42-5	8451-8461	Fagerström	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[9]	
42-6	8462-8466	Test	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[9]	
42-7	8467-8470	for	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[9]	
42-8	8471-8479	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[9]	
42-9	8480-8490	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[9]	
42-10	8491-8492	(	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[9]	
42-11	8492-8496	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[9]	
42-12	8496-8497	)	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[9]	
42-13	8498-8500	at	_	
42-14	8501-8504	the	_	
42-15	8505-8511	intake	_	
42-16	8512-8519	session	_	
42-17	8519-8520	.	_	

#Text=Nineteen participants were classified as nonsmokers, because they endorsed having smoked fewer than 5 cigarettes in their lifetime and had CO levels of<5 ppm in expired air.
43-1	8521-8529	Nineteen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-2	8530-8542	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-3	8543-8547	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-4	8548-8558	classified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-5	8559-8561	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-6	8562-8572	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]	
43-7	8572-8573	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-8	8574-8581	because	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-9	8582-8586	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-10	8587-8595	endorsed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-11	8596-8602	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-12	8603-8609	smoked	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-13	8610-8615	fewer	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-14	8616-8620	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-15	8621-8622	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-16	8623-8633	cigarettes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-17	8634-8636	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-18	8637-8642	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-19	8643-8651	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-20	8652-8655	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-21	8656-8659	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-22	8660-8662	CO	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-23	8663-8669	levels	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-24	8670-8672	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-25	8672-8673	<	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-26	8673-8674	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-27	8675-8678	ppm	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-28	8679-8681	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-29	8682-8689	expired	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-30	8690-8693	air	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
43-31	8693-8694	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=Testing was in the afternoon, and participants were instructed to avoid caffeine for 2 hours beforehand.
44-1	8695-8702	Testing	_	
44-2	8703-8706	was	_	
44-3	8707-8709	in	_	
44-4	8710-8713	the	_	
44-5	8714-8723	afternoon	_	
44-6	8723-8724	,	_	
44-7	8725-8728	and	_	
44-8	8729-8741	participants	_	
44-9	8742-8746	were	_	
44-10	8747-8757	instructed	_	
44-11	8758-8760	to	_	
44-12	8761-8766	avoid	_	
44-13	8767-8775	caffeine	_	
44-14	8776-8779	for	_	
44-15	8780-8781	2	_	
44-16	8782-8787	hours	_	
44-17	8788-8798	beforehand	_	
44-18	8798-8799	.	_	

#Text=Smokers were instructed to smoke as usual until 30 minutes before arriving at the testing site to minimize the effects of nicotine and abstinence on resting-state functional connectivity; smokers report only minimally (albeit significantly) greater withdrawal 30 minutes compared to <1 minute after smoking a cigarette.
45-1	8800-8807	Smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
45-2	8808-8812	were	_	
45-3	8813-8823	instructed	_	
45-4	8824-8826	to	_	
45-5	8827-8832	smoke	_	
45-6	8833-8835	as	_	
45-7	8836-8841	usual	_	
45-8	8842-8847	until	_	
45-9	8848-8850	30	_	
45-10	8851-8858	minutes	_	
45-11	8859-8865	before	_	
45-12	8866-8874	arriving	_	
45-13	8875-8877	at	_	
45-14	8878-8881	the	_	
45-15	8882-8889	testing	_	
45-16	8890-8894	site	_	
45-17	8895-8897	to	_	
45-18	8898-8906	minimize	_	
45-19	8907-8910	the	_	
45-20	8911-8918	effects	_	
45-21	8919-8921	of	_	
45-22	8922-8930	nicotine	_	
45-23	8931-8934	and	_	
45-24	8935-8945	abstinence	_	
45-25	8946-8948	on	_	
45-26	8949-8962	resting-state	_	
45-27	8963-8973	functional	_	
45-28	8974-8986	connectivity	_	
45-29	8986-8987	;	_	
45-30	8988-8995	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
45-31	8996-9002	report	_	
45-32	9003-9007	only	_	
45-33	9008-9017	minimally	_	
45-34	9018-9019	(	_	
45-35	9019-9025	albeit	_	
45-36	9026-9039	significantly	_	
45-37	9039-9040	)	_	
45-38	9041-9048	greater	_	
45-39	9049-9059	withdrawal	_	
45-40	9060-9062	30	_	
45-41	9063-9070	minutes	_	
45-42	9071-9079	compared	_	
45-43	9080-9082	to	_	
45-44	9083-9084	<	_	
45-45	9084-9085	1	_	
45-46	9086-9092	minute	_	
45-47	9093-9098	after	_	
45-48	9099-9106	smoking	_	
45-49	9107-9108	a	_	
45-50	9109-9118	cigarette	_	
45-51	9118-9119	.	_	

#Text=At the beginning of the testing session participants completed the Shiffman Jarvik Withdrawal Scale (SJWS) immediately before undergoing MRI scanning while in the resting state.
46-1	9120-9122	At	_	
46-2	9123-9126	the	_	
46-3	9127-9136	beginning	_	
46-4	9137-9139	of	_	
46-5	9140-9143	the	_	
46-6	9144-9151	testing	_	
46-7	9152-9159	session	_	
46-8	9160-9172	participants	_	
46-9	9173-9182	completed	_	
46-10	9183-9186	the	_	
46-11	9187-9195	Shiffman	_	
46-12	9196-9202	Jarvik	_	
46-13	9203-9213	Withdrawal	_	
46-14	9214-9219	Scale	_	
46-15	9220-9221	(	_	
46-16	9221-9225	SJWS	_	
46-17	9225-9226	)	_	
46-18	9227-9238	immediately	_	
46-19	9239-9245	before	_	
46-20	9246-9256	undergoing	_	
46-21	9257-9260	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
46-22	9261-9269	scanning	_	
46-23	9270-9275	while	_	
46-24	9276-9278	in	_	
46-25	9279-9282	the	_	
46-26	9283-9290	resting	_	
46-27	9291-9296	state	_	
46-28	9296-9297	.	_	

#Text=These procedures were part of a larger testing battery (data to be reported elsewhere).
47-1	9298-9303	These	_	
47-2	9304-9314	procedures	_	
47-3	9315-9319	were	_	
47-4	9320-9324	part	_	
47-5	9325-9327	of	_	
47-6	9328-9329	a	_	
47-7	9330-9336	larger	_	
47-8	9337-9344	testing	_	
47-9	9345-9352	battery	_	
47-10	9353-9354	(	_	
47-11	9354-9358	data	_	
47-12	9359-9361	to	_	
47-13	9362-9364	be	_	
47-14	9365-9373	reported	_	
47-15	9374-9383	elsewhere	_	
47-16	9383-9384	)	_	
47-17	9384-9385	.	_	

#Text=The average duration of abstinence before completing the first testing battery (questionnaires) was 41.56 minutes (SD=36.26 minutes), and the average duration of abstinence prior to the resting state MRI scan was 49.87 minutes (SD=41.22 minutes).
48-1	9386-9389	The	_	
48-2	9390-9397	average	_	
48-3	9398-9406	duration	_	
48-4	9407-9409	of	_	
48-5	9410-9420	abstinence	_	
48-6	9421-9427	before	_	
48-7	9428-9438	completing	_	
48-8	9439-9442	the	_	
48-9	9443-9448	first	_	
48-10	9449-9456	testing	_	
48-11	9457-9464	battery	_	
48-12	9465-9466	(	_	
48-13	9466-9480	questionnaires	_	
48-14	9480-9481	)	_	
48-15	9482-9485	was	_	
48-16	9486-9491	41.56	_	
48-17	9492-9499	minutes	_	
48-18	9500-9501	(	_	
48-19	9501-9503	SD	_	
48-20	9503-9504	=	_	
48-21	9504-9509	36.26	_	
48-22	9510-9517	minutes	_	
48-23	9517-9518	)	_	
48-24	9518-9519	,	_	
48-25	9520-9523	and	_	
48-26	9524-9527	the	_	
48-27	9528-9535	average	_	
48-28	9536-9544	duration	_	
48-29	9545-9547	of	_	
48-30	9548-9558	abstinence	_	
48-31	9559-9564	prior	_	
48-32	9565-9567	to	_	
48-33	9568-9571	the	_	
48-34	9572-9579	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[12]	
48-35	9580-9585	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[12]	
48-36	9586-9589	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[12]	
48-37	9590-9594	scan	_	
48-38	9595-9598	was	_	
48-39	9599-9604	49.87	_	
48-40	9605-9612	minutes	_	
48-41	9613-9614	(	_	
48-42	9614-9616	SD	_	
48-43	9616-9617	=	_	
48-44	9617-9622	41.22	_	
48-45	9623-9630	minutes	_	
48-46	9630-9631	)	_	
48-47	9631-9632	.	_	

#Text=For a timeline of Study 1 procedures, see supplementary Figure 1.
49-1	9633-9636	For	_	
49-2	9637-9638	a	_	
49-3	9639-9647	timeline	_	
49-4	9648-9650	of	_	
49-5	9651-9656	Study	_	
49-6	9657-9658	1	_	
49-7	9659-9669	procedures	_	
49-8	9669-9670	,	_	
49-9	9671-9674	see	_	
49-10	9675-9688	supplementary	_	
49-11	9689-9695	Figure	_	
49-12	9696-9697	1	_	
49-13	9697-9698	.	_	

#Text=Study 2: Effects of Acute Smoking
#Text=Study 2 employed a within-subjects design.
50-1	9699-9704	Study	_	
50-2	9705-9706	2	_	
50-3	9706-9707	:	_	
50-4	9708-9715	Effects	_	
50-5	9716-9718	of	_	
50-6	9719-9724	Acute	_	
50-7	9725-9732	Smoking	_	
50-8	9733-9738	Study	_	
50-9	9739-9740	2	_	
50-10	9741-9749	employed	_	
50-11	9750-9751	a	_	
50-12	9752-9767	within-subjects	_	
50-13	9768-9774	design	_	
50-14	9774-9775	.	_	

#Text=Twenty-four participants were recruited through online and print advertisements.
51-1	9776-9787	Twenty-four	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-2	9788-9800	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-3	9801-9805	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-4	9806-9815	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-5	9816-9823	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-6	9824-9830	online	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-7	9831-9834	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-8	9835-9840	print	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-9	9841-9855	advertisements	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-10	9855-9856	.	_	

#Text=At an initial intake session, participants gave written informed consent after receiving a detailed explanation of the study (approved by the UCLA Institutional Review Board; IRB# 13-001240).
52-1	9857-9859	At	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-2	9860-9862	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-3	9863-9870	initial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-4	9871-9877	intake	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-5	9878-9885	session	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-6	9885-9886	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-7	9887-9899	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-8	9900-9904	gave	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-9	9905-9912	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-10	9913-9921	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-11	9922-9929	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-12	9930-9935	after	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-13	9936-9945	receiving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-14	9946-9947	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-15	9948-9956	detailed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-16	9957-9968	explanation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-17	9969-9971	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-18	9972-9975	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-19	9976-9981	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-20	9982-9983	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-21	9983-9991	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-22	9992-9994	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-23	9995-9998	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-24	9999-10003	UCLA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-25	10004-10017	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-26	10018-10024	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-27	10025-10030	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-28	10030-10031	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-29	10032-10035	IRB	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-30	10035-10036	#	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-31	10037-10039	13	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-32	10039-10040	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-33	10040-10046	001240	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-34	10046-10047	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
52-35	10047-10048	.	_	

#Text=Inclusion criteria were: 18 to 25 years of age and smoking at least 5 cigarettes per day for at least 1 year.
53-1	10049-10058	Inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-2	10059-10067	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-3	10068-10072	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-4	10072-10073	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-5	10074-10076	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-6	10077-10079	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-7	10080-10082	25	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-8	10083-10088	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-9	10089-10091	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-10	10092-10095	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-11	10096-10099	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-12	10100-10107	smoking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-13	10108-10110	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-14	10111-10116	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-15	10117-10118	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-16	10119-10129	cigarettes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-17	10130-10133	per	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-18	10134-10137	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-19	10138-10141	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-20	10142-10144	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-21	10145-10150	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-22	10151-10152	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-23	10153-10157	year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
53-24	10157-10158	.	_	

#Text=Exclusion criteria were: positive urine test for illicit drugs (including marijuana) [using an Instant-View immunoassay urine test (ALFA Scientific Designs, Inc.)]; self-report of marijuana use >8 times per month and alcohol use >10 days per month; DSM-IV psychiatric disorders including substance use disorder (other than nicotine dependence); history of neurological injury or disease, pregnancy, or use of mentholated or electronic cigarettes; and contraindication for MRI scanning.
54-1	10159-10168	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-2	10169-10177	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-3	10178-10182	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-4	10182-10183	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-5	10184-10192	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-6	10193-10198	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-7	10199-10203	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-8	10204-10207	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-9	10208-10215	illicit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-10	10216-10221	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-11	10222-10223	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-12	10223-10232	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-13	10233-10242	marijuana	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-14	10242-10243	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-15	10244-10245	[	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-16	10245-10250	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-17	10251-10253	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-18	10254-10266	Instant-View	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-19	10267-10278	immunoassay	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-20	10279-10284	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-21	10285-10289	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-22	10290-10291	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-23	10291-10295	ALFA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-24	10296-10306	Scientific	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-25	10307-10314	Designs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-26	10314-10315	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-27	10316-10319	Inc	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-28	10319-10320	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-29	10320-10321	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-30	10321-10322	]	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-31	10322-10323	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-32	10324-10335	self-report	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-33	10336-10338	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-34	10339-10348	marijuana	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-35	10349-10352	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-36	10353-10354	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-37	10354-10355	8	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-38	10356-10361	times	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-39	10362-10365	per	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-40	10366-10371	month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-41	10372-10375	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-42	10376-10383	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-43	10384-10387	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-44	10388-10389	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-45	10389-10391	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-46	10392-10396	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-47	10397-10400	per	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-48	10401-10406	month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-49	10406-10407	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-50	10408-10414	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-51	10415-10426	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-52	10427-10436	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-53	10437-10446	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-54	10447-10456	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-55	10457-10460	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-56	10461-10469	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-57	10470-10471	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-58	10471-10476	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-59	10477-10481	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-60	10482-10490	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-61	10491-10501	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-62	10501-10502	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-63	10502-10503	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-64	10504-10511	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-65	10512-10514	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-66	10515-10527	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-67	10528-10534	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-68	10535-10537	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-69	10538-10545	disease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-70	10545-10546	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-71	10547-10556	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-72	10556-10557	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-73	10558-10560	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-74	10561-10564	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-75	10565-10567	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-76	10568-10579	mentholated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-77	10580-10582	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-78	10583-10593	electronic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-79	10594-10604	cigarettes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-80	10604-10605	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-81	10606-10609	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-82	10610-10626	contraindication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-83	10627-10630	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-84	10631-10634	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-85	10635-10643	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
54-86	10643-10644	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=Data from 3 participants with excessive head motion (>2.5 mm translation) were excluded, leaving data from 21 participants for inclusion in the final analyses.
55-1	10645-10649	Data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-2	10650-10654	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-3	10655-10656	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-4	10657-10669	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-5	10670-10674	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-6	10675-10684	excessive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-7	10685-10689	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-8	10690-10696	motion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-9	10697-10698	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-10	10698-10699	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-11	10699-10702	2.5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-12	10703-10705	mm	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-13	10706-10717	translation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-14	10717-10718	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-15	10719-10723	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-16	10724-10732	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-17	10732-10733	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-18	10734-10741	leaving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-19	10742-10746	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-20	10747-10751	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-21	10752-10754	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-22	10755-10767	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-23	10768-10771	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-24	10772-10781	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-25	10782-10784	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-26	10785-10788	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-27	10789-10794	final	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-28	10795-10803	analyses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-29	10803-10804	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=All participants were tested in the morning after overnight (~12 hours) abstinence from smoking, verified by measuring CO concentrations in expired air using a portable monitor (coVita), and again immediately after smoking one cigarette of their preferred brand.
56-1	10805-10808	All	_	
56-2	10809-10821	participants	_	
56-3	10822-10826	were	_	
56-4	10827-10833	tested	_	
56-5	10834-10836	in	_	
56-6	10837-10840	the	_	
56-7	10841-10848	morning	_	
56-8	10849-10854	after	_	
56-9	10855-10864	overnight	_	
56-10	10865-10866	(	_	
56-11	10866-10867	~	_	
56-12	10867-10869	12	_	
56-13	10870-10875	hours	_	
56-14	10875-10876	)	_	
56-15	10877-10887	abstinence	_	
56-16	10888-10892	from	_	
56-17	10893-10900	smoking	_	
56-18	10900-10901	,	_	
56-19	10902-10910	verified	_	
56-20	10911-10913	by	_	
56-21	10914-10923	measuring	_	
56-22	10924-10926	CO	_	
56-23	10927-10941	concentrations	_	
56-24	10942-10944	in	_	
56-25	10945-10952	expired	_	
56-26	10953-10956	air	_	
56-27	10957-10962	using	_	
56-28	10963-10964	a	_	
56-29	10965-10973	portable	_	
56-30	10974-10981	monitor	_	
56-31	10982-10983	(	_	
56-32	10983-10989	coVita	_	
56-33	10989-10990	)	_	
56-34	10990-10991	,	_	
56-35	10992-10995	and	_	
56-36	10996-11001	again	_	
56-37	11002-11013	immediately	_	
56-38	11014-11019	after	_	
56-39	11020-11027	smoking	_	
56-40	11028-11031	one	_	
56-41	11032-11041	cigarette	_	
56-42	11042-11044	of	_	
56-43	11045-11050	their	_	
56-44	11051-11060	preferred	_	
56-45	11061-11066	brand	_	
56-46	11066-11067	.	_	

#Text=In each of the 2 testing sessions, one before and one after smoking the first cigarette of the day, participants were administered the SJWS and underwent fMRI scanning while in the resting state.
57-1	11068-11070	In	_	
57-2	11071-11075	each	_	
57-3	11076-11078	of	_	
57-4	11079-11082	the	_	
57-5	11083-11084	2	_	
57-6	11085-11092	testing	_	
57-7	11093-11101	sessions	_	
57-8	11101-11102	,	_	
57-9	11103-11106	one	_	
57-10	11107-11113	before	_	
57-11	11114-11117	and	_	
57-12	11118-11121	one	_	
57-13	11122-11127	after	_	
57-14	11128-11135	smoking	_	
57-15	11136-11139	the	_	
57-16	11140-11145	first	_	
57-17	11146-11155	cigarette	_	
57-18	11156-11158	of	_	
57-19	11159-11162	the	_	
57-20	11163-11166	day	_	
57-21	11166-11167	,	_	
57-22	11168-11180	participants	_	
57-23	11181-11185	were	_	
57-24	11186-11198	administered	_	
57-25	11199-11202	the	_	
57-26	11203-11207	SJWS	_	
57-27	11208-11211	and	_	
57-28	11212-11221	underwent	_	
57-29	11222-11226	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
57-30	11227-11235	scanning	_	
57-31	11236-11241	while	_	
57-32	11242-11244	in	_	
57-33	11245-11248	the	_	
57-34	11249-11256	resting	_	
57-35	11257-11262	state	_	
57-36	11262-11263	.	_	

#Text=These procedures were part of a larger testing battery described previously.
58-1	11264-11269	These	_	
58-2	11270-11280	procedures	_	
58-3	11281-11285	were	_	
58-4	11286-11290	part	_	
58-5	11291-11293	of	_	
58-6	11294-11295	a	_	
58-7	11296-11302	larger	_	
58-8	11303-11310	testing	_	
58-9	11311-11318	battery	_	
58-10	11319-11328	described	_	
58-11	11329-11339	previously	_	
58-12	11339-11340	.	_	

#Text=The average time between the pre- and post-smoking scans was 66.28 (SD=8.49) minutes, and the average time between smoking and the post-smoking scan was 42.66 (SD=12.15) minutes.
59-1	11341-11344	The	_	
59-2	11345-11352	average	_	
59-3	11353-11357	time	_	
59-4	11358-11365	between	_	
59-5	11366-11369	the	_	
59-6	11370-11373	pre	_	
59-7	11373-11374	-	_	
59-8	11375-11378	and	_	
59-9	11379-11391	post-smoking	_	
59-10	11392-11397	scans	_	
59-11	11398-11401	was	_	
59-12	11402-11407	66.28	_	
59-13	11408-11409	(	_	
59-14	11409-11411	SD	_	
59-15	11411-11412	=	_	
59-16	11412-11416	8.49	_	
59-17	11416-11417	)	_	
59-18	11418-11425	minutes	_	
59-19	11425-11426	,	_	
59-20	11427-11430	and	_	
59-21	11431-11434	the	_	
59-22	11435-11442	average	_	
59-23	11443-11447	time	_	
59-24	11448-11455	between	_	
59-25	11456-11463	smoking	_	
59-26	11464-11467	and	_	
59-27	11468-11471	the	_	
59-28	11472-11484	post-smoking	_	
59-29	11485-11489	scan	_	
59-30	11490-11493	was	_	
59-31	11494-11499	42.66	_	
59-32	11500-11501	(	_	
59-33	11501-11503	SD	_	
59-34	11503-11504	=	_	
59-35	11504-11509	12.15	_	
59-36	11509-11510	)	_	
59-37	11511-11518	minutes	_	
59-38	11518-11519	.	_	

#Text=At the beginning of the intake session participants also completed the FTND.
60-1	11520-11522	At	_	
60-2	11523-11526	the	_	
60-3	11527-11536	beginning	_	
60-4	11537-11539	of	_	
60-5	11540-11543	the	_	
60-6	11544-11550	intake	_	
60-7	11551-11558	session	_	
60-8	11559-11571	participants	_	
60-9	11572-11576	also	_	
60-10	11577-11586	completed	_	
60-11	11587-11590	the	_	
60-12	11591-11595	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence	
60-13	11595-11596	.	_	

#Text=For a timeline of Study 2 procedures, see supplementary Figure 2.
61-1	11597-11600	For	_	
61-2	11601-11602	a	_	
61-3	11603-11611	timeline	_	
61-4	11612-11614	of	_	
61-5	11615-11620	Study	_	
61-6	11621-11622	2	_	
61-7	11623-11633	procedures	_	
61-8	11633-11634	,	_	
61-9	11635-11638	see	_	
61-10	11639-11652	supplementary	_	
61-11	11653-11659	Figure	_	
61-12	11660-11661	2	_	
61-13	11661-11662	.	_	

#Text=Smokers in Study 1 were, on average, significantly younger than those in Study 2 (F(1,56)=41.257, P<.001).
62-1	11663-11670	Smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
62-2	11671-11673	in	_	
62-3	11674-11679	Study	_	
62-4	11680-11681	1	_	
62-5	11682-11686	were	_	
62-6	11686-11687	,	_	
62-7	11688-11690	on	_	
62-8	11691-11698	average	_	
62-9	11698-11699	,	_	
62-10	11700-11713	significantly	_	
62-11	11714-11721	younger	_	
62-12	11722-11726	than	_	
62-13	11727-11732	those	_	
62-14	11733-11735	in	_	
62-15	11736-11741	Study	_	
62-16	11742-11743	2	_	
62-17	11744-11745	(	_	
62-18	11745-11746	F	_	
62-19	11746-11747	(	_	
62-20	11747-11751	1,56	_	
62-21	11751-11752	)	_	
62-22	11752-11753	=	_	
62-23	11753-11759	41.257	_	
62-24	11759-11760	,	_	
62-25	11761-11762	P	_	
62-26	11762-11763	<	_	
62-27	11763-11767	.001	_	
62-28	11767-11768	)	_	
62-29	11768-11769	.	_	

#Text=They also had slightly lower levels of nicotine dependence, but this difference was not statistically significant (Study 1 mean (SD): 2.56 (2.38); Study 2 mean (SD): 3.24 (1.76); F(1,37)=1.056, P=.311).
63-1	11770-11774	They	_	
63-2	11775-11779	also	_	
63-3	11780-11783	had	_	
63-4	11784-11792	slightly	_	
63-5	11793-11798	lower	_	
63-6	11799-11805	levels	_	
63-7	11806-11808	of	_	
63-8	11809-11817	nicotine	_	
63-9	11818-11828	dependence	_	
63-10	11828-11829	,	_	
63-11	11830-11833	but	_	
63-12	11834-11838	this	_	
63-13	11839-11849	difference	_	
63-14	11850-11853	was	_	
63-15	11854-11857	not	_	
63-16	11858-11871	statistically	_	
63-17	11872-11883	significant	_	
63-18	11884-11885	(	_	
63-19	11885-11890	Study	_	
63-20	11891-11892	1	_	
63-21	11893-11897	mean	_	
63-22	11898-11899	(	_	
63-23	11899-11901	SD	_	
63-24	11901-11902	)	_	
63-25	11902-11903	:	_	
63-26	11904-11908	2.56	_	
63-27	11909-11910	(	_	
63-28	11910-11914	2.38	_	
63-29	11914-11915	)	_	
63-30	11915-11916	;	_	
63-31	11917-11922	Study	_	
63-32	11923-11924	2	_	
63-33	11925-11929	mean	_	
63-34	11930-11931	(	_	
63-35	11931-11933	SD	_	
63-36	11933-11934	)	_	
63-37	11934-11935	:	_	
63-38	11936-11940	3.24	_	
63-39	11941-11942	(	_	
63-40	11942-11946	1.76	_	
63-41	11946-11947	)	_	
63-42	11947-11948	;	_	
63-43	11949-11950	F	_	
63-44	11950-11951	(	_	
63-45	11951-11955	1,37	_	
63-46	11955-11956	)	_	
63-47	11956-11957	=	_	
63-48	11957-11962	1.056	_	
63-49	11962-11963	,	_	
63-50	11964-11965	P	_	
63-51	11965-11966	=	_	
63-52	11966-11970	.311	_	
63-53	11970-11971	)	_	
63-54	11971-11972	.	_	

#Text=Both Studies
#Text=The Psychological Withdrawal and Craving subscales of the SJWS were used.
64-1	11973-11977	Both	_	
64-2	11978-11985	Studies	_	
64-3	11986-11989	The	_	
64-4	11990-12003	Psychological	_	
64-5	12004-12014	Withdrawal	_	
64-6	12015-12018	and	_	
64-7	12019-12026	Craving	_	
64-8	12027-12036	subscales	_	
64-9	12037-12039	of	_	
64-10	12040-12043	the	_	
64-11	12044-12048	SJWS	_	
64-12	12049-12053	were	_	
64-13	12054-12058	used	_	
64-14	12058-12059	.	_	

#Text=The Psychological Withdrawal subscale comprises 8 items pertaining to the affective aspects of tobacco withdrawal, and the Craving subscale comprises 7 items.
65-1	12060-12063	The	_	
65-2	12064-12077	Psychological	_	
65-3	12078-12088	Withdrawal	_	
65-4	12089-12097	subscale	_	
65-5	12098-12107	comprises	_	
65-6	12108-12109	8	_	
65-7	12110-12115	items	_	
65-8	12116-12126	pertaining	_	
65-9	12127-12129	to	_	
65-10	12130-12133	the	_	
65-11	12134-12143	affective	_	
65-12	12144-12151	aspects	_	
65-13	12152-12154	of	_	
65-14	12155-12162	tobacco	_	
65-15	12163-12173	withdrawal	_	
65-16	12173-12174	,	_	
65-17	12175-12178	and	_	
65-18	12179-12182	the	_	
65-19	12183-12190	Craving	_	
65-20	12191-12199	subscale	_	
65-21	12200-12209	comprises	_	
65-22	12210-12211	7	_	
65-23	12212-12217	items	_	
65-24	12217-12218	.	_	

#Text=Because serotonin dysfunction is associated with affective disorders (e.g.,), the primary analyses pertained to data from the Psychological Withdrawal subscale; data from the Craving subscale were used in secondary analyses because of the importance of craving to relapse (e.g.,).
#Text=fMRI Data Acquisition
#Text=Both Studies
#Text=Resting-state fMRI images were acquired over 5 minutes using a 3-T Siemens AG Trio MRI system while participants viewed a black screen (152 T2*-weighted echoplanar images; repetition time=2 seconds; echo time=30 milliseconds; slice thickness=4 mm; flip angle=90°; matrix: 64×64; field of view=192 mm).
66-1	12219-12226	Because	_	
66-2	12227-12236	serotonin	_	
66-3	12237-12248	dysfunction	_	
66-4	12249-12251	is	_	
66-5	12252-12262	associated	_	
66-6	12263-12267	with	_	
66-7	12268-12277	affective	_	
66-8	12278-12287	disorders	_	
66-9	12288-12289	(	_	
66-10	12289-12292	e.g	_	
66-11	12292-12293	.	_	
66-12	12293-12294	,	_	
66-13	12294-12295	)	_	
66-14	12295-12296	,	_	
66-15	12297-12300	the	_	
66-16	12301-12308	primary	_	
66-17	12309-12317	analyses	_	
66-18	12318-12327	pertained	_	
66-19	12328-12330	to	_	
66-20	12331-12335	data	_	
66-21	12336-12340	from	_	
66-22	12341-12344	the	_	
66-23	12345-12358	Psychological	_	
66-24	12359-12369	Withdrawal	_	
66-25	12370-12378	subscale	_	
66-26	12378-12379	;	_	
66-27	12380-12384	data	_	
66-28	12385-12389	from	_	
66-29	12390-12393	the	_	
66-30	12394-12401	Craving	_	
66-31	12402-12410	subscale	_	
66-32	12411-12415	were	_	
66-33	12416-12420	used	_	
66-34	12421-12423	in	_	
66-35	12424-12433	secondary	_	
66-36	12434-12442	analyses	_	
66-37	12443-12450	because	_	
66-38	12451-12453	of	_	
66-39	12454-12457	the	_	
66-40	12458-12468	importance	_	
66-41	12469-12471	of	_	
66-42	12472-12479	craving	_	
66-43	12480-12482	to	_	
66-44	12483-12490	relapse	_	
66-45	12491-12492	(	_	
66-46	12492-12495	e.g	_	
66-47	12495-12496	.	_	
66-48	12496-12497	,	_	
66-49	12497-12498	)	_	
66-50	12498-12499	.	_	
66-51	12500-12504	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
66-52	12505-12509	Data	_	
66-53	12510-12521	Acquisition	_	
66-54	12522-12526	Both	_	
66-55	12527-12534	Studies	_	
66-56	12535-12548	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[18]	
66-57	12549-12553	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[18]	
66-58	12554-12560	images	_	
66-59	12561-12565	were	_	
66-60	12566-12574	acquired	_	
66-61	12575-12579	over	_	
66-62	12580-12581	5	_	
66-63	12582-12589	minutes	_	
66-64	12590-12595	using	_	
66-65	12596-12597	a	_	
66-66	12598-12599	3	_	
66-67	12599-12600	-	_	
66-68	12600-12601	T	_	
66-69	12602-12609	Siemens	_	
66-70	12610-12612	AG	_	
66-71	12613-12617	Trio	_	
66-72	12618-12621	MRI	_	
66-73	12622-12628	system	_	
66-74	12629-12634	while	_	
66-75	12635-12647	participants	_	
66-76	12648-12654	viewed	_	
66-77	12655-12656	a	_	
66-78	12657-12662	black	_	
66-79	12663-12669	screen	_	
66-80	12670-12671	(	_	
66-81	12671-12674	152	_	
66-82	12675-12677	T2	_	
66-83	12677-12678	*	_	
66-84	12678-12679	-	_	
66-85	12679-12687	weighted	_	
66-86	12688-12698	echoplanar	_	
66-87	12699-12705	images	_	
66-88	12705-12706	;	_	
66-89	12707-12717	repetition	_	
66-90	12718-12722	time	_	
66-91	12722-12723	=	_	
66-92	12723-12724	2	_	
66-93	12725-12732	seconds	_	
66-94	12732-12733	;	_	
66-95	12734-12738	echo	_	
66-96	12739-12743	time	_	
66-97	12743-12744	=	_	
66-98	12744-12746	30	_	
66-99	12747-12759	milliseconds	_	
66-100	12759-12760	;	_	
66-101	12761-12766	slice	_	
66-102	12767-12776	thickness	_	
66-103	12776-12777	=	_	
66-104	12777-12778	4	_	
66-105	12779-12781	mm	_	
66-106	12781-12782	;	_	
66-107	12783-12787	flip	_	
66-108	12788-12793	angle	_	
66-109	12793-12794	=	_	
66-110	12794-12796	90	_	
66-111	12796-12797	°	_	
66-112	12797-12798	;	_	
66-113	12799-12805	matrix	_	
66-114	12805-12806	:	_	
66-115	12807-12809	64	_	
66-116	12809-12810	×	_	
66-117	12810-12812	64	_	
66-118	12812-12813	;	_	
66-119	12814-12819	field	_	
66-120	12820-12822	of	_	
66-121	12823-12827	view	_	
66-122	12827-12828	=	_	
66-123	12828-12831	192	_	
66-124	12832-12834	mm	_	
66-125	12834-12835	)	_	
66-126	12835-12836	.	_	

#Text=For Study 1 a 12-channel head-coil was used, and a 32-channel head coil was used for Study 2.
67-1	12837-12840	For	_	
67-2	12841-12846	Study	_	
67-3	12847-12848	1	_	
67-4	12849-12850	a	_	
67-5	12851-12853	12	_	
67-6	12853-12854	-	_	
67-7	12854-12861	channel	_	
67-8	12862-12871	head-coil	_	
67-9	12872-12875	was	_	
67-10	12876-12880	used	_	
67-11	12880-12881	,	_	
67-12	12882-12885	and	_	
67-13	12886-12887	a	_	
67-14	12888-12890	32	_	
67-15	12890-12891	-	_	
67-16	12891-12898	channel	_	
67-17	12899-12903	head	_	
67-18	12904-12908	coil	_	
67-19	12909-12912	was	_	
67-20	12913-12917	used	_	
67-21	12918-12921	for	_	
67-22	12922-12927	Study	_	
67-23	12928-12929	2	_	
67-24	12929-12930	.	_	

#Text=In both studies a T2-weighted matched-bandwidth anatomical scan was acquired for initial registration, and a T1-weighted magnetization-prepared rapid-acquisition gradient echo (MPRAGE) scan was acquired for further registration, including spatial normalization to standard space (Montreal Neurological Institute [MNI]).
#Text=fMRI Data Preprocessing
#Text=Image analysis was performed using the FMRIB Software Library (FSL) version 5.0.9 (www.fmrib.ox.ax.uk/fsl).
68-1	12931-12933	In	_	
68-2	12934-12938	both	_	
68-3	12939-12946	studies	_	
68-4	12947-12948	a	_	
68-5	12949-12951	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[19]	
68-6	12951-12952	-	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[19]	
68-7	12952-12960	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[19]	
68-8	12961-12978	matched-bandwidth	_	
68-9	12979-12989	anatomical	_	
68-10	12990-12994	scan	_	
68-11	12995-12998	was	_	
68-12	12999-13007	acquired	_	
68-13	13008-13011	for	_	
68-14	13012-13019	initial	_	
68-15	13020-13032	registration	_	
68-16	13032-13033	,	_	
68-17	13034-13037	and	_	
68-18	13038-13039	a	_	
68-19	13040-13042	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[20]	
68-20	13042-13043	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[20]	
68-21	13043-13051	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[20]	
68-22	13052-13074	magnetization-prepared	_	
68-23	13075-13092	rapid-acquisition	_	
68-24	13093-13101	gradient	_	
68-25	13102-13106	echo	_	
68-26	13107-13108	(	_	
68-27	13108-13114	MPRAGE	_	
68-28	13114-13115	)	_	
68-29	13116-13120	scan	_	
68-30	13121-13124	was	_	
68-31	13125-13133	acquired	_	
68-32	13134-13137	for	_	
68-33	13138-13145	further	_	
68-34	13146-13158	registration	_	
68-35	13158-13159	,	_	
68-36	13160-13169	including	_	
68-37	13170-13177	spatial	_	
68-38	13178-13191	normalization	_	
68-39	13192-13194	to	_	
68-40	13195-13203	standard	_	
68-41	13204-13209	space	_	
68-42	13210-13211	(	_	
68-43	13211-13219	Montreal	_	
68-44	13220-13232	Neurological	_	
68-45	13233-13242	Institute	_	
68-46	13243-13244	[	_	
68-47	13244-13247	MNI	_	
68-48	13247-13248	]	_	
68-49	13248-13249	)	_	
68-50	13249-13250	.	_	
68-51	13251-13255	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
68-52	13256-13260	Data	_	
68-53	13261-13274	Preprocessing	_	
68-54	13275-13280	Image	_	
68-55	13281-13289	analysis	_	
68-56	13290-13293	was	_	
68-57	13294-13303	performed	_	
68-58	13304-13309	using	_	
68-59	13310-13313	the	_	
68-60	13314-13319	FMRIB	_	
68-61	13320-13328	Software	_	
68-62	13329-13336	Library	_	
68-63	13337-13338	(	_	
68-64	13338-13341	FSL	_	
68-65	13341-13342	)	_	
68-66	13343-13350	version	_	
68-67	13351-13356	5.0.9	_	
68-68	13357-13358	(	_	
68-69	13358-13376	www.fmrib.ox.ax.uk	_	
68-70	13376-13377	/	_	
68-71	13377-13380	fsl	_	
68-72	13380-13381	)	_	
68-73	13381-13382	.	_	

#Text=The image time-course of the resting state fMRI data was first realigned to compensate for small head movements.
69-1	13383-13386	The	_	
69-2	13387-13392	image	_	
69-3	13393-13404	time-course	_	
69-4	13405-13407	of	_	
69-5	13408-13411	the	_	
69-6	13412-13419	resting	_	
69-7	13420-13425	state	_	
69-8	13426-13430	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
69-9	13431-13435	data	_	
69-10	13436-13439	was	_	
69-11	13440-13445	first	_	
69-12	13446-13455	realigned	_	
69-13	13456-13458	to	_	
69-14	13459-13469	compensate	_	
69-15	13470-13473	for	_	
69-16	13474-13479	small	_	
69-17	13480-13484	head	_	
69-18	13485-13494	movements	_	
69-19	13494-13495	.	_	

#Text=All non-brain matter was removed using FSL’s brain extraction tool.
70-1	13496-13499	All	_	
70-2	13500-13509	non-brain	_	
70-3	13510-13516	matter	_	
70-4	13517-13520	was	_	
70-5	13521-13528	removed	_	
70-6	13529-13534	using	_	
70-7	13535-13538	FSL	_	
70-8	13538-13539	’	_	
70-9	13539-13540	s	_	
70-10	13541-13546	brain	_	
70-11	13547-13557	extraction	_	
70-12	13558-13562	tool	_	
70-13	13562-13563	.	_	

#Text=Time-series statistical analysis was carried out using FMRIB’s Improved Linear Model, with local autocorrelation correction after highpass temporal filtering (Gaussian-weighted LSF straight line fitting, with sigma=50 seconds).
71-1	13564-13575	Time-series	_	
71-2	13576-13587	statistical	_	
71-3	13588-13596	analysis	_	
71-4	13597-13600	was	_	
71-5	13601-13608	carried	_	
71-6	13609-13612	out	_	
71-7	13613-13618	using	_	
71-8	13619-13624	FMRIB	_	
71-9	13624-13625	’	_	
71-10	13625-13626	s	_	
71-11	13627-13635	Improved	_	
71-12	13636-13642	Linear	_	
71-13	13643-13648	Model	_	
71-14	13648-13649	,	_	
71-15	13650-13654	with	_	
71-16	13655-13660	local	_	
71-17	13661-13676	autocorrelation	_	
71-18	13677-13687	correction	_	
71-19	13688-13693	after	_	
71-20	13694-13702	highpass	_	
71-21	13703-13711	temporal	_	
71-22	13712-13721	filtering	_	
71-23	13722-13723	(	_	
71-24	13723-13740	Gaussian-weighted	_	
71-25	13741-13744	LSF	_	
71-26	13745-13753	straight	_	
71-27	13754-13758	line	_	
71-28	13759-13766	fitting	_	
71-29	13766-13767	,	_	
71-30	13768-13772	with	_	
71-31	13773-13778	sigma	_	
71-32	13778-13779	=	_	
71-33	13779-13781	50	_	
71-34	13782-13789	seconds	_	
71-35	13789-13790	)	_	
71-36	13790-13791	.	_	

#Text=No participants were deemed to have had excessive head motion (>2.5 mm translation).
72-1	13792-13794	No	_	
72-2	13795-13807	participants	_	
72-3	13808-13812	were	_	
72-4	13813-13819	deemed	_	
72-5	13820-13822	to	_	
72-6	13823-13827	have	_	
72-7	13828-13831	had	_	
72-8	13832-13841	excessive	_	
72-9	13842-13846	head	_	
72-10	13847-13853	motion	_	
72-11	13854-13855	(	_	
72-12	13855-13856	>	_	
72-13	13856-13859	2.5	_	
72-14	13860-13862	mm	_	
72-15	13863-13874	translation	_	
72-16	13874-13875	)	_	
72-17	13875-13876	.	_	

#Text=For both studies, motion cleaning and noise reduction were performed using a 32-parameter linear regression model that included 6 motion parameters (3 translational dimensions along x, y, and z axes and 3 rotational dimensions: “pitch”, “roll,” and “yaw”) combined with the timeseries from the CSF and white matter to provide 8 parameters.
73-1	13877-13880	For	_	
73-2	13881-13885	both	_	
73-3	13886-13893	studies	_	
73-4	13893-13894	,	_	
73-5	13895-13901	motion	_	
73-6	13902-13910	cleaning	_	
73-7	13911-13914	and	_	
73-8	13915-13920	noise	_	
73-9	13921-13930	reduction	_	
73-10	13931-13935	were	_	
73-11	13936-13945	performed	_	
73-12	13946-13951	using	_	
73-13	13952-13953	a	_	
73-14	13954-13956	32	_	
73-15	13956-13957	-	_	
73-16	13957-13966	parameter	_	
73-17	13967-13973	linear	_	
73-18	13974-13984	regression	_	
73-19	13985-13990	model	_	
73-20	13991-13995	that	_	
73-21	13996-14004	included	_	
73-22	14005-14006	6	_	
73-23	14007-14013	motion	_	
73-24	14014-14024	parameters	_	
73-25	14025-14026	(	_	
73-26	14026-14027	3	_	
73-27	14028-14041	translational	_	
73-28	14042-14052	dimensions	_	
73-29	14053-14058	along	_	
73-30	14059-14060	x	_	
73-31	14060-14061	,	_	
73-32	14062-14063	y	_	
73-33	14063-14064	,	_	
73-34	14065-14068	and	_	
73-35	14069-14070	z	_	
73-36	14071-14075	axes	_	
73-37	14076-14079	and	_	
73-38	14080-14081	3	_	
73-39	14082-14092	rotational	_	
73-40	14093-14103	dimensions	_	
73-41	14103-14104	:	_	
73-42	14105-14106	“	_	
73-43	14106-14111	pitch	_	
73-44	14111-14112	”	_	
73-45	14112-14113	,	_	
73-46	14114-14115	“	_	
73-47	14115-14119	roll	_	
73-48	14119-14120	,	_	
73-49	14120-14121	”	_	
73-50	14122-14125	and	_	
73-51	14126-14127	“	_	
73-52	14127-14130	yaw	_	
73-53	14130-14131	”	_	
73-54	14131-14132	)	_	
73-55	14133-14141	combined	_	
73-56	14142-14146	with	_	
73-57	14147-14150	the	_	
73-58	14151-14161	timeseries	_	
73-59	14162-14166	from	_	
73-60	14167-14170	the	_	
73-61	14171-14174	CSF	_	
73-62	14175-14178	and	_	
73-63	14179-14184	white	_	
73-64	14185-14191	matter	_	
73-65	14192-14194	to	_	
73-66	14195-14202	provide	_	
73-67	14203-14204	8	_	
73-68	14205-14215	parameters	_	
73-69	14215-14216	.	_	

#Text=The temporal derivatives of these parameters and the quadratic of all parameters resulted in 32 parameters.
74-1	14217-14220	The	_	
74-2	14221-14229	temporal	_	
74-3	14230-14241	derivatives	_	
74-4	14242-14244	of	_	
74-5	14245-14250	these	_	
74-6	14251-14261	parameters	_	
74-7	14262-14265	and	_	
74-8	14266-14269	the	_	
74-9	14270-14279	quadratic	_	
74-10	14280-14282	of	_	
74-11	14283-14286	all	_	
74-12	14287-14297	parameters	_	
74-13	14298-14306	resulted	_	
74-14	14307-14309	in	_	
74-15	14310-14312	32	_	
74-16	14313-14323	parameters	_	
74-17	14323-14324	.	_	

#Text=In addition, framewise displacement (FD) was determined with root-mean-squared matrix calculation (using FSL’s ‘fsl_motion_outliers’ tool) to obtain the average rotation and translation parameter differences across images.
75-1	14325-14327	In	_	
75-2	14328-14336	addition	_	
75-3	14336-14337	,	_	
75-4	14338-14347	framewise	_	
75-5	14348-14360	displacement	_	
75-6	14361-14362	(	_	
75-7	14362-14364	FD	_	
75-8	14364-14365	)	_	
75-9	14366-14369	was	_	
75-10	14370-14380	determined	_	
75-11	14381-14385	with	_	
75-12	14386-14403	root-mean-squared	_	
75-13	14404-14410	matrix	_	
75-14	14411-14422	calculation	_	
75-15	14423-14424	(	_	
75-16	14424-14429	using	_	
75-17	14430-14433	FSL	_	
75-18	14433-14434	’	_	
75-19	14434-14435	s	_	
75-20	14436-14437	‘	_	
75-21	14437-14456	fsl_motion_outliers	_	
75-22	14456-14457	’	_	
75-23	14458-14462	tool	_	
75-24	14462-14463	)	_	
75-25	14464-14466	to	_	
75-26	14467-14473	obtain	_	
75-27	14474-14477	the	_	
75-28	14478-14485	average	_	
75-29	14486-14494	rotation	_	
75-30	14495-14498	and	_	
75-31	14499-14510	translation	_	
75-32	14511-14520	parameter	_	
75-33	14521-14532	differences	_	
75-34	14533-14539	across	_	
75-35	14540-14546	images	_	
75-36	14546-14547	.	_	

#Text=Time points that exceeded acceptable FD thresholds were included as “spike” regressors in the model.
76-1	14548-14552	Time	_	
76-2	14553-14559	points	_	
76-3	14560-14564	that	_	
76-4	14565-14573	exceeded	_	
76-5	14574-14584	acceptable	_	
76-6	14585-14587	FD	_	
76-7	14588-14598	thresholds	_	
76-8	14599-14603	were	_	
76-9	14604-14612	included	_	
76-10	14613-14615	as	_	
76-11	14616-14617	“	_	
76-12	14617-14622	spike	_	
76-13	14622-14623	”	_	
76-14	14624-14634	regressors	_	
76-15	14635-14637	in	_	
76-16	14638-14641	the	_	
76-17	14642-14647	model	_	
76-18	14647-14648	.	_	

#Text=A fixed threshold for all subjects was determined by calculating the SD of FD across all data and computing the following equation: 0.25 mm+2 * SD.
77-1	14649-14650	A	_	
77-2	14651-14656	fixed	_	
77-3	14657-14666	threshold	_	
77-4	14667-14670	for	_	
77-5	14671-14674	all	_	
77-6	14675-14683	subjects	_	
77-7	14684-14687	was	_	
77-8	14688-14698	determined	_	
77-9	14699-14701	by	_	
77-10	14702-14713	calculating	_	
77-11	14714-14717	the	_	
77-12	14718-14720	SD	_	
77-13	14721-14723	of	_	
77-14	14724-14726	FD	_	
77-15	14727-14733	across	_	
77-16	14734-14737	all	_	
77-17	14738-14742	data	_	
77-18	14743-14746	and	_	
77-19	14747-14756	computing	_	
77-20	14757-14760	the	_	
77-21	14761-14770	following	_	
77-22	14771-14779	equation	_	
77-23	14779-14780	:	_	
77-24	14781-14785	0.25	_	
77-25	14786-14788	mm	_	
77-26	14788-14789	+	_	
77-27	14789-14790	2	_	
77-28	14791-14792	*	_	
77-29	14793-14795	SD	_	
77-30	14795-14796	.	_	

#Text=The time series of the resultant residuals from the regression model was then scaled and normalized at each voxel: [(residuals - mean)/SD]+100.
78-1	14797-14800	The	_	
78-2	14801-14805	time	_	
78-3	14806-14812	series	_	
78-4	14813-14815	of	_	
78-5	14816-14819	the	_	
78-6	14820-14829	resultant	_	
78-7	14830-14839	residuals	_	
78-8	14840-14844	from	_	
78-9	14845-14848	the	_	
78-10	14849-14859	regression	_	
78-11	14860-14865	model	_	
78-12	14866-14869	was	_	
78-13	14870-14874	then	_	
78-14	14875-14881	scaled	_	
78-15	14882-14885	and	_	
78-16	14886-14896	normalized	_	
78-17	14897-14899	at	_	
78-18	14900-14904	each	_	
78-19	14905-14910	voxel	_	
78-20	14910-14911	:	_	
78-21	14912-14913	[	_	
78-22	14913-14914	(	_	
78-23	14914-14923	residuals	_	
78-24	14924-14925	-	_	
78-25	14926-14930	mean	_	
78-26	14930-14931	)	_	
78-27	14931-14932	/	_	
78-28	14932-14934	SD	_	
78-29	14934-14935	]	_	
78-30	14935-14936	+	_	
78-31	14936-14939	100	_	
78-32	14939-14940	.	_	

#Text=A seed-based approach was used with dorsal and median raphe nuclei masks created and provided by the authors of.
79-1	14941-14942	A	_	
79-2	14943-14953	seed-based	_	
79-3	14954-14962	approach	_	
79-4	14963-14966	was	_	
79-5	14967-14971	used	_	
79-6	14972-14976	with	_	
79-7	14977-14983	dorsal	_	
79-8	14984-14987	and	_	
79-9	14988-14994	median	_	
79-10	14995-15000	raphe	_	
79-11	15001-15007	nuclei	_	
79-12	15008-15013	masks	_	
79-13	15014-15021	created	_	
79-14	15022-15025	and	_	
79-15	15026-15034	provided	_	
79-16	15035-15037	by	_	
79-17	15038-15041	the	_	
79-18	15042-15049	authors	_	
79-19	15050-15052	of	_	
79-20	15052-15053	.	_	

#Text=Specifically, these masks were defined at the single-subject level by examining [11C]DASB binding (to measure SERT availability) using PET.
80-1	15054-15066	Specifically	_	
80-2	15066-15067	,	_	
80-3	15068-15073	these	_	
80-4	15074-15079	masks	_	
80-5	15080-15084	were	_	
80-6	15085-15092	defined	_	
80-7	15093-15095	at	_	
80-8	15096-15099	the	_	
80-9	15100-15114	single-subject	_	
80-10	15115-15120	level	_	
80-11	15121-15123	by	_	
80-12	15124-15133	examining	_	
80-13	15134-15135	[	_	
80-14	15135-15138	11C	_	
80-15	15138-15139	]	_	
80-16	15139-15143	DASB	_	
80-17	15144-15151	binding	_	
80-18	15152-15153	(	_	
80-19	15153-15155	to	_	
80-20	15156-15163	measure	_	
80-21	15164-15168	SERT	_	
80-22	15169-15181	availability	_	
80-23	15181-15182	)	_	
80-24	15183-15188	using	_	
80-25	15189-15192	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
80-26	15192-15193	.	_	

#Text=The masks were transformed into standard (MNI) space by first registering each subject’s PET image to their structural MR image (both in native space) using Freesurfer’s bbregister (https://surfer.nmr.mgh.harvard.edu/fswiki/bbregister), then by registering the native space MR image to standard space (MNI) using FLIRT and FNIRT in FSL, and then by applying the resulting transformation matrices using a “nearest neighbor” interpolation to bring the 2 raphe nuclei seeds into MNI space.
81-1	15194-15197	The	_	
81-2	15198-15203	masks	_	
81-3	15204-15208	were	_	
81-4	15209-15220	transformed	_	
81-5	15221-15225	into	_	
81-6	15226-15234	standard	_	
81-7	15235-15236	(	_	
81-8	15236-15239	MNI	_	
81-9	15239-15240	)	_	
81-10	15241-15246	space	_	
81-11	15247-15249	by	_	
81-12	15250-15255	first	_	
81-13	15256-15267	registering	_	
81-14	15268-15272	each	_	
81-15	15273-15280	subject	_	
81-16	15280-15281	’	_	
81-17	15281-15282	s	_	
81-18	15283-15286	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
81-19	15287-15292	image	_	
81-20	15293-15295	to	_	
81-21	15296-15301	their	_	
81-22	15302-15312	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[21]	
81-23	15313-15315	MR	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[21]	
81-24	15316-15321	image	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[21]	
81-25	15322-15323	(	_	
81-26	15323-15327	both	_	
81-27	15328-15330	in	_	
81-28	15331-15337	native	_	
81-29	15338-15343	space	_	
81-30	15343-15344	)	_	
81-31	15345-15350	using	_	
81-32	15351-15361	Freesurfer	_	
81-33	15361-15362	’	_	
81-34	15362-15363	s	_	
81-35	15364-15374	bbregister	_	
81-36	15375-15376	(	_	
81-37	15376-15381	https	_	
81-38	15381-15382	:	_	
81-39	15382-15383	/	_	
81-40	15383-15384	/	_	
81-41	15384-15410	surfer.nmr.mgh.harvard.edu	_	
81-42	15410-15411	/	_	
81-43	15411-15417	fswiki	_	
81-44	15417-15418	/	_	
81-45	15418-15428	bbregister	_	
81-46	15428-15429	)	_	
81-47	15429-15430	,	_	
81-48	15431-15435	then	_	
81-49	15436-15438	by	_	
81-50	15439-15450	registering	_	
81-51	15451-15454	the	_	
81-52	15455-15461	native	_	
81-53	15462-15467	space	_	
81-54	15468-15470	MR	_	
81-55	15471-15476	image	_	
81-56	15477-15479	to	_	
81-57	15480-15488	standard	_	
81-58	15489-15494	space	_	
81-59	15495-15496	(	_	
81-60	15496-15499	MNI	_	
81-61	15499-15500	)	_	
81-62	15501-15506	using	_	
81-63	15507-15512	FLIRT	_	
81-64	15513-15516	and	_	
81-65	15517-15522	FNIRT	_	
81-66	15523-15525	in	_	
81-67	15526-15529	FSL	_	
81-68	15529-15530	,	_	
81-69	15531-15534	and	_	
81-70	15535-15539	then	_	
81-71	15540-15542	by	_	
81-72	15543-15551	applying	_	
81-73	15552-15555	the	_	
81-74	15556-15565	resulting	_	
81-75	15566-15580	transformation	_	
81-76	15581-15589	matrices	_	
81-77	15590-15595	using	_	
81-78	15596-15597	a	_	
81-79	15598-15599	“	_	
81-80	15599-15606	nearest	_	
81-81	15607-15615	neighbor	_	
81-82	15615-15616	”	_	
81-83	15617-15630	interpolation	_	
81-84	15631-15633	to	_	
81-85	15634-15639	bring	_	
81-86	15640-15643	the	_	
81-87	15644-15645	2	_	
81-88	15646-15651	raphe	_	
81-89	15652-15658	nuclei	_	
81-90	15659-15664	seeds	_	
81-91	15665-15669	into	_	
81-92	15670-15673	MNI	_	
81-93	15674-15679	space	_	
81-94	15679-15680	.	_	

#Text=These masks can be seen in (supplementary Figure 3).
82-1	15681-15686	These	_	
82-2	15687-15692	masks	_	
82-3	15693-15696	can	_	
82-4	15697-15699	be	_	
82-5	15700-15704	seen	_	
82-6	15705-15707	in	_	
82-7	15708-15709	(	_	
82-8	15709-15722	supplementary	_	
82-9	15723-15729	Figure	_	
82-10	15730-15731	3	_	
82-11	15731-15732	)	_	
82-12	15732-15733	.	_	

#Text=For a full description of how these masks were defined in subject-space, see.
83-1	15734-15737	For	_	
83-2	15738-15739	a	_	
83-3	15740-15744	full	_	
83-4	15745-15756	description	_	
83-5	15757-15759	of	_	
83-6	15760-15763	how	_	
83-7	15764-15769	these	_	
83-8	15770-15775	masks	_	
83-9	15776-15780	were	_	
83-10	15781-15788	defined	_	
83-11	15789-15791	in	_	
83-12	15792-15805	subject-space	_	
83-13	15805-15806	,	_	
83-14	15807-15810	see	_	
83-15	15810-15811	.	_	

#Text=The center-of-mass locations (in MNI space) were x=0, y=-28, z=-12 for the dorsal raphe nucleus, and x=0, y=-34, z=-20 for the median raphe nucleus.
84-1	15812-15815	The	_	
84-2	15816-15830	center-of-mass	_	
84-3	15831-15840	locations	_	
84-4	15841-15842	(	_	
84-5	15842-15844	in	_	
84-6	15845-15848	MNI	_	
84-7	15849-15854	space	_	
84-8	15854-15855	)	_	
84-9	15856-15860	were	_	
84-10	15861-15862	x	_	
84-11	15862-15863	=	_	
84-12	15863-15864	0	_	
84-13	15864-15865	,	_	
84-14	15866-15867	y	_	
84-15	15867-15868	=	_	
84-16	15868-15869	-	_	
84-17	15869-15871	28	_	
84-18	15871-15872	,	_	
84-19	15873-15874	z	_	
84-20	15874-15875	=	_	
84-21	15875-15876	-	_	
84-22	15876-15878	12	_	
84-23	15879-15882	for	_	
84-24	15883-15886	the	_	
84-25	15887-15893	dorsal	_	
84-26	15894-15899	raphe	_	
84-27	15900-15907	nucleus	_	
84-28	15907-15908	,	_	
84-29	15909-15912	and	_	
84-30	15913-15914	x	_	
84-31	15914-15915	=	_	
84-32	15915-15916	0	_	
84-33	15916-15917	,	_	
84-34	15918-15919	y	_	
84-35	15919-15920	=	_	
84-36	15920-15921	-	_	
84-37	15921-15923	34	_	
84-38	15923-15924	,	_	
84-39	15925-15926	z	_	
84-40	15926-15927	=	_	
84-41	15927-15928	-	_	
84-42	15928-15930	20	_	
84-43	15931-15934	for	_	
84-44	15935-15938	the	_	
84-45	15939-15945	median	_	
84-46	15946-15951	raphe	_	
84-47	15952-15959	nucleus	_	
84-48	15959-15960	.	_	

#Text=The dorsal raphe seed location extended from x=4 to -6, y=-32 to -26, and z=-18 to -10.
85-1	15961-15964	The	_	
85-2	15965-15971	dorsal	_	
85-3	15972-15977	raphe	_	
85-4	15978-15982	seed	_	
85-5	15983-15991	location	_	
85-6	15992-16000	extended	_	
85-7	16001-16005	from	_	
85-8	16006-16007	x	_	
85-9	16007-16008	=	_	
85-10	16008-16009	4	_	
85-11	16010-16012	to	_	
85-12	16013-16014	-	_	
85-13	16014-16015	6	_	
85-14	16015-16016	,	_	
85-15	16017-16018	y	_	
85-16	16018-16019	=	_	
85-17	16019-16020	-	_	
85-18	16020-16022	32	_	
85-19	16023-16025	to	_	
85-20	16026-16027	-	_	
85-21	16027-16029	26	_	
85-22	16029-16030	,	_	
85-23	16031-16034	and	_	
85-24	16035-16036	z	_	
85-25	16036-16037	=	_	
85-26	16037-16038	-	_	
85-27	16038-16040	18	_	
85-28	16041-16043	to	_	
85-29	16044-16045	-	_	
85-30	16045-16047	10	_	
85-31	16047-16048	.	_	

#Text=The median raphe seed location extended from x=2 to -6, y=-36 to -30, and z=-26 to -18.
86-1	16049-16052	The	_	
86-2	16053-16059	median	_	
86-3	16060-16065	raphe	_	
86-4	16066-16070	seed	_	
86-5	16071-16079	location	_	
86-6	16080-16088	extended	_	
86-7	16089-16093	from	_	
86-8	16094-16095	x	_	
86-9	16095-16096	=	_	
86-10	16096-16097	2	_	
86-11	16098-16100	to	_	
86-12	16101-16102	-	_	
86-13	16102-16103	6	_	
86-14	16103-16104	,	_	
86-15	16105-16106	y	_	
86-16	16106-16107	=	_	
86-17	16107-16108	-	_	
86-18	16108-16110	36	_	
86-19	16111-16113	to	_	
86-20	16114-16115	-	_	
86-21	16115-16117	30	_	
86-22	16117-16118	,	_	
86-23	16119-16122	and	_	
86-24	16123-16124	z	_	
86-25	16124-16125	=	_	
86-26	16125-16126	-	_	
86-27	16126-16128	26	_	
86-28	16129-16131	to	_	
86-29	16132-16133	-	_	
86-30	16133-16135	18	_	
86-31	16135-16136	.	_	

#Text=Contrast images were registered through a 3-step procedure; EPI images were first registered to the matched-bandwidth high-resolution structural image, then to the MPRAGE structural image, and finally into standard (MNI) space, using 12-parameter affine transformations.
87-1	16137-16145	Contrast	_	
87-2	16146-16152	images	_	
87-3	16153-16157	were	_	
87-4	16158-16168	registered	_	
87-5	16169-16176	through	_	
87-6	16177-16178	a	_	
87-7	16179-16180	3	_	
87-8	16180-16181	-	_	
87-9	16181-16185	step	_	
87-10	16186-16195	procedure	_	
87-11	16195-16196	;	_	
87-12	16197-16200	EPI	_	
87-13	16201-16207	images	_	
87-14	16208-16212	were	_	
87-15	16213-16218	first	_	
87-16	16219-16229	registered	_	
87-17	16230-16232	to	_	
87-18	16233-16236	the	_	
87-19	16237-16254	matched-bandwidth	_	
87-20	16255-16270	high-resolution	_	
87-21	16271-16281	structural	_	
87-22	16282-16287	image	_	
87-23	16287-16288	,	_	
87-24	16289-16293	then	_	
87-25	16294-16296	to	_	
87-26	16297-16300	the	_	
87-27	16301-16307	MPRAGE	_	
87-28	16308-16318	structural	_	
87-29	16319-16324	image	_	
87-30	16324-16325	,	_	
87-31	16326-16329	and	_	
87-32	16330-16337	finally	_	
87-33	16338-16342	into	_	
87-34	16343-16351	standard	_	
87-35	16352-16353	(	_	
87-36	16353-16356	MNI	_	
87-37	16356-16357	)	_	
87-38	16358-16363	space	_	
87-39	16363-16364	,	_	
87-40	16365-16370	using	_	
87-41	16371-16373	12	_	
87-42	16373-16374	-	_	
87-43	16374-16383	parameter	_	
87-44	16384-16390	affine	_	
87-45	16391-16406	transformations	_	
87-46	16406-16407	.	_	

#Text=Registration from MPRAGE structural images to standard space was further refined using FNIRT nonlinear registration.
88-1	16408-16420	Registration	_	
88-2	16421-16425	from	_	
88-3	16426-16432	MPRAGE	_	
88-4	16433-16443	structural	_	
88-5	16444-16450	images	_	
88-6	16451-16453	to	_	
88-7	16454-16462	standard	_	
88-8	16463-16468	space	_	
88-9	16469-16472	was	_	
88-10	16473-16480	further	_	
88-11	16481-16488	refined	_	
88-12	16489-16494	using	_	
88-13	16495-16500	FNIRT	_	
88-14	16501-16510	nonlinear	_	
88-15	16511-16523	registration	_	
88-16	16523-16524	.	_	

#Text=Images were smoothed using a 5-mm full-width at half-maximum Gaussian kernel.
89-1	16525-16531	Images	_	
89-2	16532-16536	were	_	
89-3	16537-16545	smoothed	_	
89-4	16546-16551	using	_	
89-5	16552-16553	a	_	
89-6	16554-16555	5	_	
89-7	16555-16556	-	_	
89-8	16556-16558	mm	_	
89-9	16559-16569	full-width	_	
89-10	16570-16572	at	_	
89-11	16573-16585	half-maximum	_	
89-12	16586-16594	Gaussian	_	
89-13	16595-16601	kernel	_	
89-14	16601-16602	.	_	

#Text=Smoothing was performed after extraction of the timeseries data within the dorsal and median raphe nuclei to avoid the inclusion of signal from surrounding regions in higher-level analyses
#Text=fMRI Data Analysis
#Text=All group-level analyses (1 per raphe nucleus seed) were performed using the general linear model (GLM) framework provided in FSL’s FLAME1 with outlier deweighting.
90-1	16603-16612	Smoothing	_	
90-2	16613-16616	was	_	
90-3	16617-16626	performed	_	
90-4	16627-16632	after	_	
90-5	16633-16643	extraction	_	
90-6	16644-16646	of	_	
90-7	16647-16650	the	_	
90-8	16651-16661	timeseries	_	
90-9	16662-16666	data	_	
90-10	16667-16673	within	_	
90-11	16674-16677	the	_	
90-12	16678-16684	dorsal	_	
90-13	16685-16688	and	_	
90-14	16689-16695	median	_	
90-15	16696-16701	raphe	_	
90-16	16702-16708	nuclei	_	
90-17	16709-16711	to	_	
90-18	16712-16717	avoid	_	
90-19	16718-16721	the	_	
90-20	16722-16731	inclusion	_	
90-21	16732-16734	of	_	
90-22	16735-16741	signal	_	
90-23	16742-16746	from	_	
90-24	16747-16758	surrounding	_	
90-25	16759-16766	regions	_	
90-26	16767-16769	in	_	
90-27	16770-16782	higher-level	_	
90-28	16783-16791	analyses	_	
90-29	16792-16796	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
90-30	16797-16801	Data	_	
90-31	16802-16810	Analysis	_	
90-32	16811-16814	All	_	
90-33	16815-16826	group-level	_	
90-34	16827-16835	analyses	_	
90-35	16836-16837	(	_	
90-36	16837-16838	1	_	
90-37	16839-16842	per	_	
90-38	16843-16848	raphe	_	
90-39	16849-16856	nucleus	_	
90-40	16857-16861	seed	_	
90-41	16861-16862	)	_	
90-42	16863-16867	were	_	
90-43	16868-16877	performed	_	
90-44	16878-16883	using	_	
90-45	16884-16887	the	_	
90-46	16888-16895	general	_	
90-47	16896-16902	linear	_	
90-48	16903-16908	model	_	
90-49	16909-16910	(	_	
90-50	16910-16913	GLM	_	
90-51	16913-16914	)	_	
90-52	16915-16924	framework	_	
90-53	16925-16933	provided	_	
90-54	16934-16936	in	_	
90-55	16937-16940	FSL	_	
90-56	16940-16941	’	_	
90-57	16941-16942	s	_	
90-58	16943-16949	FLAME1	_	
90-59	16950-16954	with	_	
90-60	16955-16962	outlier	_	
90-61	16963-16974	deweighting	_	
90-62	16974-16975	.	_	

#Text=To assess the effect of smoking status on connectivity of the raphe nuclei with the hippocampal complex (Study 1), 2 separate GLMs (1 per raphe nucleus seed) were constructed, with 2 explanatory variables each (1 per group; smoker and nonsmoker).
91-1	16976-16978	To	_	
91-2	16979-16985	assess	_	
91-3	16986-16989	the	_	
91-4	16990-16996	effect	_	
91-5	16997-16999	of	_	
91-6	17000-17007	smoking	_	
91-7	17008-17014	status	_	
91-8	17015-17017	on	_	
91-9	17018-17030	connectivity	_	
91-10	17031-17033	of	_	
91-11	17034-17037	the	_	
91-12	17038-17043	raphe	_	
91-13	17044-17050	nuclei	_	
91-14	17051-17055	with	_	
91-15	17056-17059	the	_	
91-16	17060-17071	hippocampal	_	
91-17	17072-17079	complex	_	
91-18	17080-17081	(	_	
91-19	17081-17086	Study	_	
91-20	17087-17088	1	_	
91-21	17088-17089	)	_	
91-22	17089-17090	,	_	
91-23	17091-17092	2	_	
91-24	17093-17101	separate	_	
91-25	17102-17106	GLMs	_	
91-26	17107-17108	(	_	
91-27	17108-17109	1	_	
91-28	17110-17113	per	_	
91-29	17114-17119	raphe	_	
91-30	17120-17127	nucleus	_	
91-31	17128-17132	seed	_	
91-32	17132-17133	)	_	
91-33	17134-17138	were	_	
91-34	17139-17150	constructed	_	
91-35	17150-17151	,	_	
91-36	17152-17156	with	_	
91-37	17157-17158	2	_	
91-38	17159-17170	explanatory	_	
91-39	17171-17180	variables	_	
91-40	17181-17185	each	_	
91-41	17186-17187	(	_	
91-42	17187-17188	1	_	
91-43	17189-17192	per	_	
91-44	17193-17198	group	_	
91-45	17198-17199	;	_	
91-46	17200-17206	smoker	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
91-47	17207-17210	and	_	
91-48	17211-17220	nonsmoker	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
91-49	17220-17221	)	_	
91-50	17221-17222	.	_	

#Text=Group differences were assessed by contrasting the parameter estimates for these 2 explanatory variables.
92-1	17223-17228	Group	_	
92-2	17229-17240	differences	_	
92-3	17241-17245	were	_	
92-4	17246-17254	assessed	_	
92-5	17255-17257	by	_	
92-6	17258-17269	contrasting	_	
92-7	17270-17273	the	_	
92-8	17274-17283	parameter	_	
92-9	17284-17293	estimates	_	
92-10	17294-17297	for	_	
92-11	17298-17303	these	_	
92-12	17304-17305	2	_	
92-13	17306-17317	explanatory	_	
92-14	17318-17327	variables	_	
92-15	17327-17328	.	_	

#Text=To assess the acute effect of smoking on connectivity (Study 2), pre- vs post-smoking images were created using a fixed effects model in FSL’s FEAT, with each pre- and post-smoking image modelled with a 1 and -1, respectively.
93-1	17329-17331	To	_	
93-2	17332-17338	assess	_	
93-3	17339-17342	the	_	
93-4	17343-17348	acute	_	
93-5	17349-17355	effect	_	
93-6	17356-17358	of	_	
93-7	17359-17366	smoking	_	
93-8	17367-17369	on	_	
93-9	17370-17382	connectivity	_	
93-10	17383-17384	(	_	
93-11	17384-17389	Study	_	
93-12	17390-17391	2	_	
93-13	17391-17392	)	_	
93-14	17392-17393	,	_	
93-15	17394-17397	pre	_	
93-16	17397-17398	-	_	
93-17	17399-17401	vs	_	
93-18	17402-17414	post-smoking	_	
93-19	17415-17421	images	_	
93-20	17422-17426	were	_	
93-21	17427-17434	created	_	
93-22	17435-17440	using	_	
93-23	17441-17442	a	_	
93-24	17443-17448	fixed	_	
93-25	17449-17456	effects	_	
93-26	17457-17462	model	_	
93-27	17463-17465	in	_	
93-28	17466-17469	FSL	_	
93-29	17469-17470	’	_	
93-30	17470-17471	s	_	
93-31	17472-17476	FEAT	_	
93-32	17476-17477	,	_	
93-33	17478-17482	with	_	
93-34	17483-17487	each	_	
93-35	17488-17491	pre	_	
93-36	17491-17492	-	_	
93-37	17493-17496	and	_	
93-38	17497-17509	post-smoking	_	
93-39	17510-17515	image	_	
93-40	17516-17524	modelled	_	
93-41	17525-17529	with	_	
93-42	17530-17531	a	_	
93-43	17532-17533	1	_	
93-44	17534-17537	and	_	
93-45	17538-17539	-	_	
93-46	17539-17540	1	_	
93-47	17540-17541	,	_	
93-48	17542-17554	respectively	_	
93-49	17554-17555	.	_	

#Text=The resulting contrast image for each participant was then submitted to a group-level analysis that contained one explanatory variable, denoting the group mean.
94-1	17556-17559	The	_	
94-2	17560-17569	resulting	_	
94-3	17570-17578	contrast	_	
94-4	17579-17584	image	_	
94-5	17585-17588	for	_	
94-6	17589-17593	each	_	
94-7	17594-17605	participant	_	
94-8	17606-17609	was	_	
94-9	17610-17614	then	_	
94-10	17615-17624	submitted	_	
94-11	17625-17627	to	_	
94-12	17628-17629	a	_	
94-13	17630-17641	group-level	_	
94-14	17642-17650	analysis	_	
94-15	17651-17655	that	_	
94-16	17656-17665	contained	_	
94-17	17666-17669	one	_	
94-18	17670-17681	explanatory	_	
94-19	17682-17690	variable	_	
94-20	17690-17691	,	_	
94-21	17692-17700	denoting	_	
94-22	17701-17704	the	_	
94-23	17705-17710	group	_	
94-24	17711-17715	mean	_	
94-25	17715-17716	.	_	

#Text=Because the hypotheses tested concerned connectivity of the raphe nuclei with the hippocampal complex, all group-level analyses were constrained by a hippocampal complex mask that contained the hippocampus, parahippocampal gyrus, and entorhinal cortex as defined by the Harvard-Oxford Atlas distributed within FSL.
95-1	17717-17724	Because	_	
95-2	17725-17728	the	_	
95-3	17729-17739	hypotheses	_	
95-4	17740-17746	tested	_	
95-5	17747-17756	concerned	_	
95-6	17757-17769	connectivity	_	
95-7	17770-17772	of	_	
95-8	17773-17776	the	_	
95-9	17777-17782	raphe	_	
95-10	17783-17789	nuclei	_	
95-11	17790-17794	with	_	
95-12	17795-17798	the	_	
95-13	17799-17810	hippocampal	_	
95-14	17811-17818	complex	_	
95-15	17818-17819	,	_	
95-16	17820-17823	all	_	
95-17	17824-17835	group-level	_	
95-18	17836-17844	analyses	_	
95-19	17845-17849	were	_	
95-20	17850-17861	constrained	_	
95-21	17862-17864	by	_	
95-22	17865-17866	a	_	
95-23	17867-17878	hippocampal	_	
95-24	17879-17886	complex	_	
95-25	17887-17891	mask	_	
95-26	17892-17896	that	_	
95-27	17897-17906	contained	_	
95-28	17907-17910	the	_	
95-29	17911-17922	hippocampus	_	
95-30	17922-17923	,	_	
95-31	17924-17939	parahippocampal	_	
95-32	17940-17945	gyrus	_	
95-33	17945-17946	,	_	
95-34	17947-17950	and	_	
95-35	17951-17961	entorhinal	_	
95-36	17962-17968	cortex	_	
95-37	17969-17971	as	_	
95-38	17972-17979	defined	_	
95-39	17980-17982	by	_	
95-40	17983-17986	the	_	
95-41	17987-18001	Harvard-Oxford	_	
95-42	18002-18007	Atlas	_	
95-43	18008-18019	distributed	_	
95-44	18020-18026	within	_	
95-45	18027-18030	FSL	_	
95-46	18030-18031	.	_	

#Text=These analyses were followed by exploratory, whole-brain analyses to determine selectivity of the effects (see supplementary Materials).
96-1	18032-18037	These	_	
96-2	18038-18046	analyses	_	
96-3	18047-18051	were	_	
96-4	18052-18060	followed	_	
96-5	18061-18063	by	_	
96-6	18064-18075	exploratory	_	
96-7	18075-18076	,	_	
96-8	18077-18088	whole-brain	_	
96-9	18089-18097	analyses	_	
96-10	18098-18100	to	_	
96-11	18101-18110	determine	_	
96-12	18111-18122	selectivity	_	
96-13	18123-18125	of	_	
96-14	18126-18129	the	_	
96-15	18130-18137	effects	_	
96-16	18138-18139	(	_	
96-17	18139-18142	see	_	
96-18	18143-18156	supplementary	_	
96-19	18157-18166	Materials	_	
96-20	18166-18167	)	_	
96-21	18167-18168	.	_	

#Text=All group-level statistical maps were cluster-corrected for multiple comparisons (voxel height threshold: Z>3.1; cluster significance, P<.05).
97-1	18169-18172	All	_	
97-2	18173-18184	group-level	_	
97-3	18185-18196	statistical	_	
97-4	18197-18201	maps	_	
97-5	18202-18206	were	_	
97-6	18207-18224	cluster-corrected	_	
97-7	18225-18228	for	_	
97-8	18229-18237	multiple	_	
97-9	18238-18249	comparisons	_	
97-10	18250-18251	(	_	
97-11	18251-18256	voxel	_	
97-12	18257-18263	height	_	
97-13	18264-18273	threshold	_	
97-14	18273-18274	:	_	
97-15	18275-18276	Z	_	
97-16	18276-18277	>	_	
97-17	18277-18280	3.1	_	
97-18	18280-18281	;	_	
97-19	18282-18289	cluster	_	
97-20	18290-18302	significance	_	
97-21	18302-18303	,	_	
97-22	18304-18305	P	_	
97-23	18305-18306	<	_	
97-24	18306-18309	.05	_	
97-25	18309-18310	)	_	
97-26	18310-18311	.	_	

#Text=To examine the relationships of psychological withdrawal and craving with group differences in connectivity (Study 1), as well as with the acute effects of smoking on connectivity (Study 2), connectivity values (z scores) were extracted from significant clusters and entered into the SPSS (SPSS Inc.) for correlation with behavioral measures.
98-1	18312-18314	To	_	
98-2	18315-18322	examine	_	
98-3	18323-18326	the	_	
98-4	18327-18340	relationships	_	
98-5	18341-18343	of	_	
98-6	18344-18357	psychological	_	
98-7	18358-18368	withdrawal	_	
98-8	18369-18372	and	_	
98-9	18373-18380	craving	_	
98-10	18381-18385	with	_	
98-11	18386-18391	group	_	
98-12	18392-18403	differences	_	
98-13	18404-18406	in	_	
98-14	18407-18419	connectivity	_	
98-15	18420-18421	(	_	
98-16	18421-18426	Study	_	
98-17	18427-18428	1	_	
98-18	18428-18429	)	_	
98-19	18429-18430	,	_	
98-20	18431-18433	as	_	
98-21	18434-18438	well	_	
98-22	18439-18441	as	_	
98-23	18442-18446	with	_	
98-24	18447-18450	the	_	
98-25	18451-18456	acute	_	
98-26	18457-18464	effects	_	
98-27	18465-18467	of	_	
98-28	18468-18475	smoking	_	
98-29	18476-18478	on	_	
98-30	18479-18491	connectivity	_	
98-31	18492-18493	(	_	
98-32	18493-18498	Study	_	
98-33	18499-18500	2	_	
98-34	18500-18501	)	_	
98-35	18501-18502	,	_	
98-36	18503-18515	connectivity	_	
98-37	18516-18522	values	_	
98-38	18523-18524	(	_	
98-39	18524-18525	z	_	
98-40	18526-18532	scores	_	
98-41	18532-18533	)	_	
98-42	18534-18538	were	_	
98-43	18539-18548	extracted	_	
98-44	18549-18553	from	_	
98-45	18554-18565	significant	_	
98-46	18566-18574	clusters	_	
98-47	18575-18578	and	_	
98-48	18579-18586	entered	_	
98-49	18587-18591	into	_	
98-50	18592-18595	the	_	
98-51	18596-18600	SPSS	_	
98-52	18601-18602	(	_	
98-53	18602-18606	SPSS	_	
98-54	18607-18610	Inc	_	
98-55	18610-18611	.	_	
98-56	18611-18612	)	_	
98-57	18613-18616	for	_	
98-58	18617-18628	correlation	_	
98-59	18629-18633	with	_	
98-60	18634-18644	behavioral	_	
98-61	18645-18653	measures	_	
98-62	18653-18654	.	_	

#Text=Association of Connectivity with Behavioral Measures
#Text=Study 1
#Text=To test for associations of connectivity with psychological withdrawal and craving in smokers, values of mean connectivity (z scores) from significant clusters were extracted and entered as one factor, along with sex, into 2 separate full-factorial ANOVAs, in which scores on the Psychological Withdrawal or Craving subscales were the dependent variables.
99-1	18655-18666	Association	_	
99-2	18667-18669	of	_	
99-3	18670-18682	Connectivity	_	
99-4	18683-18687	with	_	
99-5	18688-18698	Behavioral	_	
99-6	18699-18707	Measures	_	
99-7	18708-18713	Study	_	
99-8	18714-18715	1	_	
99-9	18716-18718	To	_	
99-10	18719-18723	test	_	
99-11	18724-18727	for	_	
99-12	18728-18740	associations	_	
99-13	18741-18743	of	_	
99-14	18744-18756	connectivity	_	
99-15	18757-18761	with	_	
99-16	18762-18775	psychological	_	
99-17	18776-18786	withdrawal	_	
99-18	18787-18790	and	_	
99-19	18791-18798	craving	_	
99-20	18799-18801	in	_	
99-21	18802-18809	smokers	_	
99-22	18809-18810	,	_	
99-23	18811-18817	values	_	
99-24	18818-18820	of	_	
99-25	18821-18825	mean	_	
99-26	18826-18838	connectivity	_	
99-27	18839-18840	(	_	
99-28	18840-18841	z	_	
99-29	18842-18848	scores	_	
99-30	18848-18849	)	_	
99-31	18850-18854	from	_	
99-32	18855-18866	significant	_	
99-33	18867-18875	clusters	_	
99-34	18876-18880	were	_	
99-35	18881-18890	extracted	_	
99-36	18891-18894	and	_	
99-37	18895-18902	entered	_	
99-38	18903-18905	as	_	
99-39	18906-18909	one	_	
99-40	18910-18916	factor	_	
99-41	18916-18917	,	_	
99-42	18918-18923	along	_	
99-43	18924-18928	with	_	
99-44	18929-18932	sex	_	
99-45	18932-18933	,	_	
99-46	18934-18938	into	_	
99-47	18939-18940	2	_	
99-48	18941-18949	separate	_	
99-49	18950-18964	full-factorial	_	
99-50	18965-18971	ANOVAs	_	
99-51	18971-18972	,	_	
99-52	18973-18975	in	_	
99-53	18976-18981	which	_	
99-54	18982-18988	scores	_	
99-55	18989-18991	on	_	
99-56	18992-18995	the	_	
99-57	18996-19009	Psychological	_	
99-58	19010-19020	Withdrawal	_	
99-59	19021-19023	or	_	
99-60	19024-19031	Craving	_	
99-61	19032-19041	subscales	_	
99-62	19042-19046	were	_	
99-63	19047-19050	the	_	
99-64	19051-19060	dependent	_	
99-65	19061-19070	variables	_	
99-66	19070-19071	.	_	

#Text=Sex was included as a separate factor because it influences tobacco withdrawal symptoms (e.g.,).
100-1	19072-19075	Sex	_	
100-2	19076-19079	was	_	
100-3	19080-19088	included	_	
100-4	19089-19091	as	_	
100-5	19092-19093	a	_	
100-6	19094-19102	separate	_	
100-7	19103-19109	factor	_	
100-8	19110-19117	because	_	
100-9	19118-19120	it	_	
100-10	19121-19131	influences	_	
100-11	19132-19139	tobacco	_	
100-12	19140-19150	withdrawal	_	
100-13	19151-19159	symptoms	_	
100-14	19160-19161	(	_	
100-15	19161-19164	e.g	_	
100-16	19164-19165	.	_	
100-17	19165-19166	,	_	
100-18	19166-19167	)	_	
100-19	19167-19168	.	_	

#Text=All analyses were performed in SPSS.
101-1	19169-19172	All	_	
101-2	19173-19181	analyses	_	
101-3	19182-19186	were	_	
101-4	19187-19196	performed	_	
101-5	19197-19199	in	_	
101-6	19200-19204	SPSS	_	
101-7	19204-19205	.	_	

#Text=Bonferroni corrections for all higher-level tests involving the 2 raphe nuclei were applied.
102-1	19206-19216	Bonferroni	_	
102-2	19217-19228	corrections	_	
102-3	19229-19232	for	_	
102-4	19233-19236	all	_	
102-5	19237-19249	higher-level	_	
102-6	19250-19255	tests	_	
102-7	19256-19265	involving	_	
102-8	19266-19269	the	_	
102-9	19270-19271	2	_	
102-10	19272-19277	raphe	_	
102-11	19278-19284	nuclei	_	
102-12	19285-19289	were	_	
102-13	19290-19297	applied	_	
102-14	19297-19298	.	_	

#Text=However, given the role of serotonergic function in affective disorders, the hypotheses primarily tested relationships between raphe nuclei connectivity and psychological withdrawal; relationships between connectivity and craving were secondarily considered.
103-1	19299-19306	However	_	
103-2	19306-19307	,	_	
103-3	19308-19313	given	_	
103-4	19314-19317	the	_	
103-5	19318-19322	role	_	
103-6	19323-19325	of	_	
103-7	19326-19338	serotonergic	_	
103-8	19339-19347	function	_	
103-9	19348-19350	in	_	
103-10	19351-19360	affective	_	
103-11	19361-19370	disorders	_	
103-12	19370-19371	,	_	
103-13	19372-19375	the	_	
103-14	19376-19386	hypotheses	_	
103-15	19387-19396	primarily	_	
103-16	19397-19403	tested	_	
103-17	19404-19417	relationships	_	
103-18	19418-19425	between	_	
103-19	19426-19431	raphe	_	
103-20	19432-19438	nuclei	_	
103-21	19439-19451	connectivity	_	
103-22	19452-19455	and	_	
103-23	19456-19469	psychological	_	
103-24	19470-19480	withdrawal	_	
103-25	19480-19481	;	_	
103-26	19482-19495	relationships	_	
103-27	19496-19503	between	_	
103-28	19504-19516	connectivity	_	
103-29	19517-19520	and	_	
103-30	19521-19528	craving	_	
103-31	19529-19533	were	_	
103-32	19534-19545	secondarily	_	
103-33	19546-19556	considered	_	
103-34	19556-19557	.	_	

#Text=As such, Bonferroni corrections for the number of measures were not performed.
104-1	19558-19560	As	_	
104-2	19561-19565	such	_	
104-3	19565-19566	,	_	
104-4	19567-19577	Bonferroni	_	
104-5	19578-19589	corrections	_	
104-6	19590-19593	for	_	
104-7	19594-19597	the	_	
104-8	19598-19604	number	_	
104-9	19605-19607	of	_	
104-10	19608-19616	measures	_	
104-11	19617-19621	were	_	
104-12	19622-19625	not	_	
104-13	19626-19635	performed	_	
104-14	19635-19636	.	_	

#Text=Study 2
#Text=To test for associations of psychological withdrawal and craving with connectivity of the raphe nuclei with the hippocampal complex during abstinence, 2 separate group level analyses (one per self-report measure) were performed using FSL’s FLAME1 modeling with outlier deweighting; these models contained either psychological withdrawal or craving scores as one EV.
105-1	19637-19642	Study	_	
105-2	19643-19644	2	_	
105-3	19645-19647	To	_	
105-4	19648-19652	test	_	
105-5	19653-19656	for	_	
105-6	19657-19669	associations	_	
105-7	19670-19672	of	_	
105-8	19673-19686	psychological	_	
105-9	19687-19697	withdrawal	_	
105-10	19698-19701	and	_	
105-11	19702-19709	craving	_	
105-12	19710-19714	with	_	
105-13	19715-19727	connectivity	_	
105-14	19728-19730	of	_	
105-15	19731-19734	the	_	
105-16	19735-19740	raphe	_	
105-17	19741-19747	nuclei	_	
105-18	19748-19752	with	_	
105-19	19753-19756	the	_	
105-20	19757-19768	hippocampal	_	
105-21	19769-19776	complex	_	
105-22	19777-19783	during	_	
105-23	19784-19794	abstinence	_	
105-24	19794-19795	,	_	
105-25	19796-19797	2	_	
105-26	19798-19806	separate	_	
105-27	19807-19812	group	_	
105-28	19813-19818	level	_	
105-29	19819-19827	analyses	_	
105-30	19828-19829	(	_	
105-31	19829-19832	one	_	
105-32	19833-19836	per	_	
105-33	19837-19848	self-report	_	
105-34	19849-19856	measure	_	
105-35	19856-19857	)	_	
105-36	19858-19862	were	_	
105-37	19863-19872	performed	_	
105-38	19873-19878	using	_	
105-39	19879-19882	FSL	_	
105-40	19882-19883	’	_	
105-41	19883-19884	s	_	
105-42	19885-19891	FLAME1	_	
105-43	19892-19900	modeling	_	
105-44	19901-19905	with	_	
105-45	19906-19913	outlier	_	
105-46	19914-19925	deweighting	_	
105-47	19925-19926	;	_	
105-48	19927-19932	these	_	
105-49	19933-19939	models	_	
105-50	19940-19949	contained	_	
105-51	19950-19956	either	_	
105-52	19957-19970	psychological	_	
105-53	19971-19981	withdrawal	_	
105-54	19982-19984	or	_	
105-55	19985-19992	craving	_	
105-56	19993-19999	scores	_	
105-57	20000-20002	as	_	
105-58	20003-20006	one	_	
105-59	20007-20009	EV	_	
105-60	20009-20010	.	_	

#Text=These statistical maps were cluster-corrected for multiple comparisons (voxel height threshold: Z>3.09; cluster significance, P<.05).
106-1	20011-20016	These	_	
106-2	20017-20028	statistical	_	
106-3	20029-20033	maps	_	
106-4	20034-20038	were	_	
106-5	20039-20056	cluster-corrected	_	
106-6	20057-20060	for	_	
106-7	20061-20069	multiple	_	
106-8	20070-20081	comparisons	_	
106-9	20082-20083	(	_	
106-10	20083-20088	voxel	_	
106-11	20089-20095	height	_	
106-12	20096-20105	threshold	_	
106-13	20105-20106	:	_	
106-14	20107-20108	Z	_	
106-15	20108-20109	>	_	
106-16	20109-20113	3.09	_	
106-17	20113-20114	;	_	
106-18	20115-20122	cluster	_	
106-19	20123-20135	significance	_	
106-20	20135-20136	,	_	
106-21	20137-20138	P	_	
106-22	20138-20139	<	_	
106-23	20139-20142	.05	_	
106-24	20142-20143	)	_	
106-25	20143-20144	.	_	

#Text=To test for associations between the smoking-induced change in connectivity and the change in both psychological withdrawal and craving, 2 separate full-factorial ANOVAs were employed with scores on the psychological withdrawal or craving subscales as dependent variables and values of mean pre-post smoking connectivity (z scores) from significant clusters entered as one factor, along with sex.
107-1	20145-20147	To	_	
107-2	20148-20152	test	_	
107-3	20153-20156	for	_	
107-4	20157-20169	associations	_	
107-5	20170-20177	between	_	
107-6	20178-20181	the	_	
107-7	20182-20197	smoking-induced	_	
107-8	20198-20204	change	_	
107-9	20205-20207	in	_	
107-10	20208-20220	connectivity	_	
107-11	20221-20224	and	_	
107-12	20225-20228	the	_	
107-13	20229-20235	change	_	
107-14	20236-20238	in	_	
107-15	20239-20243	both	_	
107-16	20244-20257	psychological	_	
107-17	20258-20268	withdrawal	_	
107-18	20269-20272	and	_	
107-19	20273-20280	craving	_	
107-20	20280-20281	,	_	
107-21	20282-20283	2	_	
107-22	20284-20292	separate	_	
107-23	20293-20307	full-factorial	_	
107-24	20308-20314	ANOVAs	_	
107-25	20315-20319	were	_	
107-26	20320-20328	employed	_	
107-27	20329-20333	with	_	
107-28	20334-20340	scores	_	
107-29	20341-20343	on	_	
107-30	20344-20347	the	_	
107-31	20348-20361	psychological	_	
107-32	20362-20372	withdrawal	_	
107-33	20373-20375	or	_	
107-34	20376-20383	craving	_	
107-35	20384-20393	subscales	_	
107-36	20394-20396	as	_	
107-37	20397-20406	dependent	_	
107-38	20407-20416	variables	_	
107-39	20417-20420	and	_	
107-40	20421-20427	values	_	
107-41	20428-20430	of	_	
107-42	20431-20435	mean	_	
107-43	20436-20444	pre-post	_	
107-44	20445-20452	smoking	_	
107-45	20453-20465	connectivity	_	
107-46	20466-20467	(	_	
107-47	20467-20468	z	_	
107-48	20469-20475	scores	_	
107-49	20475-20476	)	_	
107-50	20477-20481	from	_	
107-51	20482-20493	significant	_	
107-52	20494-20502	clusters	_	
107-53	20503-20510	entered	_	
107-54	20511-20513	as	_	
107-55	20514-20517	one	_	
107-56	20518-20524	factor	_	
107-57	20524-20525	,	_	
107-58	20526-20531	along	_	
107-59	20532-20536	with	_	
107-60	20537-20540	sex	_	
107-61	20540-20541	.	_	

#Text=Bonferroni corrections for the 2 raphe seeds were applied.
108-1	20542-20552	Bonferroni	_	
108-2	20553-20564	corrections	_	
108-3	20565-20568	for	_	
108-4	20569-20572	the	_	
108-5	20573-20574	2	_	
108-6	20575-20580	raphe	_	
108-7	20581-20586	seeds	_	
108-8	20587-20591	were	_	
108-9	20592-20599	applied	_	
108-10	20599-20600	.	_	

#Text=Results
#Text=Study 1
#Text=Self-Reports
#Text=Of the 37 participants who completed testing, 27 were male and 10 were female (mean age 19.52±2.20 years).
109-1	20601-20608	Results	_	
109-2	20609-20614	Study	_	
109-3	20615-20616	1	_	
109-4	20617-20629	Self-Reports	_	
109-5	20630-20632	Of	_	
109-6	20633-20636	the	_	
109-7	20637-20639	37	_	
109-8	20640-20652	participants	_	
109-9	20653-20656	who	_	
109-10	20657-20666	completed	_	
109-11	20667-20674	testing	_	
109-12	20674-20675	,	_	
109-13	20676-20678	27	_	
109-14	20679-20683	were	_	
109-15	20684-20688	male	_	
109-16	20689-20692	and	_	
109-17	20693-20695	10	_	
109-18	20696-20700	were	_	
109-19	20701-20707	female	_	
109-20	20708-20709	(	_	
109-21	20709-20713	mean	_	
109-22	20714-20717	age	_	
109-23	20718-20723	19.52	_	
109-24	20723-20724	±	_	
109-25	20724-20728	2.20	_	
109-26	20729-20734	years	_	
109-27	20734-20735	)	_	
109-28	20735-20736	.	_	

#Text=A full description of participant characteristics for study 1 can be seen in Table 1.
110-1	20737-20738	A	_	
110-2	20739-20743	full	_	
110-3	20744-20755	description	_	
110-4	20756-20758	of	_	
110-5	20759-20770	participant	_	
110-6	20771-20786	characteristics	_	
110-7	20787-20790	for	_	
110-8	20791-20796	study	_	
110-9	20797-20798	1	_	
110-10	20799-20802	can	_	
110-11	20803-20805	be	_	
110-12	20806-20810	seen	_	
110-13	20811-20813	in	_	
110-14	20814-20819	Table	_	
110-15	20820-20821	1	_	
110-16	20821-20822	.	_	

#Text=A full-factorial ANOVA, constructed to examine the effects of smoking status, sex, and the interaction between the 2 on age of participants, showed no difference between smokers and nonsmokers in terms of age (smokers: 19.11±4.60 years; nonsmokers: 19.89±1.20 years; F(1,33)=0.381, P=.541).
111-1	20823-20824	A	_	
111-2	20825-20839	full-factorial	_	
111-3	20840-20845	ANOVA	_	
111-4	20845-20846	,	_	
111-5	20847-20858	constructed	_	
111-6	20859-20861	to	_	
111-7	20862-20869	examine	_	
111-8	20870-20873	the	_	
111-9	20874-20881	effects	_	
111-10	20882-20884	of	_	
111-11	20885-20892	smoking	_	
111-12	20893-20899	status	_	
111-13	20899-20900	,	_	
111-14	20901-20904	sex	_	
111-15	20904-20905	,	_	
111-16	20906-20909	and	_	
111-17	20910-20913	the	_	
111-18	20914-20925	interaction	_	
111-19	20926-20933	between	_	
111-20	20934-20937	the	_	
111-21	20938-20939	2	_	
111-22	20940-20942	on	_	
111-23	20943-20946	age	_	
111-24	20947-20949	of	_	
111-25	20950-20962	participants	_	
111-26	20962-20963	,	_	
111-27	20964-20970	showed	_	
111-28	20971-20973	no	_	
111-29	20974-20984	difference	_	
111-30	20985-20992	between	_	
111-31	20993-21000	smokers	_	
111-32	21001-21004	and	_	
111-33	21005-21015	nonsmokers	_	
111-34	21016-21018	in	_	
111-35	21019-21024	terms	_	
111-36	21025-21027	of	_	
111-37	21028-21031	age	_	
111-38	21032-21033	(	_	
111-39	21033-21040	smokers	_	
111-40	21040-21041	:	_	
111-41	21042-21047	19.11	_	
111-42	21047-21048	±	_	
111-43	21048-21052	4.60	_	
111-44	21053-21058	years	_	
111-45	21058-21059	;	_	
111-46	21060-21070	nonsmokers	_	
111-47	21070-21071	:	_	
111-48	21072-21077	19.89	_	
111-49	21077-21078	±	_	
111-50	21078-21082	1.20	_	
111-51	21083-21088	years	_	
111-52	21088-21089	;	_	
111-53	21090-21091	F	_	
111-54	21091-21092	(	_	
111-55	21092-21096	1,33	_	
111-56	21096-21097	)	_	
111-57	21097-21098	=	_	
111-58	21098-21103	0.381	_	
111-59	21103-21104	,	_	
111-60	21105-21106	P	_	
111-61	21106-21107	=	_	
111-62	21107-21111	.541	_	
111-63	21111-21112	)	_	
111-64	21112-21113	.	_	

#Text=There was also no main effect of sex on age (males: 19.82±0.96 years; females: 1.940±1.27 years; F(1,33)=2.297, P=.179), and no smoking-status-by-sex interaction (F=(1,33)=0.700, p=.409).
112-1	21114-21119	There	_	
112-2	21120-21123	was	_	
112-3	21124-21128	also	_	
112-4	21129-21131	no	_	
112-5	21132-21136	main	_	
112-6	21137-21143	effect	_	
112-7	21144-21146	of	_	
112-8	21147-21150	sex	_	
112-9	21151-21153	on	_	
112-10	21154-21157	age	_	
112-11	21158-21159	(	_	
112-12	21159-21164	males	_	
112-13	21164-21165	:	_	
112-14	21166-21171	19.82	_	
112-15	21171-21172	±	_	
112-16	21172-21176	0.96	_	
112-17	21177-21182	years	_	
112-18	21182-21183	;	_	
112-19	21184-21191	females	_	
112-20	21191-21192	:	_	
112-21	21193-21198	1.940	_	
112-22	21198-21199	±	_	
112-23	21199-21203	1.27	_	
112-24	21204-21209	years	_	
112-25	21209-21210	;	_	
112-26	21211-21212	F	_	
112-27	21212-21213	(	_	
112-28	21213-21217	1,33	_	
112-29	21217-21218	)	_	
112-30	21218-21219	=	_	
112-31	21219-21224	2.297	_	
112-32	21224-21225	,	_	
112-33	21226-21227	P	_	
112-34	21227-21228	=	_	
112-35	21228-21232	.179	_	
112-36	21232-21233	)	_	
112-37	21233-21234	,	_	
112-38	21235-21238	and	_	
112-39	21239-21241	no	_	
112-40	21242-21263	smoking-status-by-sex	_	
112-41	21264-21275	interaction	_	
112-42	21276-21277	(	_	
112-43	21277-21278	F	_	
112-44	21278-21279	=	_	
112-45	21279-21280	(	_	
112-46	21280-21284	1,33	_	
112-47	21284-21285	)	_	
112-48	21285-21286	=	_	
112-49	21286-21291	0.700	_	
112-50	21291-21292	,	_	
112-51	21293-21294	p	_	
112-52	21294-21295	=	_	
112-53	21295-21299	.409	_	
112-54	21299-21300	)	_	
112-55	21300-21301	.	_	

#Text=Psychological withdrawal and craving were not significantly correlated (r=0.293, P=.239).
113-1	21302-21315	Psychological	_	
113-2	21316-21326	withdrawal	_	
113-3	21327-21330	and	_	
113-4	21331-21338	craving	_	
113-5	21339-21343	were	_	
113-6	21344-21347	not	_	
113-7	21348-21361	significantly	_	
113-8	21362-21372	correlated	_	
113-9	21373-21374	(	_	
113-10	21374-21375	r	_	
113-11	21375-21376	=	_	
113-12	21376-21381	0.293	_	
113-13	21381-21382	,	_	
113-14	21383-21384	P	_	
113-15	21384-21385	=	_	
113-16	21385-21389	.239	_	
113-17	21389-21390	)	_	
113-18	21390-21391	.	_	

#Text=Participant Characteristics
#Text=\tStudy 1\tStudy 2\t \t\t(Smokers)\t(Nonsmokers)\t(Smokers)\t \tn\t18\t19\t21\t \tSex (M/F)\t14/4\t13/6\t11/10\t \tAge (y)a\t19.11 (4.60)\t19.89 (1.20)\t22.28 (2.19)\t \tEducation (y)a\t10.78 (1.38)\t11.23 (1.45)\t13.79 (1.70)\t \tEthnicity (no. of participants)\t\t\t\t \t White Caucasian\t13\t12\t19\t \t African American\t0\t1\t10\t \t Asian American\t2\t2\t8\t \t Hispanic\t2\t2\t6\t \t Other\t1\t2\t3\t \tCigarette smokinga\t\t\t\t \t Age of first use (y)\t16.50 (2.17)\t-\t16.37 (2.20)\t \t Cigarettes per day\t9.31 (6.78)\t-\t11.59 (6.17)\t \t Nicotine dependencea\t2.57 (2.38)\t-\t3.55 (2.03)\t \tSubstance use a\t\t\t\t \t Marijuana (days used in past 30)\t0.73 (0.48)\t0.52 (0.54)\t1.43 (2.10)\t \t Alcohol (drinks/week)\t1.12 (2.31)\t0.98 (1.73)\t2.92 (3.89)\t \t
#Text=aDenotes mean (SD).
114-1	21392-21403	Participant	_	
114-2	21404-21419	Characteristics	_	
114-3	21421-21426	Study	_	
114-4	21427-21428	1	_	
114-5	21429-21434	Study	_	
114-6	21435-21436	2	_	
114-7	21440-21441	(	_	
114-8	21441-21448	Smokers	_	
114-9	21448-21449	)	_	
114-10	21450-21451	(	_	
114-11	21451-21461	Nonsmokers	_	
114-12	21461-21462	)	_	
114-13	21463-21464	(	_	
114-14	21464-21471	Smokers	_	
114-15	21471-21472	)	_	
114-16	21475-21476	n	_	
114-17	21477-21479	18	_	
114-18	21480-21482	19	_	
114-19	21483-21485	21	_	
114-20	21488-21491	Sex	_	
114-21	21492-21493	(	_	
114-22	21493-21494	M	_	
114-23	21494-21495	/	_	
114-24	21495-21496	F	_	
114-25	21496-21497	)	_	
114-26	21498-21500	14	_	
114-27	21500-21501	/	_	
114-28	21501-21502	4	_	
114-29	21503-21505	13	_	
114-30	21505-21506	/	_	
114-31	21506-21507	6	_	
114-32	21508-21510	11	_	
114-33	21510-21511	/	_	
114-34	21511-21513	10	_	
114-35	21516-21519	Age	_	
114-36	21520-21521	(	_	
114-37	21521-21522	y	_	
114-38	21522-21523	)	_	
114-39	21523-21524	a	_	
114-40	21525-21530	19.11	_	
114-41	21531-21532	(	_	
114-42	21532-21536	4.60	_	
114-43	21536-21537	)	_	
114-44	21538-21543	19.89	_	
114-45	21544-21545	(	_	
114-46	21545-21549	1.20	_	
114-47	21549-21550	)	_	
114-48	21551-21556	22.28	_	
114-49	21557-21558	(	_	
114-50	21558-21562	2.19	_	
114-51	21562-21563	)	_	
114-52	21566-21575	Education	_	
114-53	21576-21577	(	_	
114-54	21577-21578	y	_	
114-55	21578-21579	)	_	
114-56	21579-21580	a	_	
114-57	21581-21586	10.78	_	
114-58	21587-21588	(	_	
114-59	21588-21592	1.38	_	
114-60	21592-21593	)	_	
114-61	21594-21599	11.23	_	
114-62	21600-21601	(	_	
114-63	21601-21605	1.45	_	
114-64	21605-21606	)	_	
114-65	21607-21612	13.79	_	
114-66	21613-21614	(	_	
114-67	21614-21618	1.70	_	
114-68	21618-21619	)	_	
114-69	21622-21631	Ethnicity	_	
114-70	21632-21633	(	_	
114-71	21633-21635	no	_	
114-72	21635-21636	.	_	
114-73	21637-21639	of	_	
114-74	21640-21652	participants	_	
114-75	21652-21653	)	_	
114-76	21660-21665	White	_	
114-77	21666-21675	Caucasian	_	
114-78	21676-21678	13	_	
114-79	21679-21681	12	_	
114-80	21682-21684	19	_	
114-81	21688-21695	African	_	
114-82	21696-21704	American	_	
114-83	21705-21706	0	_	
114-84	21707-21708	1	_	
114-85	21709-21711	10	_	
114-86	21715-21720	Asian	_	
114-87	21721-21729	American	_	
114-88	21730-21731	2	_	
114-89	21732-21733	2	_	
114-90	21734-21735	8	_	
114-91	21739-21747	Hispanic	_	
114-92	21748-21749	2	_	
114-93	21750-21751	2	_	
114-94	21752-21753	6	_	
114-95	21757-21762	Other	_	
114-96	21763-21764	1	_	
114-97	21765-21766	2	_	
114-98	21767-21768	3	_	
114-99	21771-21780	Cigarette	_	
114-100	21781-21789	smokinga	_	
114-101	21796-21799	Age	_	
114-102	21800-21802	of	_	
114-103	21803-21808	first	_	
114-104	21809-21812	use	_	
114-105	21813-21814	(	_	
114-106	21814-21815	y	_	
114-107	21815-21816	)	_	
114-108	21817-21822	16.50	_	
114-109	21823-21824	(	_	
114-110	21824-21828	2.17	_	
114-111	21828-21829	)	_	
114-112	21830-21831	-	_	
114-113	21832-21837	16.37	_	
114-114	21838-21839	(	_	
114-115	21839-21843	2.20	_	
114-116	21843-21844	)	_	
114-117	21848-21858	Cigarettes	_	
114-118	21859-21862	per	_	
114-119	21863-21866	day	_	
114-120	21867-21871	9.31	_	
114-121	21872-21873	(	_	
114-122	21873-21877	6.78	_	
114-123	21877-21878	)	_	
114-124	21879-21880	-	_	
114-125	21881-21886	11.59	_	
114-126	21887-21888	(	_	
114-127	21888-21892	6.17	_	
114-128	21892-21893	)	_	
114-129	21897-21905	Nicotine	_	
114-130	21906-21917	dependencea	_	
114-131	21918-21922	2.57	_	
114-132	21923-21924	(	_	
114-133	21924-21928	2.38	_	
114-134	21928-21929	)	_	
114-135	21930-21931	-	_	
114-136	21932-21936	3.55	_	
114-137	21937-21938	(	_	
114-138	21938-21942	2.03	_	
114-139	21942-21943	)	_	
114-140	21946-21955	Substance	_	
114-141	21956-21959	use	_	
114-142	21960-21961	a	_	
114-143	21968-21977	Marijuana	_	
114-144	21978-21979	(	_	
114-145	21979-21983	days	_	
114-146	21984-21988	used	_	
114-147	21989-21991	in	_	
114-148	21992-21996	past	_	
114-149	21997-21999	30	_	
114-150	21999-22000	)	_	
114-151	22001-22005	0.73	_	
114-152	22006-22007	(	_	
114-153	22007-22011	0.48	_	
114-154	22011-22012	)	_	
114-155	22013-22017	0.52	_	
114-156	22018-22019	(	_	
114-157	22019-22023	0.54	_	
114-158	22023-22024	)	_	
114-159	22025-22029	1.43	_	
114-160	22030-22031	(	_	
114-161	22031-22035	2.10	_	
114-162	22035-22036	)	_	
114-163	22040-22047	Alcohol	_	
114-164	22048-22049	(	_	
114-165	22049-22055	drinks	_	
114-166	22055-22056	/	_	
114-167	22056-22060	week	_	
114-168	22060-22061	)	_	
114-169	22062-22066	1.12	_	
114-170	22067-22068	(	_	
114-171	22068-22072	2.31	_	
114-172	22072-22073	)	_	
114-173	22074-22078	0.98	_	
114-174	22079-22080	(	_	
114-175	22080-22084	1.73	_	
114-176	22084-22085	)	_	
114-177	22086-22090	2.92	_	
114-178	22091-22092	(	_	
114-179	22092-22096	3.89	_	
114-180	22096-22097	)	_	
114-181	22101-22109	aDenotes	_	
114-182	22110-22114	mean	_	
114-183	22115-22116	(	_	
114-184	22116-22118	SD	_	
114-185	22118-22119	)	_	
114-186	22119-22120	.	_	

#Text=Two of the participants were statistical outliers with respect to duration of smoking abstinence prior to testing (155 minutes and 142 minutes; group mean=41.56 minutes, SD=36.26) but not for psychological withdrawal (2.63 and 2.55, respectively; group mean=2.48, SD=0.61) or craving (4.40 and 1.00, respectively; group mean=2.12, SD=1.23).
115-1	22121-22124	Two	_	
115-2	22125-22127	of	_	
115-3	22128-22131	the	_	
115-4	22132-22144	participants	_	
115-5	22145-22149	were	_	
115-6	22150-22161	statistical	_	
115-7	22162-22170	outliers	_	
115-8	22171-22175	with	_	
115-9	22176-22183	respect	_	
115-10	22184-22186	to	_	
115-11	22187-22195	duration	_	
115-12	22196-22198	of	_	
115-13	22199-22206	smoking	_	
115-14	22207-22217	abstinence	_	
115-15	22218-22223	prior	_	
115-16	22224-22226	to	_	
115-17	22227-22234	testing	_	
115-18	22235-22236	(	_	
115-19	22236-22239	155	_	
115-20	22240-22247	minutes	_	
115-21	22248-22251	and	_	
115-22	22252-22255	142	_	
115-23	22256-22263	minutes	_	
115-24	22263-22264	;	_	
115-25	22265-22270	group	_	
115-26	22271-22275	mean	_	
115-27	22275-22276	=	_	
115-28	22276-22281	41.56	_	
115-29	22282-22289	minutes	_	
115-30	22289-22290	,	_	
115-31	22291-22293	SD	_	
115-32	22293-22294	=	_	
115-33	22294-22299	36.26	_	
115-34	22299-22300	)	_	
115-35	22301-22304	but	_	
115-36	22305-22308	not	_	
115-37	22309-22312	for	_	
115-38	22313-22326	psychological	_	
115-39	22327-22337	withdrawal	_	
115-40	22338-22339	(	_	
115-41	22339-22343	2.63	_	
115-42	22344-22347	and	_	
115-43	22348-22352	2.55	_	
115-44	22352-22353	,	_	
115-45	22354-22366	respectively	_	
115-46	22366-22367	;	_	
115-47	22368-22373	group	_	
115-48	22374-22378	mean	_	
115-49	22378-22379	=	_	
115-50	22379-22383	2.48	_	
115-51	22383-22384	,	_	
115-52	22385-22387	SD	_	
115-53	22387-22388	=	_	
115-54	22388-22392	0.61	_	
115-55	22392-22393	)	_	
115-56	22394-22396	or	_	
115-57	22397-22404	craving	_	
115-58	22405-22406	(	_	
115-59	22406-22410	4.40	_	
115-60	22411-22414	and	_	
115-61	22415-22419	1.00	_	
115-62	22419-22420	,	_	
115-63	22421-22433	respectively	_	
115-64	22433-22434	;	_	
115-65	22435-22440	group	_	
115-66	22441-22445	mean	_	
115-67	22445-22446	=	_	
115-68	22446-22450	2.12	_	
115-69	22450-22451	,	_	
115-70	22452-22454	SD	_	
115-71	22454-22455	=	_	
115-72	22455-22459	1.23	_	
115-73	22459-22460	)	_	
115-74	22460-22461	.	_	

#Text=The time since last cigarette was not correlated with psychological withdrawal (r=0.221, P=.278) or craving (r=-0.092, P=.716).
116-1	22462-22465	The	_	
116-2	22466-22470	time	_	
116-3	22471-22476	since	_	
116-4	22477-22481	last	_	
116-5	22482-22491	cigarette	_	
116-6	22492-22495	was	_	
116-7	22496-22499	not	_	
116-8	22500-22510	correlated	_	
116-9	22511-22515	with	_	
116-10	22516-22529	psychological	_	
116-11	22530-22540	withdrawal	_	
116-12	22541-22542	(	_	
116-13	22542-22543	r	_	
116-14	22543-22544	=	_	
116-15	22544-22549	0.221	_	
116-16	22549-22550	,	_	
116-17	22551-22552	P	_	
116-18	22552-22553	=	_	
116-19	22553-22557	.278	_	
116-20	22557-22558	)	_	
116-21	22559-22561	or	_	
116-22	22562-22569	craving	_	
116-23	22570-22571	(	_	
116-24	22571-22572	r	_	
116-25	22572-22573	=	_	
116-26	22573-22574	-	_	
116-27	22574-22579	0.092	_	
116-28	22579-22580	,	_	
116-29	22581-22582	P	_	
116-30	22582-22583	=	_	
116-31	22583-22587	.716	_	
116-32	22587-22588	)	_	
116-33	22588-22589	.	_	

#Text=The full-factorial ANOVA revealed that there was no main effect of sex on either psychological withdrawal (F(1,16)=0.022, P=.884), craving (F(1,16)=0.415, P=.528), or FTND (F(1,16)=0.573, P=.460).
117-1	22590-22593	The	_	
117-2	22594-22608	full-factorial	_	
117-3	22609-22614	ANOVA	_	
117-4	22615-22623	revealed	_	
117-5	22624-22628	that	_	
117-6	22629-22634	there	_	
117-7	22635-22638	was	_	
117-8	22639-22641	no	_	
117-9	22642-22646	main	_	
117-10	22647-22653	effect	_	
117-11	22654-22656	of	_	
117-12	22657-22660	sex	_	
117-13	22661-22663	on	_	
117-14	22664-22670	either	_	
117-15	22671-22684	psychological	_	
117-16	22685-22695	withdrawal	_	
117-17	22696-22697	(	_	
117-18	22697-22698	F	_	
117-19	22698-22699	(	_	
117-20	22699-22703	1,16	_	
117-21	22703-22704	)	_	
117-22	22704-22705	=	_	
117-23	22705-22710	0.022	_	
117-24	22710-22711	,	_	
117-25	22712-22713	P	_	
117-26	22713-22714	=	_	
117-27	22714-22718	.884	_	
117-28	22718-22719	)	_	
117-29	22719-22720	,	_	
117-30	22721-22728	craving	_	
117-31	22729-22730	(	_	
117-32	22730-22731	F	_	
117-33	22731-22732	(	_	
117-34	22732-22736	1,16	_	
117-35	22736-22737	)	_	
117-36	22737-22738	=	_	
117-37	22738-22743	0.415	_	
117-38	22743-22744	,	_	
117-39	22745-22746	P	_	
117-40	22746-22747	=	_	
117-41	22747-22751	.528	_	
117-42	22751-22752	)	_	
117-43	22752-22753	,	_	
117-44	22754-22756	or	_	
117-45	22757-22761	FTND	_	
117-46	22762-22763	(	_	
117-47	22763-22764	F	_	
117-48	22764-22765	(	_	
117-49	22765-22769	1,16	_	
117-50	22769-22770	)	_	
117-51	22770-22771	=	_	
117-52	22771-22776	0.573	_	
117-53	22776-22777	,	_	
117-54	22778-22779	P	_	
117-55	22779-22780	=	_	
117-56	22780-22784	.460	_	
117-57	22784-22785	)	_	
117-58	22785-22786	.	_	

#Text=Resting-State Connectivity
#Text=The mean number of images regressed out was 7.56 (SD=5.44, range 0–21) for the smokers and 6.63 (SD=5.44, range 0–19) for the nonsmokers.
118-1	22787-22800	Resting-State	_	
118-2	22801-22813	Connectivity	_	
118-3	22814-22817	The	_	
118-4	22818-22822	mean	_	
118-5	22823-22829	number	_	
118-6	22830-22832	of	_	
118-7	22833-22839	images	_	
118-8	22840-22849	regressed	_	
118-9	22850-22853	out	_	
118-10	22854-22857	was	_	
118-11	22858-22862	7.56	_	
118-12	22863-22864	(	_	
118-13	22864-22866	SD	_	
118-14	22866-22867	=	_	
118-15	22867-22871	5.44	_	
118-16	22871-22872	,	_	
118-17	22873-22878	range	_	
118-18	22879-22880	0	_	
118-19	22880-22881	–	_	
118-20	22881-22883	21	_	
118-21	22883-22884	)	_	
118-22	22885-22888	for	_	
118-23	22889-22892	the	_	
118-24	22893-22900	smokers	_	
118-25	22901-22904	and	_	
118-26	22905-22909	6.63	_	
118-27	22910-22911	(	_	
118-28	22911-22913	SD	_	
118-29	22913-22914	=	_	
118-30	22914-22918	5.44	_	
118-31	22918-22919	,	_	
118-32	22920-22925	range	_	
118-33	22926-22927	0	_	
118-34	22927-22928	–	_	
118-35	22928-22930	19	_	
118-36	22930-22931	)	_	
118-37	22932-22935	for	_	
118-38	22936-22939	the	_	
118-39	22940-22950	nonsmokers	_	
118-40	22950-22951	.	_	

#Text=There was no significant difference between the number of images regressed out for each group (F(1,35)=0.269, P=.607).
119-1	22952-22957	There	_	
119-2	22958-22961	was	_	
119-3	22962-22964	no	_	
119-4	22965-22976	significant	_	
119-5	22977-22987	difference	_	
119-6	22988-22995	between	_	
119-7	22996-22999	the	_	
119-8	23000-23006	number	_	
119-9	23007-23009	of	_	
119-10	23010-23016	images	_	
119-11	23017-23026	regressed	_	
119-12	23027-23030	out	_	
119-13	23031-23034	for	_	
119-14	23035-23039	each	_	
119-15	23040-23045	group	_	
119-16	23046-23047	(	_	
119-17	23047-23048	F	_	
119-18	23048-23049	(	_	
119-19	23049-23053	1,35	_	
119-20	23053-23054	)	_	
119-21	23054-23055	=	_	
119-22	23055-23060	0.269	_	
119-23	23060-23061	,	_	
119-24	23062-23063	P	_	
119-25	23063-23064	=	_	
119-26	23064-23068	.607	_	
119-27	23068-23069	)	_	
119-28	23069-23070	.	_	

#Text=The voxel-wise GLM analysis revealed that, compared to nonsmokers, smokers displayed lower functional connectivity of the median raphe nucleus with the right hippocampal complex (Figure 1).
120-1	23071-23074	The	_	
120-2	23075-23085	voxel-wise	_	
120-3	23086-23089	GLM	_	
120-4	23090-23098	analysis	_	
120-5	23099-23107	revealed	_	
120-6	23108-23112	that	_	
120-7	23112-23113	,	_	
120-8	23114-23122	compared	_	
120-9	23123-23125	to	_	
120-10	23126-23136	nonsmokers	_	
120-11	23136-23137	,	_	
120-12	23138-23145	smokers	_	
120-13	23146-23155	displayed	_	
120-14	23156-23161	lower	_	
120-15	23162-23172	functional	_	
120-16	23173-23185	connectivity	_	
120-17	23186-23188	of	_	
120-18	23189-23192	the	_	
120-19	23193-23199	median	_	
120-20	23200-23205	raphe	_	
120-21	23206-23213	nucleus	_	
120-22	23214-23218	with	_	
120-23	23219-23222	the	_	
120-24	23223-23228	right	_	
120-25	23229-23240	hippocampal	_	
120-26	23241-23248	complex	_	
120-27	23249-23250	(	_	
120-28	23250-23256	Figure	_	
120-29	23257-23258	1	_	
120-30	23258-23259	)	_	
120-31	23259-23260	.	_	

#Text=There was no group difference in connectivity involving the dorsal raphe nucleus and no significant results observed for the “smokers>nonsmokers” contrast.
121-1	23261-23266	There	_	
121-2	23267-23270	was	_	
121-3	23271-23273	no	_	
121-4	23274-23279	group	_	
121-5	23280-23290	difference	_	
121-6	23291-23293	in	_	
121-7	23294-23306	connectivity	_	
121-8	23307-23316	involving	_	
121-9	23317-23320	the	_	
121-10	23321-23327	dorsal	_	
121-11	23328-23333	raphe	_	
121-12	23334-23341	nucleus	_	
121-13	23342-23345	and	_	
121-14	23346-23348	no	_	
121-15	23349-23360	significant	_	
121-16	23361-23368	results	_	
121-17	23369-23377	observed	_	
121-18	23378-23381	for	_	
121-19	23382-23385	the	_	
121-20	23386-23387	“	_	
121-21	23387-23394	smokers	_	
121-22	23394-23395	>	_	
121-23	23395-23405	nonsmokers	_	
121-24	23405-23406	”	_	
121-25	23407-23415	contrast	_	
121-26	23415-23416	.	_	

#Text=Group difference in connectivity of the median raphe nucleus.
122-1	23417-23422	Group	_	
122-2	23423-23433	difference	_	
122-3	23434-23436	in	_	
122-4	23437-23449	connectivity	_	
122-5	23450-23452	of	_	
122-6	23453-23456	the	_	
122-7	23457-23463	median	_	
122-8	23464-23469	raphe	_	
122-9	23470-23477	nucleus	_	
122-10	23477-23478	.	_	

#Text=Data shown are from Study 1.
123-1	23479-23483	Data	_	
123-2	23484-23489	shown	_	
123-3	23490-23493	are	_	
123-4	23494-23498	from	_	
123-5	23499-23504	Study	_	
123-6	23505-23506	1	_	
123-7	23506-23507	.	_	

#Text=(A) Cluster denotes the region in which connectivity with the median raphe nucleus is weaker in smokers than in nonsmokers.
124-1	23508-23509	(	_	
124-2	23509-23510	A	_	
124-3	23510-23511	)	_	
124-4	23512-23519	Cluster	_	
124-5	23520-23527	denotes	_	
124-6	23528-23531	the	_	
124-7	23532-23538	region	_	
124-8	23539-23541	in	_	
124-9	23542-23547	which	_	
124-10	23548-23560	connectivity	_	
124-11	23561-23565	with	_	
124-12	23566-23569	the	_	
124-13	23570-23576	median	_	
124-14	23577-23582	raphe	_	
124-15	23583-23590	nucleus	_	
124-16	23591-23593	is	_	
124-17	23594-23600	weaker	_	
124-18	23601-23603	in	_	
124-19	23604-23611	smokers	_	
124-20	23612-23616	than	_	
124-21	23617-23619	in	_	
124-22	23620-23630	nonsmokers	_	
124-23	23630-23631	.	_	

#Text=Result is cluster-corrected for multiple comparisons (voxel height threshold: Z>3.09; cluster significance: P<.05).
125-1	23632-23638	Result	_	
125-2	23639-23641	is	_	
125-3	23642-23659	cluster-corrected	_	
125-4	23660-23663	for	_	
125-5	23664-23672	multiple	_	
125-6	23673-23684	comparisons	_	
125-7	23685-23686	(	_	
125-8	23686-23691	voxel	_	
125-9	23692-23698	height	_	
125-10	23699-23708	threshold	_	
125-11	23708-23709	:	_	
125-12	23710-23711	Z	_	
125-13	23711-23712	>	_	
125-14	23712-23716	3.09	_	
125-15	23716-23717	;	_	
125-16	23718-23725	cluster	_	
125-17	23726-23738	significance	_	
125-18	23738-23739	:	_	
125-19	23740-23741	P	_	
125-20	23741-23742	<	_	
125-21	23742-23745	.05	_	
125-22	23745-23746	)	_	
125-23	23746-23747	.	_	

#Text=(B) Graph depicts mean Z values from the cluster shown in (A) for the smoking and nonsmoking group and are for illustrative purposes only.
126-1	23748-23749	(	_	
126-2	23749-23750	B	_	
126-3	23750-23751	)	_	
126-4	23752-23757	Graph	_	
126-5	23758-23765	depicts	_	
126-6	23766-23770	mean	_	
126-7	23771-23772	Z	_	
126-8	23773-23779	values	_	
126-9	23780-23784	from	_	
126-10	23785-23788	the	_	
126-11	23789-23796	cluster	_	
126-12	23797-23802	shown	_	
126-13	23803-23805	in	_	
126-14	23806-23807	(	_	
126-15	23807-23808	A	_	
126-16	23808-23809	)	_	
126-17	23810-23813	for	_	
126-18	23814-23817	the	_	
126-19	23818-23825	smoking	_	
126-20	23826-23829	and	_	
126-21	23830-23840	nonsmoking	_	
126-22	23841-23846	group	_	
126-23	23847-23850	and	_	
126-24	23851-23854	are	_	
126-25	23855-23858	for	_	
126-26	23859-23871	illustrative	_	
126-27	23872-23880	purposes	_	
126-28	23881-23885	only	_	
126-29	23885-23886	.	_	

#Text=The full-factorial ANOVA showed that, in smokers, connectivity of the median raphe nucleus with the cluster of voxels within the hippocampal complex shown in Figure 1 was significantly negatively correlated with psychological withdrawal; this relationship survived Bonferroni correction for the 2 raphe seeds (F(1,14)=6.618, P=.022; Bonferroni-corrected P=.043) (Figure 2a).
127-1	23887-23890	The	_	
127-2	23891-23905	full-factorial	_	
127-3	23906-23911	ANOVA	_	
127-4	23912-23918	showed	_	
127-5	23919-23923	that	_	
127-6	23923-23924	,	_	
127-7	23925-23927	in	_	
127-8	23928-23935	smokers	_	
127-9	23935-23936	,	_	
127-10	23937-23949	connectivity	_	
127-11	23950-23952	of	_	
127-12	23953-23956	the	_	
127-13	23957-23963	median	_	
127-14	23964-23969	raphe	_	
127-15	23970-23977	nucleus	_	
127-16	23978-23982	with	_	
127-17	23983-23986	the	_	
127-18	23987-23994	cluster	_	
127-19	23995-23997	of	_	
127-20	23998-24004	voxels	_	
127-21	24005-24011	within	_	
127-22	24012-24015	the	_	
127-23	24016-24027	hippocampal	_	
127-24	24028-24035	complex	_	
127-25	24036-24041	shown	_	
127-26	24042-24044	in	_	
127-27	24045-24051	Figure	_	
127-28	24052-24053	1	_	
127-29	24054-24057	was	_	
127-30	24058-24071	significantly	_	
127-31	24072-24082	negatively	_	
127-32	24083-24093	correlated	_	
127-33	24094-24098	with	_	
127-34	24099-24112	psychological	_	
127-35	24113-24123	withdrawal	_	
127-36	24123-24124	;	_	
127-37	24125-24129	this	_	
127-38	24130-24142	relationship	_	
127-39	24143-24151	survived	_	
127-40	24152-24162	Bonferroni	_	
127-41	24163-24173	correction	_	
127-42	24174-24177	for	_	
127-43	24178-24181	the	_	
127-44	24182-24183	2	_	
127-45	24184-24189	raphe	_	
127-46	24190-24195	seeds	_	
127-47	24196-24197	(	_	
127-48	24197-24198	F	_	
127-49	24198-24199	(	_	
127-50	24199-24203	1,14	_	
127-51	24203-24204	)	_	
127-52	24204-24205	=	_	
127-53	24205-24210	6.618	_	
127-54	24210-24211	,	_	
127-55	24212-24213	P	_	
127-56	24213-24214	=	_	
127-57	24214-24218	.022	_	
127-58	24218-24219	;	_	
127-59	24220-24240	Bonferroni-corrected	_	
127-60	24241-24242	P	_	
127-61	24242-24243	=	_	
127-62	24243-24247	.043	_	
127-63	24247-24248	)	_	
127-64	24249-24250	(	_	
127-65	24250-24256	Figure	_	
127-66	24257-24259	2a	_	
127-67	24259-24260	)	_	
127-68	24260-24261	.	_	

#Text=There was no effect of sex on this relationship (no sex-by-connectivity interaction: F(1,14)=0.578, P=.460).
128-1	24262-24267	There	_	
128-2	24268-24271	was	_	
128-3	24272-24274	no	_	
128-4	24275-24281	effect	_	
128-5	24282-24284	of	_	
128-6	24285-24288	sex	_	
128-7	24289-24291	on	_	
128-8	24292-24296	this	_	
128-9	24297-24309	relationship	_	
128-10	24310-24311	(	_	
128-11	24311-24313	no	_	
128-12	24314-24333	sex-by-connectivity	_	
128-13	24334-24345	interaction	_	
128-14	24345-24346	:	_	
128-15	24347-24348	F	_	
128-16	24348-24349	(	_	
128-17	24349-24353	1,14	_	
128-18	24353-24354	)	_	
128-19	24354-24355	=	_	
128-20	24355-24360	0.578	_	
128-21	24360-24361	,	_	
128-22	24362-24363	P	_	
128-23	24363-24364	=	_	
128-24	24364-24368	.460	_	
128-25	24368-24369	)	_	
128-26	24369-24370	.	_	

#Text=There was no significant correlation of connectivity between the median raphe nucleus and hippocampal complex with craving (F(1,14)=0.014, P=.907) (Figure 2b) and no effect of sex on this relationship (sex-by-connectivity interaction: F(1,14)=2.160, P=.164)
#Text=Relationship of connectivity of the median raphe nucleus and hippocampal complex with psychological withdrawal (A) and craving (B) in smokers.
129-1	24371-24376	There	_	
129-2	24377-24380	was	_	
129-3	24381-24383	no	_	
129-4	24384-24395	significant	_	
129-5	24396-24407	correlation	_	
129-6	24408-24410	of	_	
129-7	24411-24423	connectivity	_	
129-8	24424-24431	between	_	
129-9	24432-24435	the	_	
129-10	24436-24442	median	_	
129-11	24443-24448	raphe	_	
129-12	24449-24456	nucleus	_	
129-13	24457-24460	and	_	
129-14	24461-24472	hippocampal	_	
129-15	24473-24480	complex	_	
129-16	24481-24485	with	_	
129-17	24486-24493	craving	_	
129-18	24494-24495	(	_	
129-19	24495-24496	F	_	
129-20	24496-24497	(	_	
129-21	24497-24501	1,14	_	
129-22	24501-24502	)	_	
129-23	24502-24503	=	_	
129-24	24503-24508	0.014	_	
129-25	24508-24509	,	_	
129-26	24510-24511	P	_	
129-27	24511-24512	=	_	
129-28	24512-24516	.907	_	
129-29	24516-24517	)	_	
129-30	24518-24519	(	_	
129-31	24519-24525	Figure	_	
129-32	24526-24528	2b	_	
129-33	24528-24529	)	_	
129-34	24530-24533	and	_	
129-35	24534-24536	no	_	
129-36	24537-24543	effect	_	
129-37	24544-24546	of	_	
129-38	24547-24550	sex	_	
129-39	24551-24553	on	_	
129-40	24554-24558	this	_	
129-41	24559-24571	relationship	_	
129-42	24572-24573	(	_	
129-43	24573-24592	sex-by-connectivity	_	
129-44	24593-24604	interaction	_	
129-45	24604-24605	:	_	
129-46	24606-24607	F	_	
129-47	24607-24608	(	_	
129-48	24608-24612	1,14	_	
129-49	24612-24613	)	_	
129-50	24613-24614	=	_	
129-51	24614-24619	2.160	_	
129-52	24619-24620	,	_	
129-53	24621-24622	P	_	
129-54	24622-24623	=	_	
129-55	24623-24627	.164	_	
129-56	24627-24628	)	_	
129-57	24629-24641	Relationship	_	
129-58	24642-24644	of	_	
129-59	24645-24657	connectivity	_	
129-60	24658-24660	of	_	
129-61	24661-24664	the	_	
129-62	24665-24671	median	_	
129-63	24672-24677	raphe	_	
129-64	24678-24685	nucleus	_	
129-65	24686-24689	and	_	
129-66	24690-24701	hippocampal	_	
129-67	24702-24709	complex	_	
129-68	24710-24714	with	_	
129-69	24715-24728	psychological	_	
129-70	24729-24739	withdrawal	_	
129-71	24740-24741	(	_	
129-72	24741-24742	A	_	
129-73	24742-24743	)	_	
129-74	24744-24747	and	_	
129-75	24748-24755	craving	_	
129-76	24756-24757	(	_	
129-77	24757-24758	B	_	
129-78	24758-24759	)	_	
129-79	24760-24762	in	_	
129-80	24763-24770	smokers	_	
129-81	24770-24771	.	_	

#Text=Data shown are from Study 1.
130-1	24772-24776	Data	_	
130-2	24777-24782	shown	_	
130-3	24783-24786	are	_	
130-4	24787-24791	from	_	
130-5	24792-24797	Study	_	
130-6	24798-24799	1	_	
130-7	24799-24800	.	_	

#Text=Plots depict Z values from each participant reflecting connectivity strength.
131-1	24801-24806	Plots	_	
131-2	24807-24813	depict	_	
131-3	24814-24815	Z	_	
131-4	24816-24822	values	_	
131-5	24823-24827	from	_	
131-6	24828-24832	each	_	
131-7	24833-24844	participant	_	
131-8	24845-24855	reflecting	_	
131-9	24856-24868	connectivity	_	
131-10	24869-24877	strength	_	
131-11	24877-24878	.	_	

#Text=Study 2
#Text=Pre-smoking
#Text=Self-Reports
#Text=Of the 21 participants who completed testing, 11 were male and 10 were female (mean age 22.28±2.19 years).
132-1	24879-24884	Study	_	
132-2	24885-24886	2	_	
132-3	24887-24898	Pre-smoking	_	
132-4	24899-24911	Self-Reports	_	
132-5	24912-24914	Of	_	
132-6	24915-24918	the	_	
132-7	24919-24921	21	_	
132-8	24922-24934	participants	_	
132-9	24935-24938	who	_	
132-10	24939-24948	completed	_	
132-11	24949-24956	testing	_	
132-12	24956-24957	,	_	
132-13	24958-24960	11	_	
132-14	24961-24965	were	_	
132-15	24966-24970	male	_	
132-16	24971-24974	and	_	
132-17	24975-24977	10	_	
132-18	24978-24982	were	_	
132-19	24983-24989	female	_	
132-20	24990-24991	(	_	
132-21	24991-24995	mean	_	
132-22	24996-24999	age	_	
132-23	25000-25005	22.28	_	
132-24	25005-25006	±	_	
132-25	25006-25010	2.19	_	
132-26	25011-25016	years	_	
132-27	25016-25017	)	_	
132-28	25017-25018	.	_	

#Text=A full description of participant characteristics for study 2 can be seen in Table 1.
133-1	25019-25020	A	_	
133-2	25021-25025	full	_	
133-3	25026-25037	description	_	
133-4	25038-25040	of	_	
133-5	25041-25052	participant	_	
133-6	25053-25068	characteristics	_	
133-7	25069-25072	for	_	
133-8	25073-25078	study	_	
133-9	25079-25080	2	_	
133-10	25081-25084	can	_	
133-11	25085-25087	be	_	
133-12	25088-25092	seen	_	
133-13	25093-25095	in	_	
133-14	25096-25101	Table	_	
133-15	25102-25103	1	_	
133-16	25103-25104	.	_	

#Text=There was no main effect of sex on age (males: 23.08±1.87 years; females: 22.09±2.19 years; F(1,19)=1.239, P=.280).
134-1	25105-25110	There	_	
134-2	25111-25114	was	_	
134-3	25115-25117	no	_	
134-4	25118-25122	main	_	
134-5	25123-25129	effect	_	
134-6	25130-25132	of	_	
134-7	25133-25136	sex	_	
134-8	25137-25139	on	_	
134-9	25140-25143	age	_	
134-10	25144-25145	(	_	
134-11	25145-25150	males	_	
134-12	25150-25151	:	_	
134-13	25152-25157	23.08	_	
134-14	25157-25158	±	_	
134-15	25158-25162	1.87	_	
134-16	25163-25168	years	_	
134-17	25168-25169	;	_	
134-18	25170-25177	females	_	
134-19	25177-25178	:	_	
134-20	25179-25184	22.09	_	
134-21	25184-25185	±	_	
134-22	25185-25189	2.19	_	
134-23	25190-25195	years	_	
134-24	25195-25196	;	_	
134-25	25197-25198	F	_	
134-26	25198-25199	(	_	
134-27	25199-25203	1,19	_	
134-28	25203-25204	)	_	
134-29	25204-25205	=	_	
134-30	25205-25210	1.239	_	
134-31	25210-25211	,	_	
134-32	25212-25213	P	_	
134-33	25213-25214	=	_	
134-34	25214-25218	.280	_	
134-35	25218-25219	)	_	
134-36	25219-25220	.	_	

#Text=The mean psychological withdrawal was 3.32 (SD=1.28), and the mean craving was 5.09 (SD=1.70).
135-1	25221-25224	The	_	
135-2	25225-25229	mean	_	
135-3	25230-25243	psychological	_	
135-4	25244-25254	withdrawal	_	
135-5	25255-25258	was	_	
135-6	25259-25263	3.32	_	
135-7	25264-25265	(	_	
135-8	25265-25267	SD	_	
135-9	25267-25268	=	_	
135-10	25268-25272	1.28	_	
135-11	25272-25273	)	_	
135-12	25273-25274	,	_	
135-13	25275-25278	and	_	
135-14	25279-25282	the	_	
135-15	25283-25287	mean	_	
135-16	25288-25295	craving	_	
135-17	25296-25299	was	_	
135-18	25300-25304	5.09	_	
135-19	25305-25306	(	_	
135-20	25306-25308	SD	_	
135-21	25308-25309	=	_	
135-22	25309-25313	1.70	_	
135-23	25313-25314	)	_	
135-24	25314-25315	.	_	

#Text=The full-factorial ANOVA revealed that there was no main effect of sex on psychological withdrawal (F(1,18)=2.425, P=.136), craving (F(1,18)=1.140, P=.200), or FTND (F(1,18)=0.256, P=.619).
136-1	25316-25319	The	_	
136-2	25320-25334	full-factorial	_	
136-3	25335-25340	ANOVA	_	
136-4	25341-25349	revealed	_	
136-5	25350-25354	that	_	
136-6	25355-25360	there	_	
136-7	25361-25364	was	_	
136-8	25365-25367	no	_	
136-9	25368-25372	main	_	
136-10	25373-25379	effect	_	
136-11	25380-25382	of	_	
136-12	25383-25386	sex	_	
136-13	25387-25389	on	_	
136-14	25390-25403	psychological	_	
136-15	25404-25414	withdrawal	_	
136-16	25415-25416	(	_	
136-17	25416-25417	F	_	
136-18	25417-25418	(	_	
136-19	25418-25422	1,18	_	
136-20	25422-25423	)	_	
136-21	25423-25424	=	_	
136-22	25424-25429	2.425	_	
136-23	25429-25430	,	_	
136-24	25431-25432	P	_	
136-25	25432-25433	=	_	
136-26	25433-25437	.136	_	
136-27	25437-25438	)	_	
136-28	25438-25439	,	_	
136-29	25440-25447	craving	_	
136-30	25448-25449	(	_	
136-31	25449-25450	F	_	
136-32	25450-25451	(	_	
136-33	25451-25455	1,18	_	
136-34	25455-25456	)	_	
136-35	25456-25457	=	_	
136-36	25457-25462	1.140	_	
136-37	25462-25463	,	_	
136-38	25464-25465	P	_	
136-39	25465-25466	=	_	
136-40	25466-25470	.200	_	
136-41	25470-25471	)	_	
136-42	25471-25472	,	_	
136-43	25473-25475	or	_	
136-44	25476-25480	FTND	_	
136-45	25481-25482	(	_	
136-46	25482-25483	F	_	
136-47	25483-25484	(	_	
136-48	25484-25488	1,18	_	
136-49	25488-25489	)	_	
136-50	25489-25490	=	_	
136-51	25490-25495	0.256	_	
136-52	25495-25496	,	_	
136-53	25497-25498	P	_	
136-54	25498-25499	=	_	
136-55	25499-25503	.619	_	
136-56	25503-25504	)	_	
136-57	25504-25505	.	_	

#Text=During abstinence, one participant was an outlier with regard to craving (female; craving=0); therefore, abstinence data from only the remaining 20 participants were analyzed (11 males, 9 females; mean age 22.47±2.23 years).
137-1	25506-25512	During	_	
137-2	25513-25523	abstinence	_	
137-3	25523-25524	,	_	
137-4	25525-25528	one	_	
137-5	25529-25540	participant	_	
137-6	25541-25544	was	_	
137-7	25545-25547	an	_	
137-8	25548-25555	outlier	_	
137-9	25556-25560	with	_	
137-10	25561-25567	regard	_	
137-11	25568-25570	to	_	
137-12	25571-25578	craving	_	
137-13	25579-25580	(	_	
137-14	25580-25586	female	_	
137-15	25586-25587	;	_	
137-16	25588-25595	craving	_	
137-17	25595-25596	=	_	
137-18	25596-25597	0	_	
137-19	25597-25598	)	_	
137-20	25598-25599	;	_	
137-21	25600-25609	therefore	_	
137-22	25609-25610	,	_	
137-23	25611-25621	abstinence	_	
137-24	25622-25626	data	_	
137-25	25627-25631	from	_	
137-26	25632-25636	only	_	
137-27	25637-25640	the	_	
137-28	25641-25650	remaining	_	
137-29	25651-25653	20	_	
137-30	25654-25666	participants	_	
137-31	25667-25671	were	_	
137-32	25672-25680	analyzed	_	
137-33	25681-25682	(	_	
137-34	25682-25684	11	_	
137-35	25685-25690	males	_	
137-36	25690-25691	,	_	
137-37	25692-25693	9	_	
137-38	25694-25701	females	_	
137-39	25701-25702	;	_	
137-40	25703-25707	mean	_	
137-41	25708-25711	age	_	
137-42	25712-25717	22.47	_	
137-43	25717-25718	±	_	
137-44	25718-25722	2.23	_	
137-45	25723-25728	years	_	
137-46	25728-25729	)	_	
137-47	25729-25730	.	_	

#Text=Mean psychological withdrawal was 3.46 (SD=1.15), and mean craving was 5.49 (SD=1.27), with no differences between these 11 males and 9 females [psychological withdrawal: F(1,17)=1.422, P=.248; and craving: F(1,17)=0.022, P=.884].
138-1	25731-25735	Mean	_	
138-2	25736-25749	psychological	_	
138-3	25750-25760	withdrawal	_	
138-4	25761-25764	was	_	
138-5	25765-25769	3.46	_	
138-6	25770-25771	(	_	
138-7	25771-25773	SD	_	
138-8	25773-25774	=	_	
138-9	25774-25778	1.15	_	
138-10	25778-25779	)	_	
138-11	25779-25780	,	_	
138-12	25781-25784	and	_	
138-13	25785-25789	mean	_	
138-14	25790-25797	craving	_	
138-15	25798-25801	was	_	
138-16	25802-25806	5.49	_	
138-17	25807-25808	(	_	
138-18	25808-25810	SD	_	
138-19	25810-25811	=	_	
138-20	25811-25815	1.27	_	
138-21	25815-25816	)	_	
138-22	25816-25817	,	_	
138-23	25818-25822	with	_	
138-24	25823-25825	no	_	
138-25	25826-25837	differences	_	
138-26	25838-25845	between	_	
138-27	25846-25851	these	_	
138-28	25852-25854	11	_	
138-29	25855-25860	males	_	
138-30	25861-25864	and	_	
138-31	25865-25866	9	_	
138-32	25867-25874	females	_	
138-33	25875-25876	[	_	
138-34	25876-25889	psychological	_	
138-35	25890-25900	withdrawal	_	
138-36	25900-25901	:	_	
138-37	25902-25903	F	_	
138-38	25903-25904	(	_	
138-39	25904-25908	1,17	_	
138-40	25908-25909	)	_	
138-41	25909-25910	=	_	
138-42	25910-25915	1.422	_	
138-43	25915-25916	,	_	
138-44	25917-25918	P	_	
138-45	25918-25919	=	_	
138-46	25919-25923	.248	_	
138-47	25923-25924	;	_	
138-48	25925-25928	and	_	
138-49	25929-25936	craving	_	
138-50	25936-25937	:	_	
138-51	25938-25939	F	_	
138-52	25939-25940	(	_	
138-53	25940-25944	1,17	_	
138-54	25944-25945	)	_	
138-55	25945-25946	=	_	
138-56	25946-25951	0.022	_	
138-57	25951-25952	,	_	
138-58	25953-25954	P	_	
138-59	25954-25955	=	_	
138-60	25955-25959	.884	_	
138-61	25959-25960	]	_	
138-62	25960-25961	.	_	

#Text=Resting-State Connectivity
#Text=Examination of the correlations between connectivity of the raphe nuclei and hippocampal complex with psychological withdrawal and craving values from the pre-smoking testing session revealed no significant clusters, both when including and excluding the outlying participant.
139-1	25962-25975	Resting-State	_	
139-2	25976-25988	Connectivity	_	
139-3	25989-26000	Examination	_	
139-4	26001-26003	of	_	
139-5	26004-26007	the	_	
139-6	26008-26020	correlations	_	
139-7	26021-26028	between	_	
139-8	26029-26041	connectivity	_	
139-9	26042-26044	of	_	
139-10	26045-26048	the	_	
139-11	26049-26054	raphe	_	
139-12	26055-26061	nuclei	_	
139-13	26062-26065	and	_	
139-14	26066-26077	hippocampal	_	
139-15	26078-26085	complex	_	
139-16	26086-26090	with	_	
139-17	26091-26104	psychological	_	
139-18	26105-26115	withdrawal	_	
139-19	26116-26119	and	_	
139-20	26120-26127	craving	_	
139-21	26128-26134	values	_	
139-22	26135-26139	from	_	
139-23	26140-26143	the	_	
139-24	26144-26155	pre-smoking	_	
139-25	26156-26163	testing	_	
139-26	26164-26171	session	_	
139-27	26172-26180	revealed	_	
139-28	26181-26183	no	_	
139-29	26184-26195	significant	_	
139-30	26196-26204	clusters	_	
139-31	26204-26205	,	_	
139-32	26206-26210	both	_	
139-33	26211-26215	when	_	
139-34	26216-26225	including	_	
139-35	26226-26229	and	_	
139-36	26230-26239	excluding	_	
139-37	26240-26243	the	_	
139-38	26244-26252	outlying	_	
139-39	26253-26264	participant	_	
139-40	26264-26265	.	_	

#Text=Changes from Pre- to Post-Smoking
#Text=Self-Reports
#Text=The full-factorial ANOVAs revealed that smoking decreased psychological withdrawal (F(1,36)=6.151, P=.017; Bonferroni-corrected P=.033) and craving (F(1,36)=17.380, P<.001; Bonferroni-corrected P<.001).
140-1	26266-26273	Changes	_	
140-2	26274-26278	from	_	
140-3	26279-26282	Pre	_	
140-4	26282-26283	-	_	
140-5	26284-26286	to	_	
140-6	26287-26299	Post-Smoking	_	
140-7	26300-26312	Self-Reports	_	
140-8	26313-26316	The	_	
140-9	26317-26331	full-factorial	_	
140-10	26332-26338	ANOVAs	_	
140-11	26339-26347	revealed	_	
140-12	26348-26352	that	_	
140-13	26353-26360	smoking	_	
140-14	26361-26370	decreased	_	
140-15	26371-26384	psychological	_	
140-16	26385-26395	withdrawal	_	
140-17	26396-26397	(	_	
140-18	26397-26398	F	_	
140-19	26398-26399	(	_	
140-20	26399-26403	1,36	_	
140-21	26403-26404	)	_	
140-22	26404-26405	=	_	
140-23	26405-26410	6.151	_	
140-24	26410-26411	,	_	
140-25	26412-26413	P	_	
140-26	26413-26414	=	_	
140-27	26414-26418	.017	_	
140-28	26418-26419	;	_	
140-29	26420-26440	Bonferroni-corrected	_	
140-30	26441-26442	P	_	
140-31	26442-26443	=	_	
140-32	26443-26447	.033	_	
140-33	26447-26448	)	_	
140-34	26449-26452	and	_	
140-35	26453-26460	craving	_	
140-36	26461-26462	(	_	
140-37	26462-26463	F	_	
140-38	26463-26464	(	_	
140-39	26464-26468	1,36	_	
140-40	26468-26469	)	_	
140-41	26469-26470	=	_	
140-42	26470-26476	17.380	_	
140-43	26476-26477	,	_	
140-44	26478-26479	P	_	
140-45	26479-26480	<	_	
140-46	26480-26484	.001	_	
140-47	26484-26485	;	_	
140-48	26486-26506	Bonferroni-corrected	_	
140-49	26507-26508	P	_	
140-50	26508-26509	<	_	
140-51	26509-26513	.001	_	
140-52	26513-26514	)	_	
140-53	26514-26515	.	_	

#Text=There was a significant main effect of sex on smoking-induced reductions in psychological withdrawal (36% reduction in women, 17% reduction in men; F(1,17)=12.233, P=.003; Bonferroni-corrected P=.006), and in craving (28% reduction in women, 22% reduction in men; F(1,17)=8.074, P=.011; Bonferroni-corrected P=.021) (supplementary Figure 8).
141-1	26516-26521	There	_	
141-2	26522-26525	was	_	
141-3	26526-26527	a	_	
141-4	26528-26539	significant	_	
141-5	26540-26544	main	_	
141-6	26545-26551	effect	_	
141-7	26552-26554	of	_	
141-8	26555-26558	sex	_	
141-9	26559-26561	on	_	
141-10	26562-26577	smoking-induced	_	
141-11	26578-26588	reductions	_	
141-12	26589-26591	in	_	
141-13	26592-26605	psychological	_	
141-14	26606-26616	withdrawal	_	
141-15	26617-26618	(	_	
141-16	26618-26621	36%	_	
141-17	26622-26631	reduction	_	
141-18	26632-26634	in	_	
141-19	26635-26640	women	_	
141-20	26640-26641	,	_	
141-21	26642-26645	17%	_	
141-22	26646-26655	reduction	_	
141-23	26656-26658	in	_	
141-24	26659-26662	men	_	
141-25	26662-26663	;	_	
141-26	26664-26665	F	_	
141-27	26665-26666	(	_	
141-28	26666-26670	1,17	_	
141-29	26670-26671	)	_	
141-30	26671-26672	=	_	
141-31	26672-26678	12.233	_	
141-32	26678-26679	,	_	
141-33	26680-26681	P	_	
141-34	26681-26682	=	_	
141-35	26682-26686	.003	_	
141-36	26686-26687	;	_	
141-37	26688-26708	Bonferroni-corrected	_	
141-38	26709-26710	P	_	
141-39	26710-26711	=	_	
141-40	26711-26715	.006	_	
141-41	26715-26716	)	_	
141-42	26716-26717	,	_	
141-43	26718-26721	and	_	
141-44	26722-26724	in	_	
141-45	26725-26732	craving	_	
141-46	26733-26734	(	_	
141-47	26734-26737	28%	_	
141-48	26738-26747	reduction	_	
141-49	26748-26750	in	_	
141-50	26751-26756	women	_	
141-51	26756-26757	,	_	
141-52	26758-26761	22%	_	
141-53	26762-26771	reduction	_	
141-54	26772-26774	in	_	
141-55	26775-26778	men	_	
141-56	26778-26779	;	_	
141-57	26780-26781	F	_	
141-58	26781-26782	(	_	
141-59	26782-26786	1,17	_	
141-60	26786-26787	)	_	
141-61	26787-26788	=	_	
141-62	26788-26793	8.074	_	
141-63	26793-26794	,	_	
141-64	26795-26796	P	_	
141-65	26796-26797	=	_	
141-66	26797-26801	.011	_	
141-67	26801-26802	;	_	
141-68	26803-26823	Bonferroni-corrected	_	
141-69	26824-26825	P	_	
141-70	26825-26826	=	_	
141-71	26826-26830	.021	_	
141-72	26830-26831	)	_	
141-73	26832-26833	(	_	
141-74	26833-26846	supplementary	_	
141-75	26847-26853	Figure	_	
141-76	26854-26855	8	_	
141-77	26855-26856	)	_	
141-78	26856-26857	.	_	

#Text=None of the change scores were statistical outliers; therefore, examinations of the relationship between dorsal and median raphe nuclei connectivity and both psychological withdrawal and craving included data from all 21 participants.
142-1	26858-26862	None	_	
142-2	26863-26865	of	_	
142-3	26866-26869	the	_	
142-4	26870-26876	change	_	
142-5	26877-26883	scores	_	
142-6	26884-26888	were	_	
142-7	26889-26900	statistical	_	
142-8	26901-26909	outliers	_	
142-9	26909-26910	;	_	
142-10	26911-26920	therefore	_	
142-11	26920-26921	,	_	
142-12	26922-26934	examinations	_	
142-13	26935-26937	of	_	
142-14	26938-26941	the	_	
142-15	26942-26954	relationship	_	
142-16	26955-26962	between	_	
142-17	26963-26969	dorsal	_	
142-18	26970-26973	and	_	
142-19	26974-26980	median	_	
142-20	26981-26986	raphe	_	
142-21	26987-26993	nuclei	_	
142-22	26994-27006	connectivity	_	
142-23	27007-27010	and	_	
142-24	27011-27015	both	_	
142-25	27016-27029	psychological	_	
142-26	27030-27040	withdrawal	_	
142-27	27041-27044	and	_	
142-28	27045-27052	craving	_	
142-29	27053-27061	included	_	
142-30	27062-27066	data	_	
142-31	27067-27071	from	_	
142-32	27072-27075	all	_	
142-33	27076-27078	21	_	
142-34	27079-27091	participants	_	
142-35	27091-27092	.	_	

#Text=Resting-State Connectivity
#Text=The voxel-wise GLM showed that smoking increased connectivity of the median raphe nucleus with a cluster of voxels in the right hippocampal complex (Figure 3).
143-1	27093-27106	Resting-State	_	
143-2	27107-27119	Connectivity	_	
143-3	27120-27123	The	_	
143-4	27124-27134	voxel-wise	_	
143-5	27135-27138	GLM	_	
143-6	27139-27145	showed	_	
143-7	27146-27150	that	_	
143-8	27151-27158	smoking	_	
143-9	27159-27168	increased	_	
143-10	27169-27181	connectivity	_	
143-11	27182-27184	of	_	
143-12	27185-27188	the	_	
143-13	27189-27195	median	_	
143-14	27196-27201	raphe	_	
143-15	27202-27209	nucleus	_	
143-16	27210-27214	with	_	
143-17	27215-27216	a	_	
143-18	27217-27224	cluster	_	
143-19	27225-27227	of	_	
143-20	27228-27234	voxels	_	
143-21	27235-27237	in	_	
143-22	27238-27241	the	_	
143-23	27242-27247	right	_	
143-24	27248-27259	hippocampal	_	
143-25	27260-27267	complex	_	
143-26	27268-27269	(	_	
143-27	27269-27275	Figure	_	
143-28	27276-27277	3	_	
143-29	27277-27278	)	_	
143-30	27278-27279	.	_	

#Text=There was no significant effect of smoking on connectivity of the dorsal raphe nucleus with the hippocampal complex.
144-1	27280-27285	There	_	
144-2	27286-27289	was	_	
144-3	27290-27292	no	_	
144-4	27293-27304	significant	_	
144-5	27305-27311	effect	_	
144-6	27312-27314	of	_	
144-7	27315-27322	smoking	_	
144-8	27323-27325	on	_	
144-9	27326-27338	connectivity	_	
144-10	27339-27341	of	_	
144-11	27342-27345	the	_	
144-12	27346-27352	dorsal	_	
144-13	27353-27358	raphe	_	
144-14	27359-27366	nucleus	_	
144-15	27367-27371	with	_	
144-16	27372-27375	the	_	
144-17	27376-27387	hippocampal	_	
144-18	27388-27395	complex	_	
144-19	27395-27396	.	_	

#Text=Effect of acute smoking on connectivity of the median raphe nucleus with the hippocampal complex in smokers after overnight abstinence.
145-1	27397-27403	Effect	_	
145-2	27404-27406	of	_	
145-3	27407-27412	acute	_	
145-4	27413-27420	smoking	_	
145-5	27421-27423	on	_	
145-6	27424-27436	connectivity	_	
145-7	27437-27439	of	_	
145-8	27440-27443	the	_	
145-9	27444-27450	median	_	
145-10	27451-27456	raphe	_	
145-11	27457-27464	nucleus	_	
145-12	27465-27469	with	_	
145-13	27470-27473	the	_	
145-14	27474-27485	hippocampal	_	
145-15	27486-27493	complex	_	
145-16	27494-27496	in	_	
145-17	27497-27504	smokers	_	
145-18	27505-27510	after	_	
145-19	27511-27520	overnight	_	
145-20	27521-27531	abstinence	_	
145-21	27531-27532	.	_	

#Text=Data shown are from Study 2.
146-1	27533-27537	Data	_	
146-2	27538-27543	shown	_	
146-3	27544-27547	are	_	
146-4	27548-27552	from	_	
146-5	27553-27558	Study	_	
146-6	27559-27560	2	_	
146-7	27560-27561	.	_	

#Text=(A) Cluster denotes the region in which connectivity with the median raphe nucleus increased due to smoking.
147-1	27562-27563	(	_	
147-2	27563-27564	A	_	
147-3	27564-27565	)	_	
147-4	27566-27573	Cluster	_	
147-5	27574-27581	denotes	_	
147-6	27582-27585	the	_	
147-7	27586-27592	region	_	
147-8	27593-27595	in	_	
147-9	27596-27601	which	_	
147-10	27602-27614	connectivity	_	
147-11	27615-27619	with	_	
147-12	27620-27623	the	_	
147-13	27624-27630	median	_	
147-14	27631-27636	raphe	_	
147-15	27637-27644	nucleus	_	
147-16	27645-27654	increased	_	
147-17	27655-27658	due	_	
147-18	27659-27661	to	_	
147-19	27662-27669	smoking	_	
147-20	27669-27670	.	_	

#Text=Result is cluster-corrected for multiple comparisons (voxel height threshold: Z>3.09; cluster significance: P<.05).
148-1	27671-27677	Result	_	
148-2	27678-27680	is	_	
148-3	27681-27698	cluster-corrected	_	
148-4	27699-27702	for	_	
148-5	27703-27711	multiple	_	
148-6	27712-27723	comparisons	_	
148-7	27724-27725	(	_	
148-8	27725-27730	voxel	_	
148-9	27731-27737	height	_	
148-10	27738-27747	threshold	_	
148-11	27747-27748	:	_	
148-12	27749-27750	Z	_	
148-13	27750-27751	>	_	
148-14	27751-27755	3.09	_	
148-15	27755-27756	;	_	
148-16	27757-27764	cluster	_	
148-17	27765-27777	significance	_	
148-18	27777-27778	:	_	
148-19	27779-27780	P	_	
148-20	27780-27781	<	_	
148-21	27781-27784	.05	_	
148-22	27784-27785	)	_	
148-23	27785-27786	.	_	

#Text=(B) Graph depicts mean Z values from the cluster shown in (A) for the pre- and post-smoking session and are for illustrative purposes only.
149-1	27787-27788	(	_	
149-2	27788-27789	B	_	
149-3	27789-27790	)	_	
149-4	27791-27796	Graph	_	
149-5	27797-27804	depicts	_	
149-6	27805-27809	mean	_	
149-7	27810-27811	Z	_	
149-8	27812-27818	values	_	
149-9	27819-27823	from	_	
149-10	27824-27827	the	_	
149-11	27828-27835	cluster	_	
149-12	27836-27841	shown	_	
149-13	27842-27844	in	_	
149-14	27845-27846	(	_	
149-15	27846-27847	A	_	
149-16	27847-27848	)	_	
149-17	27849-27852	for	_	
149-18	27853-27856	the	_	
149-19	27857-27860	pre	_	
149-20	27860-27861	-	_	
149-21	27862-27865	and	_	
149-22	27866-27878	post-smoking	_	
149-23	27879-27886	session	_	
149-24	27887-27890	and	_	
149-25	27891-27894	are	_	
149-26	27895-27898	for	_	
149-27	27899-27911	illustrative	_	
149-28	27912-27920	purposes	_	
149-29	27921-27925	only	_	
149-30	27925-27926	.	_	

#Text=The full-factorial ANOVA determined that the smoking-induced increase in connectivity of the median raphe nucleus with the hippocampal complex cluster shown in Figure 3a was negatively correlated with the reduction in psychological withdrawal (F(1,18)=6.409, P=.020) but not with the reduction in craving (F(1,18)=0.828, P=.375) (Figure 4).
150-1	27927-27930	The	_	
150-2	27931-27945	full-factorial	_	
150-3	27946-27951	ANOVA	_	
150-4	27952-27962	determined	_	
150-5	27963-27967	that	_	
150-6	27968-27971	the	_	
150-7	27972-27987	smoking-induced	_	
150-8	27988-27996	increase	_	
150-9	27997-27999	in	_	
150-10	28000-28012	connectivity	_	
150-11	28013-28015	of	_	
150-12	28016-28019	the	_	
150-13	28020-28026	median	_	
150-14	28027-28032	raphe	_	
150-15	28033-28040	nucleus	_	
150-16	28041-28045	with	_	
150-17	28046-28049	the	_	
150-18	28050-28061	hippocampal	_	
150-19	28062-28069	complex	_	
150-20	28070-28077	cluster	_	
150-21	28078-28083	shown	_	
150-22	28084-28086	in	_	
150-23	28087-28093	Figure	_	
150-24	28094-28096	3a	_	
150-25	28097-28100	was	_	
150-26	28101-28111	negatively	_	
150-27	28112-28122	correlated	_	
150-28	28123-28127	with	_	
150-29	28128-28131	the	_	
150-30	28132-28141	reduction	_	
150-31	28142-28144	in	_	
150-32	28145-28158	psychological	_	
150-33	28159-28169	withdrawal	_	
150-34	28170-28171	(	_	
150-35	28171-28172	F	_	
150-36	28172-28173	(	_	
150-37	28173-28177	1,18	_	
150-38	28177-28178	)	_	
150-39	28178-28179	=	_	
150-40	28179-28184	6.409	_	
150-41	28184-28185	,	_	
150-42	28186-28187	P	_	
150-43	28187-28188	=	_	
150-44	28188-28192	.020	_	
150-45	28192-28193	)	_	
150-46	28194-28197	but	_	
150-47	28198-28201	not	_	
150-48	28202-28206	with	_	
150-49	28207-28210	the	_	
150-50	28211-28220	reduction	_	
150-51	28221-28223	in	_	
150-52	28224-28231	craving	_	
150-53	28232-28233	(	_	
150-54	28233-28234	F	_	
150-55	28234-28235	(	_	
150-56	28235-28239	1,18	_	
150-57	28239-28240	)	_	
150-58	28240-28241	=	_	
150-59	28241-28246	0.828	_	
150-60	28246-28247	,	_	
150-61	28248-28249	P	_	
150-62	28249-28250	=	_	
150-63	28250-28254	.375	_	
150-64	28254-28255	)	_	
150-65	28256-28257	(	_	
150-66	28257-28263	Figure	_	
150-67	28264-28265	4	_	
150-68	28265-28266	)	_	
150-69	28266-28267	.	_	

#Text=There was no effect of sex on either relationship (i.e., no sex-by-connectivity interaction on psychological withdrawal: F(1,18)=2.288, P=.148, or craving: F(1,18)=0.035, P=.853).
151-1	28268-28273	There	_	
151-2	28274-28277	was	_	
151-3	28278-28280	no	_	
151-4	28281-28287	effect	_	
151-5	28288-28290	of	_	
151-6	28291-28294	sex	_	
151-7	28295-28297	on	_	
151-8	28298-28304	either	_	
151-9	28305-28317	relationship	_	
151-10	28318-28319	(	_	
151-11	28319-28322	i.e	_	
151-12	28322-28323	.	_	
151-13	28323-28324	,	_	
151-14	28325-28327	no	_	
151-15	28328-28347	sex-by-connectivity	_	
151-16	28348-28359	interaction	_	
151-17	28360-28362	on	_	
151-18	28363-28376	psychological	_	
151-19	28377-28387	withdrawal	_	
151-20	28387-28388	:	_	
151-21	28389-28390	F	_	
151-22	28390-28391	(	_	
151-23	28391-28395	1,18	_	
151-24	28395-28396	)	_	
151-25	28396-28397	=	_	
151-26	28397-28402	2.288	_	
151-27	28402-28403	,	_	
151-28	28404-28405	P	_	
151-29	28405-28406	=	_	
151-30	28406-28410	.148	_	
151-31	28410-28411	,	_	
151-32	28412-28414	or	_	
151-33	28415-28422	craving	_	
151-34	28422-28423	:	_	
151-35	28424-28425	F	_	
151-36	28425-28426	(	_	
151-37	28426-28430	1,18	_	
151-38	28430-28431	)	_	
151-39	28431-28432	=	_	
151-40	28432-28437	0.035	_	
151-41	28437-28438	,	_	
151-42	28439-28440	P	_	
151-43	28440-28441	=	_	
151-44	28441-28445	.853	_	
151-45	28445-28446	)	_	
151-46	28446-28447	.	_	

#Text=Relationship of the smoking-induced increase in connectivity of the median raphe nucleus with the hippocampal complex to the reduction in psychological withdrawal (A) and craving (B).
152-1	28448-28460	Relationship	_	
152-2	28461-28463	of	_	
152-3	28464-28467	the	_	
152-4	28468-28483	smoking-induced	_	
152-5	28484-28492	increase	_	
152-6	28493-28495	in	_	
152-7	28496-28508	connectivity	_	
152-8	28509-28511	of	_	
152-9	28512-28515	the	_	
152-10	28516-28522	median	_	
152-11	28523-28528	raphe	_	
152-12	28529-28536	nucleus	_	
152-13	28537-28541	with	_	
152-14	28542-28545	the	_	
152-15	28546-28557	hippocampal	_	
152-16	28558-28565	complex	_	
152-17	28566-28568	to	_	
152-18	28569-28572	the	_	
152-19	28573-28582	reduction	_	
152-20	28583-28585	in	_	
152-21	28586-28599	psychological	_	
152-22	28600-28610	withdrawal	_	
152-23	28611-28612	(	_	
152-24	28612-28613	A	_	
152-25	28613-28614	)	_	
152-26	28615-28618	and	_	
152-27	28619-28626	craving	_	
152-28	28627-28628	(	_	
152-29	28628-28629	B	_	
152-30	28629-28630	)	_	
152-31	28630-28631	.	_	

#Text=Data shown are from Study 2.
153-1	28632-28636	Data	_	
153-2	28637-28642	shown	_	
153-3	28643-28646	are	_	
153-4	28647-28651	from	_	
153-5	28652-28657	Study	_	
153-6	28658-28659	2	_	
153-7	28659-28660	.	_	

#Text=Plots depict Z values from each participant extracted from the cluster in the hippocampal complex observed in Figure 3A.
154-1	28661-28666	Plots	_	
154-2	28667-28673	depict	_	
154-3	28674-28675	Z	_	
154-4	28676-28682	values	_	
154-5	28683-28687	from	_	
154-6	28688-28692	each	_	
154-7	28693-28704	participant	_	
154-8	28705-28714	extracted	_	
154-9	28715-28719	from	_	
154-10	28720-28723	the	_	
154-11	28724-28731	cluster	_	
154-12	28732-28734	in	_	
154-13	28735-28738	the	_	
154-14	28739-28750	hippocampal	_	
154-15	28751-28758	complex	_	
154-16	28759-28767	observed	_	
154-17	28768-28770	in	_	
154-18	28771-28777	Figure	_	
154-19	28778-28780	3A	_	
154-20	28780-28781	.	_	

#Text=Discussion
#Text=Compared to nonsmokers, smokers displayed weaker resting-state functional connectivity between the median raphe nuclei and hippocampal complex.
155-1	28782-28792	Discussion	_	
155-2	28793-28801	Compared	_	
155-3	28802-28804	to	_	
155-4	28805-28815	nonsmokers	_	
155-5	28815-28816	,	_	
155-6	28817-28824	smokers	_	
155-7	28825-28834	displayed	_	
155-8	28835-28841	weaker	_	
155-9	28842-28855	resting-state	_	
155-10	28856-28866	functional	_	
155-11	28867-28879	connectivity	_	
155-12	28880-28887	between	_	
155-13	28888-28891	the	_	
155-14	28892-28898	median	_	
155-15	28899-28904	raphe	_	
155-16	28905-28911	nuclei	_	
155-17	28912-28915	and	_	
155-18	28916-28927	hippocampal	_	
155-19	28928-28935	complex	_	
155-20	28935-28936	.	_	

#Text=Connectivity of the median raphe nuclei was related to psychological withdrawal, and smoking-induced increases in this potential marker of serotonin function were related to the acute relief of the psychological, affective aspects of tobacco withdrawal.
156-1	28937-28949	Connectivity	_	
156-2	28950-28952	of	_	
156-3	28953-28956	the	_	
156-4	28957-28963	median	_	
156-5	28964-28969	raphe	_	
156-6	28970-28976	nuclei	_	
156-7	28977-28980	was	_	
156-8	28981-28988	related	_	
156-9	28989-28991	to	_	
156-10	28992-29005	psychological	_	
156-11	29006-29016	withdrawal	_	
156-12	29016-29017	,	_	
156-13	29018-29021	and	_	
156-14	29022-29037	smoking-induced	_	
156-15	29038-29047	increases	_	
156-16	29048-29050	in	_	
156-17	29051-29055	this	_	
156-18	29056-29065	potential	_	
156-19	29066-29072	marker	_	
156-20	29073-29075	of	_	
156-21	29076-29085	serotonin	_	
156-22	29086-29094	function	_	
156-23	29095-29099	were	_	
156-24	29100-29107	related	_	
156-25	29108-29110	to	_	
156-26	29111-29114	the	_	
156-27	29115-29120	acute	_	
156-28	29121-29127	relief	_	
156-29	29128-29130	of	_	
156-30	29131-29134	the	_	
156-31	29135-29148	psychological	_	
156-32	29148-29149	,	_	
156-33	29150-29159	affective	_	
156-34	29160-29167	aspects	_	
156-35	29168-29170	of	_	
156-36	29171-29178	tobacco	_	
156-37	29179-29189	withdrawal	_	
156-38	29189-29190	.	_	

#Text=These results suggest that increasing connectivity of the median raphe nuclei with the hippocampal complex may reduce psychological withdrawal and possibly facilitate smoking cessation.
157-1	29191-29196	These	_	
157-2	29197-29204	results	_	
157-3	29205-29212	suggest	_	
157-4	29213-29217	that	_	
157-5	29218-29228	increasing	_	
157-6	29229-29241	connectivity	_	
157-7	29242-29244	of	_	
157-8	29245-29248	the	_	
157-9	29249-29255	median	_	
157-10	29256-29261	raphe	_	
157-11	29262-29268	nuclei	_	
157-12	29269-29273	with	_	
157-13	29274-29277	the	_	
157-14	29278-29289	hippocampal	_	
157-15	29290-29297	complex	_	
157-16	29298-29301	may	_	
157-17	29302-29308	reduce	_	
157-18	29309-29322	psychological	_	
157-19	29323-29333	withdrawal	_	
157-20	29334-29337	and	_	
157-21	29338-29346	possibly	_	
157-22	29347-29357	facilitate	_	
157-23	29358-29365	smoking	_	
157-24	29366-29375	cessation	_	
157-25	29375-29376	.	_	

#Text=Smoking-induced increases in connectivity between the median raphe nucleus and hippocampal formation may reflect nicotine-induced serotonin release within these regions, as observed in rodents.
158-1	29377-29392	Smoking-induced	_	
158-2	29393-29402	increases	_	
158-3	29403-29405	in	_	
158-4	29406-29418	connectivity	_	
158-5	29419-29426	between	_	
158-6	29427-29430	the	_	
158-7	29431-29437	median	_	
158-8	29438-29443	raphe	_	
158-9	29444-29451	nucleus	_	
158-10	29452-29455	and	_	
158-11	29456-29467	hippocampal	_	
158-12	29468-29477	formation	_	
158-13	29478-29481	may	_	
158-14	29482-29489	reflect	_	
158-15	29490-29506	nicotine-induced	_	
158-16	29507-29516	serotonin	_	
158-17	29517-29524	release	_	
158-18	29525-29531	within	_	
158-19	29532-29537	these	_	
158-20	29538-29545	regions	_	
158-21	29545-29546	,	_	
158-22	29547-29549	as	_	
158-23	29550-29558	observed	_	
158-24	29559-29561	in	_	
158-25	29562-29569	rodents	_	
158-26	29569-29570	.	_	

#Text=Weaker connectivity of the median raphe nucleus with the hippocampal complex in smokers relative to nonsmokers may reflect both greater 5-HT1A receptor binding and lower serotonin concentrations, which have been observed in these regions in smokers.
159-1	29571-29577	Weaker	_	
159-2	29578-29590	connectivity	_	
159-3	29591-29593	of	_	
159-4	29594-29597	the	_	
159-5	29598-29604	median	_	
159-6	29605-29610	raphe	_	
159-7	29611-29618	nucleus	_	
159-8	29619-29623	with	_	
159-9	29624-29627	the	_	
159-10	29628-29639	hippocampal	_	
159-11	29640-29647	complex	_	
159-12	29648-29650	in	_	
159-13	29651-29658	smokers	_	
159-14	29659-29667	relative	_	
159-15	29668-29670	to	_	
159-16	29671-29681	nonsmokers	_	
159-17	29682-29685	may	_	
159-18	29686-29693	reflect	_	
159-19	29694-29698	both	_	
159-20	29699-29706	greater	_	
159-21	29707-29708	5	_	
159-22	29708-29709	-	_	
159-23	29709-29713	HT1A	_	
159-24	29714-29722	receptor	_	
159-25	29723-29730	binding	_	
159-26	29731-29734	and	_	
159-27	29735-29740	lower	_	
159-28	29741-29750	serotonin	_	
159-29	29751-29765	concentrations	_	
159-30	29765-29766	,	_	
159-31	29767-29772	which	_	
159-32	29773-29777	have	_	
159-33	29778-29782	been	_	
159-34	29783-29791	observed	_	
159-35	29792-29794	in	_	
159-36	29795-29800	these	_	
159-37	29801-29808	regions	_	
159-38	29809-29811	in	_	
159-39	29812-29819	smokers	_	
159-40	29819-29820	.	_	

#Text=It has been argued that repetitive nicotine–induced serotonin release in the raphe nuclei and hippocampal complex produces upregulation of 5-HT1A receptors in these regions, thereby inhibiting serotonergic neuronal firing and decreasing serotonin levels.
160-1	29821-29823	It	_	
160-2	29824-29827	has	_	
160-3	29828-29832	been	_	
160-4	29833-29839	argued	_	
160-5	29840-29844	that	_	
160-6	29845-29855	repetitive	_	
160-7	29856-29872	nicotine–induced	_	
160-8	29873-29882	serotonin	_	
160-9	29883-29890	release	_	
160-10	29891-29893	in	_	
160-11	29894-29897	the	_	
160-12	29898-29903	raphe	_	
160-13	29904-29910	nuclei	_	
160-14	29911-29914	and	_	
160-15	29915-29926	hippocampal	_	
160-16	29927-29934	complex	_	
160-17	29935-29943	produces	_	
160-18	29944-29956	upregulation	_	
160-19	29957-29959	of	_	
160-20	29960-29961	5	_	
160-21	29961-29962	-	_	
160-22	29962-29966	HT1A	_	
160-23	29967-29976	receptors	_	
160-24	29977-29979	in	_	
160-25	29980-29985	these	_	
160-26	29986-29993	regions	_	
160-27	29993-29994	,	_	
160-28	29995-30002	thereby	_	
160-29	30003-30013	inhibiting	_	
160-30	30014-30026	serotonergic	_	
160-31	30027-30035	neuronal	_	
160-32	30036-30042	firing	_	
160-33	30043-30046	and	_	
160-34	30047-30057	decreasing	_	
160-35	30058-30067	serotonin	_	
160-36	30068-30074	levels	_	
160-37	30074-30075	.	_	

#Text=This hypothesis is supported by a negative correlation between serotonin concentrations in the median raphe nucleus and 5-HT1A receptor availability in the hippocampal complex.
161-1	30076-30080	This	_	
161-2	30081-30091	hypothesis	_	
161-3	30092-30094	is	_	
161-4	30095-30104	supported	_	
161-5	30105-30107	by	_	
161-6	30108-30109	a	_	
161-7	30110-30118	negative	_	
161-8	30119-30130	correlation	_	
161-9	30131-30138	between	_	
161-10	30139-30148	serotonin	_	
161-11	30149-30163	concentrations	_	
161-12	30164-30166	in	_	
161-13	30167-30170	the	_	
161-14	30171-30177	median	_	
161-15	30178-30183	raphe	_	
161-16	30184-30191	nucleus	_	
161-17	30192-30195	and	_	
161-18	30196-30197	5	_	
161-19	30197-30198	-	_	
161-20	30198-30202	HT1A	_	
161-21	30203-30211	receptor	_	
161-22	30212-30224	availability	_	
161-23	30225-30227	in	_	
161-24	30228-30231	the	_	
161-25	30232-30243	hippocampal	_	
161-26	30244-30251	complex	_	
161-27	30251-30252	.	_	

#Text=Future research could examine whether pharmacotherapies that desensitize or downregulate 5-HT1A receptors in the median raphe nucleus and hippocampal complex can increase both serotonin levels and connectivity between these 2 regions to influence smoking cessation.
162-1	30253-30259	Future	_	
162-2	30260-30268	research	_	
162-3	30269-30274	could	_	
162-4	30275-30282	examine	_	
162-5	30283-30290	whether	_	
162-6	30291-30308	pharmacotherapies	_	
162-7	30309-30313	that	_	
162-8	30314-30325	desensitize	_	
162-9	30326-30328	or	_	
162-10	30329-30341	downregulate	_	
162-11	30342-30343	5	_	
162-12	30343-30344	-	_	
162-13	30344-30348	HT1A	_	
162-14	30349-30358	receptors	_	
162-15	30359-30361	in	_	
162-16	30362-30365	the	_	
162-17	30366-30372	median	_	
162-18	30373-30378	raphe	_	
162-19	30379-30386	nucleus	_	
162-20	30387-30390	and	_	
162-21	30391-30402	hippocampal	_	
162-22	30403-30410	complex	_	
162-23	30411-30414	can	_	
162-24	30415-30423	increase	_	
162-25	30424-30428	both	_	
162-26	30429-30438	serotonin	_	
162-27	30439-30445	levels	_	
162-28	30446-30449	and	_	
162-29	30450-30462	connectivity	_	
162-30	30463-30470	between	_	
162-31	30471-30476	these	_	
162-32	30477-30478	2	_	
162-33	30479-30486	regions	_	
162-34	30487-30489	to	_	
162-35	30490-30499	influence	_	
162-36	30500-30507	smoking	_	
162-37	30508-30517	cessation	_	
162-38	30517-30518	.	_	

#Text=The correlation between connectivity of the median raphe nucleus with the hippocampal complex and psychological withdrawal was predicted on the basis of the proposed role of serotonin in affective disorders (e.g.,).
163-1	30519-30522	The	_	
163-2	30523-30534	correlation	_	
163-3	30535-30542	between	_	
163-4	30543-30555	connectivity	_	
163-5	30556-30558	of	_	
163-6	30559-30562	the	_	
163-7	30563-30569	median	_	
163-8	30570-30575	raphe	_	
163-9	30576-30583	nucleus	_	
163-10	30584-30588	with	_	
163-11	30589-30592	the	_	
163-12	30593-30604	hippocampal	_	
163-13	30605-30612	complex	_	
163-14	30613-30616	and	_	
163-15	30617-30630	psychological	_	
163-16	30631-30641	withdrawal	_	
163-17	30642-30645	was	_	
163-18	30646-30655	predicted	_	
163-19	30656-30658	on	_	
163-20	30659-30662	the	_	
163-21	30663-30668	basis	_	
163-22	30669-30671	of	_	
163-23	30672-30675	the	_	
163-24	30676-30684	proposed	_	
163-25	30685-30689	role	_	
163-26	30690-30692	of	_	
163-27	30693-30702	serotonin	_	
163-28	30703-30705	in	_	
163-29	30706-30715	affective	_	
163-30	30716-30725	disorders	_	
163-31	30726-30727	(	_	
163-32	30727-30730	e.g	_	
163-33	30730-30731	.	_	
163-34	30731-30732	,	_	
163-35	30732-30733	)	_	
163-36	30733-30734	.	_	

#Text=While this study did not examine serotonin function per se, the results encourage future research on the potential involvement of serotonergic dysfunction in other aspects of tobacco withdrawal.
164-1	30735-30740	While	_	
164-2	30741-30745	this	_	
164-3	30746-30751	study	_	
164-4	30752-30755	did	_	
164-5	30756-30759	not	_	
164-6	30760-30767	examine	_	
164-7	30768-30777	serotonin	_	
164-8	30778-30786	function	_	
164-9	30787-30790	per	_	
164-10	30791-30793	se	_	
164-11	30793-30794	,	_	
164-12	30795-30798	the	_	
164-13	30799-30806	results	_	
164-14	30807-30816	encourage	_	
164-15	30817-30823	future	_	
164-16	30824-30832	research	_	
164-17	30833-30835	on	_	
164-18	30836-30839	the	_	
164-19	30840-30849	potential	_	
164-20	30850-30861	involvement	_	
164-21	30862-30864	of	_	
164-22	30865-30877	serotonergic	_	
164-23	30878-30889	dysfunction	_	
164-24	30890-30892	in	_	
164-25	30893-30898	other	_	
164-26	30899-30906	aspects	_	
164-27	30907-30909	of	_	
164-28	30910-30917	tobacco	_	
164-29	30918-30928	withdrawal	_	
164-30	30928-30929	.	_	

#Text=For example, high impulsivity predicts relapse during a cessation attempt, is increased by serotonergic hypofunction, and is related to hippocampal 5-HT1A availability in healthy controls.
165-1	30930-30933	For	_	
165-2	30934-30941	example	_	
165-3	30941-30942	,	_	
165-4	30943-30947	high	_	
165-5	30948-30959	impulsivity	_	
165-6	30960-30968	predicts	_	
165-7	30969-30976	relapse	_	
165-8	30977-30983	during	_	
165-9	30984-30985	a	_	
165-10	30986-30995	cessation	_	
165-11	30996-31003	attempt	_	
165-12	31003-31004	,	_	
165-13	31005-31007	is	_	
165-14	31008-31017	increased	_	
165-15	31018-31020	by	_	
165-16	31021-31033	serotonergic	_	
165-17	31034-31046	hypofunction	_	
165-18	31046-31047	,	_	
165-19	31048-31051	and	_	
165-20	31052-31054	is	_	
165-21	31055-31062	related	_	
165-22	31063-31065	to	_	
165-23	31066-31077	hippocampal	_	
165-24	31078-31079	5	_	
165-25	31079-31080	-	_	
165-26	31080-31084	HT1A	_	
165-27	31085-31097	availability	_	
165-28	31098-31100	in	_	
165-29	31101-31108	healthy	_	
165-30	31109-31117	controls	_	
165-31	31117-31118	.	_	

#Text=SSRIs, which increase central serotonin levels, have only mild efficacy in aiding smoking cessation (e.g.,).
166-1	31119-31124	SSRIs	_	
166-2	31124-31125	,	_	
166-3	31126-31131	which	_	
166-4	31132-31140	increase	_	
166-5	31141-31148	central	_	
166-6	31149-31158	serotonin	_	
166-7	31159-31165	levels	_	
166-8	31165-31166	,	_	
166-9	31167-31171	have	_	
166-10	31172-31176	only	_	
166-11	31177-31181	mild	_	
166-12	31182-31190	efficacy	_	
166-13	31191-31193	in	_	
166-14	31194-31200	aiding	_	
166-15	31201-31208	smoking	_	
166-16	31209-31218	cessation	_	
166-17	31219-31220	(	_	
166-18	31220-31223	e.g	_	
166-19	31223-31224	.	_	
166-20	31224-31225	,	_	
166-21	31225-31226	)	_	
166-22	31226-31227	.	_	

#Text=As mentioned, this may be due to the nonselective effect of these drugs on serotonergic transmission.
167-1	31228-31230	As	_	
167-2	31231-31240	mentioned	_	
167-3	31240-31241	,	_	
167-4	31242-31246	this	_	
167-5	31247-31250	may	_	
167-6	31251-31253	be	_	
167-7	31254-31257	due	_	
167-8	31258-31260	to	_	
167-9	31261-31264	the	_	
167-10	31265-31277	nonselective	_	
167-11	31278-31284	effect	_	
167-12	31285-31287	of	_	
167-13	31288-31293	these	_	
167-14	31294-31299	drugs	_	
167-15	31300-31302	on	_	
167-16	31303-31315	serotonergic	_	
167-17	31316-31328	transmission	_	
167-18	31328-31329	.	_	

#Text=In contrast, lorcaserin, a 5-HT2C receptor agonist, facilitates smoking cessation.
168-1	31330-31332	In	_	
168-2	31333-31341	contrast	_	
168-3	31341-31342	,	_	
168-4	31343-31353	lorcaserin	_	
168-5	31353-31354	,	_	
168-6	31355-31356	a	_	
168-7	31357-31358	5	_	
168-8	31358-31359	-	_	
168-9	31359-31363	HT2C	_	
168-10	31364-31372	receptor	_	
168-11	31373-31380	agonist	_	
168-12	31380-31381	,	_	
168-13	31382-31393	facilitates	_	
168-14	31394-31401	smoking	_	
168-15	31402-31411	cessation	_	
168-16	31411-31412	.	_	

#Text=This effect of lorcaserin and its ability to reduce nicotine self-administration in rats may reflect links between the 5-HT2C receptors and the dopaminergic reward system.
169-1	31413-31417	This	_	
169-2	31418-31424	effect	_	
169-3	31425-31427	of	_	
169-4	31428-31438	lorcaserin	_	
169-5	31439-31442	and	_	
169-6	31443-31446	its	_	
169-7	31447-31454	ability	_	
169-8	31455-31457	to	_	
169-9	31458-31464	reduce	_	
169-10	31465-31473	nicotine	_	
169-11	31474-31493	self-administration	_	
169-12	31494-31496	in	_	
169-13	31497-31501	rats	_	
169-14	31502-31505	may	_	
169-15	31506-31513	reflect	_	
169-16	31514-31519	links	_	
169-17	31520-31527	between	_	
169-18	31528-31531	the	_	
169-19	31532-31533	5	_	
169-20	31533-31534	-	_	
169-21	31534-31538	HT2C	_	
169-22	31539-31548	receptors	_	
169-23	31549-31552	and	_	
169-24	31553-31556	the	_	
169-25	31557-31569	dopaminergic	_	
169-26	31570-31576	reward	_	
169-27	31577-31583	system	_	
169-28	31583-31584	.	_	

#Text=In rodents, activation of 5-HT2C receptors by RO 60–0175 blocks the stimulatory action of nicotine on midbrain dopamine neuron firing.
170-1	31585-31587	In	_	
170-2	31588-31595	rodents	_	
170-3	31595-31596	,	_	
170-4	31597-31607	activation	_	
170-5	31608-31610	of	_	
170-6	31611-31612	5	_	
170-7	31612-31613	-	_	
170-8	31613-31617	HT2C	_	
170-9	31618-31627	receptors	_	
170-10	31628-31630	by	_	
170-11	31631-31633	RO	_	
170-12	31634-31636	60	_	
170-13	31636-31637	–	_	
170-14	31637-31641	0175	_	
170-15	31642-31648	blocks	_	
170-16	31649-31652	the	_	
170-17	31653-31664	stimulatory	_	
170-18	31665-31671	action	_	
170-19	31672-31674	of	_	
170-20	31675-31683	nicotine	_	
170-21	31684-31686	on	_	
170-22	31687-31695	midbrain	_	
170-23	31696-31704	dopamine	_	
170-24	31705-31711	neuron	_	
170-25	31712-31718	firing	_	
170-26	31718-31719	.	_	

#Text=Other serotonergic medications may help smokers to quit.
171-1	31720-31725	Other	_	
171-2	31726-31738	serotonergic	_	
171-3	31739-31750	medications	_	
171-4	31751-31754	may	_	
171-5	31755-31759	help	_	
171-6	31760-31767	smokers	_	
171-7	31768-31770	to	_	
171-8	31771-31775	quit	_	
171-9	31775-31776	.	_	

#Text=The low efficacy of conventional SSRIs for smoking cessation may reflect their initial action to decrease serotonin levels through serotonin activity at inhibitory 5-HT1A autoreceptors in the raphe nuclei (e.g.,).
172-1	31777-31780	The	_	
172-2	31781-31784	low	_	
172-3	31785-31793	efficacy	_	
172-4	31794-31796	of	_	
172-5	31797-31809	conventional	_	
172-6	31810-31815	SSRIs	_	
172-7	31816-31819	for	_	
172-8	31820-31827	smoking	_	
172-9	31828-31837	cessation	_	
172-10	31838-31841	may	_	
172-11	31842-31849	reflect	_	
172-12	31850-31855	their	_	
172-13	31856-31863	initial	_	
172-14	31864-31870	action	_	
172-15	31871-31873	to	_	
172-16	31874-31882	decrease	_	
172-17	31883-31892	serotonin	_	
172-18	31893-31899	levels	_	
172-19	31900-31907	through	_	
172-20	31908-31917	serotonin	_	
172-21	31918-31926	activity	_	
172-22	31927-31929	at	_	
172-23	31930-31940	inhibitory	_	
172-24	31941-31942	5	_	
172-25	31942-31943	-	_	
172-26	31943-31947	HT1A	_	
172-27	31948-31961	autoreceptors	_	
172-28	31962-31964	in	_	
172-29	31965-31968	the	_	
172-30	31969-31974	raphe	_	
172-31	31975-31981	nuclei	_	
172-32	31982-31983	(	_	
172-33	31983-31986	e.g	_	
172-34	31986-31987	.	_	
172-35	31987-31988	,	_	
172-36	31988-31989	)	_	
172-37	31989-31990	.	_	

#Text=Because of the high concentration of 5-HT1A receptors in the hippocampal complex, blocking 5-HT1A receptors in this region may increase the efficacy of serotonergic pharmacotherapies for smoking cessation (e.g.,).
173-1	31991-31998	Because	_	
173-2	31999-32001	of	_	
173-3	32002-32005	the	_	
173-4	32006-32010	high	_	
173-5	32011-32024	concentration	_	
173-6	32025-32027	of	_	
173-7	32028-32029	5	_	
173-8	32029-32030	-	_	
173-9	32030-32034	HT1A	_	
173-10	32035-32044	receptors	_	
173-11	32045-32047	in	_	
173-12	32048-32051	the	_	
173-13	32052-32063	hippocampal	_	
173-14	32064-32071	complex	_	
173-15	32071-32072	,	_	
173-16	32073-32081	blocking	_	
173-17	32082-32083	5	_	
173-18	32083-32084	-	_	
173-19	32084-32088	HT1A	_	
173-20	32089-32098	receptors	_	
173-21	32099-32101	in	_	
173-22	32102-32106	this	_	
173-23	32107-32113	region	_	
173-24	32114-32117	may	_	
173-25	32118-32126	increase	_	
173-26	32127-32130	the	_	
173-27	32131-32139	efficacy	_	
173-28	32140-32142	of	_	
173-29	32143-32155	serotonergic	_	
173-30	32156-32173	pharmacotherapies	_	
173-31	32174-32177	for	_	
173-32	32178-32185	smoking	_	
173-33	32186-32195	cessation	_	
173-34	32196-32197	(	_	
173-35	32197-32200	e.g	_	
173-36	32200-32201	.	_	
173-37	32201-32202	,	_	
173-38	32202-32203	)	_	
173-39	32203-32204	.	_	

#Text=Indeed, fluoxetine has a greater effect to decrease nicotine withdrawal in rats when co-administered with the 5-HT1A receptor antagonist, p-MPPI than when administered alone.
174-1	32205-32211	Indeed	_	
174-2	32211-32212	,	_	
174-3	32213-32223	fluoxetine	_	
174-4	32224-32227	has	_	
174-5	32228-32229	a	_	
174-6	32230-32237	greater	_	
174-7	32238-32244	effect	_	
174-8	32245-32247	to	_	
174-9	32248-32256	decrease	_	
174-10	32257-32265	nicotine	_	
174-11	32266-32276	withdrawal	_	
174-12	32277-32279	in	_	
174-13	32280-32284	rats	_	
174-14	32285-32289	when	_	
174-15	32290-32305	co-administered	_	
174-16	32306-32310	with	_	
174-17	32311-32314	the	_	
174-18	32315-32316	5	_	
174-19	32316-32317	-	_	
174-20	32317-32321	HT1A	_	
174-21	32322-32330	receptor	_	
174-22	32331-32341	antagonist	_	
174-23	32341-32342	,	_	
174-24	32343-32349	p-MPPI	_	
174-25	32350-32354	than	_	
174-26	32355-32359	when	_	
174-27	32360-32372	administered	_	
174-28	32373-32378	alone	_	
174-29	32378-32379	.	_	

#Text=Future studies could examine whether blocking 5-HT1A receptors in the raphe nuclei or hippocampus could alter raphe function and augment serotonergic functioning sufficiently to facilitate smoking cessation.
175-1	32380-32386	Future	_	
175-2	32387-32394	studies	_	
175-3	32395-32400	could	_	
175-4	32401-32408	examine	_	
175-5	32409-32416	whether	_	
175-6	32417-32425	blocking	_	
175-7	32426-32427	5	_	
175-8	32427-32428	-	_	
175-9	32428-32432	HT1A	_	
175-10	32433-32442	receptors	_	
175-11	32443-32445	in	_	
175-12	32446-32449	the	_	
175-13	32450-32455	raphe	_	
175-14	32456-32462	nuclei	_	
175-15	32463-32465	or	_	
175-16	32466-32477	hippocampus	_	
175-17	32478-32483	could	_	
175-18	32484-32489	alter	_	
175-19	32490-32495	raphe	_	
175-20	32496-32504	function	_	
175-21	32505-32508	and	_	
175-22	32509-32516	augment	_	
175-23	32517-32529	serotonergic	_	
175-24	32530-32541	functioning	_	
175-25	32542-32554	sufficiently	_	
175-26	32555-32557	to	_	
175-27	32558-32568	facilitate	_	
175-28	32569-32576	smoking	_	
175-29	32577-32586	cessation	_	
175-30	32586-32587	.	_	

#Text=Although nicotine promotes serotonin release in the raphe nucleus, which has a high density of α4β2 nicotinic acetylcholine receptors localized to serotonergic neurons, other neurochemical mechanisms may also explain the current results.
176-1	32588-32596	Although	_	
176-2	32597-32605	nicotine	_	
176-3	32606-32614	promotes	_	
176-4	32615-32624	serotonin	_	
176-5	32625-32632	release	_	
176-6	32633-32635	in	_	
176-7	32636-32639	the	_	
176-8	32640-32645	raphe	_	
176-9	32646-32653	nucleus	_	
176-10	32653-32654	,	_	
176-11	32655-32660	which	_	
176-12	32661-32664	has	_	
176-13	32665-32666	a	_	
176-14	32667-32671	high	_	
176-15	32672-32679	density	_	
176-16	32680-32682	of	_	
176-17	32683-32687	α4β2	_	
176-18	32688-32697	nicotinic	_	
176-19	32698-32711	acetylcholine	_	
176-20	32712-32721	receptors	_	
176-21	32722-32731	localized	_	
176-22	32732-32734	to	_	
176-23	32735-32747	serotonergic	_	
176-24	32748-32755	neurons	_	
176-25	32755-32756	,	_	
176-26	32757-32762	other	_	
176-27	32763-32776	neurochemical	_	
176-28	32777-32787	mechanisms	_	
176-29	32788-32791	may	_	
176-30	32792-32796	also	_	
176-31	32797-32804	explain	_	
176-32	32805-32808	the	_	
176-33	32809-32816	current	_	
176-34	32817-32824	results	_	
176-35	32824-32825	.	_	

#Text=One possible mechanism is smoking-induced dopamine release, considering the moderate number of dopamine neurons in the dorsal raphe nucleus.
177-1	32826-32829	One	_	
177-2	32830-32838	possible	_	
177-3	32839-32848	mechanism	_	
177-4	32849-32851	is	_	
177-5	32852-32867	smoking-induced	_	
177-6	32868-32876	dopamine	_	
177-7	32877-32884	release	_	
177-8	32884-32885	,	_	
177-9	32886-32897	considering	_	
177-10	32898-32901	the	_	
177-11	32902-32910	moderate	_	
177-12	32911-32917	number	_	
177-13	32918-32920	of	_	
177-14	32921-32929	dopamine	_	
177-15	32930-32937	neurons	_	
177-16	32938-32940	in	_	
177-17	32941-32944	the	_	
177-18	32945-32951	dorsal	_	
177-19	32952-32957	raphe	_	
177-20	32958-32965	nucleus	_	
177-21	32965-32966	.	_	

#Text=However, interactions at dopamine D2-like receptors on serotonin neurons in the raphe nuclei increase extracellular serotonin concentrations in the raphe nuclei, indicating that serotonergic mechanisms, at least in part, explain the results.
178-1	32967-32974	However	_	
178-2	32974-32975	,	_	
178-3	32976-32988	interactions	_	
178-4	32989-32991	at	_	
178-5	32992-33000	dopamine	_	
178-6	33001-33003	D2	_	
178-7	33003-33004	-	_	
178-8	33004-33008	like	_	
178-9	33009-33018	receptors	_	
178-10	33019-33021	on	_	
178-11	33022-33031	serotonin	_	
178-12	33032-33039	neurons	_	
178-13	33040-33042	in	_	
178-14	33043-33046	the	_	
178-15	33047-33052	raphe	_	
178-16	33053-33059	nuclei	_	
178-17	33060-33068	increase	_	
178-18	33069-33082	extracellular	_	
178-19	33083-33092	serotonin	_	
178-20	33093-33107	concentrations	_	
178-21	33108-33110	in	_	
178-22	33111-33114	the	_	
178-23	33115-33120	raphe	_	
178-24	33121-33127	nuclei	_	
178-25	33127-33128	,	_	
178-26	33129-33139	indicating	_	
178-27	33140-33144	that	_	
178-28	33145-33157	serotonergic	_	
178-29	33158-33168	mechanisms	_	
178-30	33168-33169	,	_	
178-31	33170-33172	at	_	
178-32	33173-33178	least	_	
178-33	33179-33181	in	_	
178-34	33182-33186	part	_	
178-35	33186-33187	,	_	
178-36	33188-33195	explain	_	
178-37	33196-33199	the	_	
178-38	33200-33207	results	_	
178-39	33207-33208	.	_	

#Text=This study has limitations.
179-1	33209-33213	This	_	
179-2	33214-33219	study	_	
179-3	33220-33223	has	_	
179-4	33224-33235	limitations	_	
179-5	33235-33236	.	_	

#Text=Because fMRI does not allow direct examination of the serotonin system, the role of serotonin in the effects observed is only inferred.
180-1	33237-33244	Because	_	
180-2	33245-33249	fMRI	_	
180-3	33250-33254	does	_	
180-4	33255-33258	not	_	
180-5	33259-33264	allow	_	
180-6	33265-33271	direct	_	
180-7	33272-33283	examination	_	
180-8	33284-33286	of	_	
180-9	33287-33290	the	_	
180-10	33291-33300	serotonin	_	
180-11	33301-33307	system	_	
180-12	33307-33308	,	_	
180-13	33309-33312	the	_	
180-14	33313-33317	role	_	
180-15	33318-33320	of	_	
180-16	33321-33330	serotonin	_	
180-17	33331-33333	in	_	
180-18	33334-33337	the	_	
180-19	33338-33345	effects	_	
180-20	33346-33354	observed	_	
180-21	33355-33357	is	_	
180-22	33358-33362	only	_	
180-23	33363-33371	inferred	_	
180-24	33371-33372	.	_	

#Text=To help clarify the role of serotonin on the relationship between tobacco withdrawal and connectivity of the median raphe nuclei, future studies could examine effects of serotonergic medications on withdrawal symptoms and associated changes in brain function.
181-1	33373-33375	To	_	
181-2	33376-33380	help	_	
181-3	33381-33388	clarify	_	
181-4	33389-33392	the	_	
181-5	33393-33397	role	_	
181-6	33398-33400	of	_	
181-7	33401-33410	serotonin	_	
181-8	33411-33413	on	_	
181-9	33414-33417	the	_	
181-10	33418-33430	relationship	_	
181-11	33431-33438	between	_	
181-12	33439-33446	tobacco	_	
181-13	33447-33457	withdrawal	_	
181-14	33458-33461	and	_	
181-15	33462-33474	connectivity	_	
181-16	33475-33477	of	_	
181-17	33478-33481	the	_	
181-18	33482-33488	median	_	
181-19	33489-33494	raphe	_	
181-20	33495-33501	nuclei	_	
181-21	33501-33502	,	_	
181-22	33503-33509	future	_	
181-23	33510-33517	studies	_	
181-24	33518-33523	could	_	
181-25	33524-33531	examine	_	
181-26	33532-33539	effects	_	
181-27	33540-33542	of	_	
181-28	33543-33555	serotonergic	_	
181-29	33556-33567	medications	_	
181-30	33568-33570	on	_	
181-31	33571-33581	withdrawal	_	
181-32	33582-33590	symptoms	_	
181-33	33591-33594	and	_	
181-34	33595-33605	associated	_	
181-35	33606-33613	changes	_	
181-36	33614-33616	in	_	
181-37	33617-33622	brain	_	
181-38	33623-33631	function	_	
181-39	33631-33632	.	_	

#Text=As the participants were exclusively young smokers with short smoking histories and mild-to-moderate levels of nicotine dependence, as expected from smokers within this age range (e.g.,), the results may not be generalizable to the wider population of smokers.
182-1	33633-33635	As	_	
182-2	33636-33639	the	_	
182-3	33640-33652	participants	_	
182-4	33653-33657	were	_	
182-5	33658-33669	exclusively	_	
182-6	33670-33675	young	_	
182-7	33676-33683	smokers	_	
182-8	33684-33688	with	_	
182-9	33689-33694	short	_	
182-10	33695-33702	smoking	_	
182-11	33703-33712	histories	_	
182-12	33713-33716	and	_	
182-13	33717-33733	mild-to-moderate	_	
182-14	33734-33740	levels	_	
182-15	33741-33743	of	_	
182-16	33744-33752	nicotine	_	
182-17	33753-33763	dependence	_	
182-18	33763-33764	,	_	
182-19	33765-33767	as	_	
182-20	33768-33776	expected	_	
182-21	33777-33781	from	_	
182-22	33782-33789	smokers	_	
182-23	33790-33796	within	_	
182-24	33797-33801	this	_	
182-25	33802-33805	age	_	
182-26	33806-33811	range	_	
182-27	33812-33813	(	_	
182-28	33813-33816	e.g	_	
182-29	33816-33817	.	_	
182-30	33817-33818	,	_	
182-31	33818-33819	)	_	
182-32	33819-33820	,	_	
182-33	33821-33824	the	_	
182-34	33825-33832	results	_	
182-35	33833-33836	may	_	
182-36	33837-33840	not	_	
182-37	33841-33843	be	_	
182-38	33844-33857	generalizable	_	
182-39	33858-33860	to	_	
182-40	33861-33864	the	_	
182-41	33865-33870	wider	_	
182-42	33871-33881	population	_	
182-43	33882-33884	of	_	
182-44	33885-33892	smokers	_	
182-45	33892-33893	.	_	

#Text=Also, the small sample size and uneven gender distribution made it difficult to examine the influence of sex.
183-1	33894-33898	Also	_	
183-2	33898-33899	,	_	
183-3	33900-33903	the	_	
183-4	33904-33909	small	_	
183-5	33910-33916	sample	_	
183-6	33917-33921	size	_	
183-7	33922-33925	and	_	
183-8	33926-33932	uneven	_	
183-9	33933-33939	gender	_	
183-10	33940-33952	distribution	_	
183-11	33953-33957	made	_	
183-12	33958-33960	it	_	
183-13	33961-33970	difficult	_	
183-14	33971-33973	to	_	
183-15	33974-33981	examine	_	
183-16	33982-33985	the	_	
183-17	33986-33995	influence	_	
183-18	33996-33998	of	_	
183-19	33999-34002	sex	_	
183-20	34002-34003	.	_	

#Text=Further, because of differences between the dorsal and median raphe nuclei in resting-state functional connectivity, connectivity of these 2 regions was tested separately, increasing the chance of a type-1 error occurring due to the number of GLMs performed.
184-1	34004-34011	Further	_	
184-2	34011-34012	,	_	
184-3	34013-34020	because	_	
184-4	34021-34023	of	_	
184-5	34024-34035	differences	_	
184-6	34036-34043	between	_	
184-7	34044-34047	the	_	
184-8	34048-34054	dorsal	_	
184-9	34055-34058	and	_	
184-10	34059-34065	median	_	
184-11	34066-34071	raphe	_	
184-12	34072-34078	nuclei	_	
184-13	34079-34081	in	_	
184-14	34082-34095	resting-state	_	
184-15	34096-34106	functional	_	
184-16	34107-34119	connectivity	_	
184-17	34119-34120	,	_	
184-18	34121-34133	connectivity	_	
184-19	34134-34136	of	_	
184-20	34137-34142	these	_	
184-21	34143-34144	2	_	
184-22	34145-34152	regions	_	
184-23	34153-34156	was	_	
184-24	34157-34163	tested	_	
184-25	34164-34174	separately	_	
184-26	34174-34175	,	_	
184-27	34176-34186	increasing	_	
184-28	34187-34190	the	_	
184-29	34191-34197	chance	_	
184-30	34198-34200	of	_	
184-31	34201-34202	a	_	
184-32	34203-34207	type	_	
184-33	34207-34208	-	_	
184-34	34208-34209	1	_	
184-35	34210-34215	error	_	
184-36	34216-34225	occurring	_	
184-37	34226-34229	due	_	
184-38	34230-34232	to	_	
184-39	34233-34236	the	_	
184-40	34237-34243	number	_	
184-41	34244-34246	of	_	
184-42	34247-34251	GLMs	_	
184-43	34252-34261	performed	_	
184-44	34261-34262	.	_	

#Text=However, Bonferroni corrections for the number of seeds were performed on all higher-level analyses.
185-1	34263-34270	However	_	
185-2	34270-34271	,	_	
185-3	34272-34282	Bonferroni	_	
185-4	34283-34294	corrections	_	
185-5	34295-34298	for	_	
185-6	34299-34302	the	_	
185-7	34303-34309	number	_	
185-8	34310-34312	of	_	
185-9	34313-34318	seeds	_	
185-10	34319-34323	were	_	
185-11	34324-34333	performed	_	
185-12	34334-34336	on	_	
185-13	34337-34340	all	_	
185-14	34341-34353	higher-level	_	
185-15	34354-34362	analyses	_	
185-16	34362-34363	.	_	

#Text=Finally, the short fMRI scan duration (5 minutes) is a potential limitation.
186-1	34364-34371	Finally	_	
186-2	34371-34372	,	_	
186-3	34373-34376	the	_	
186-4	34377-34382	short	_	
186-5	34383-34387	fMRI	_	
186-6	34388-34392	scan	_	
186-7	34393-34401	duration	_	
186-8	34402-34403	(	_	
186-9	34403-34404	5	_	
186-10	34405-34412	minutes	_	
186-11	34412-34413	)	_	
186-12	34414-34416	is	_	
186-13	34417-34418	a	_	
186-14	34419-34428	potential	_	
186-15	34429-34439	limitation	_	
186-16	34439-34440	.	_	

#Text=However, when resting-state connectivity analyses were performed on data collected from 2 to 11 minutes, the average correlation strengths of time-courses in data collected during 5 minutes were comparable with the correlation strengths in data collected over 11 minutes.
187-1	34441-34448	However	_	
187-2	34448-34449	,	_	
187-3	34450-34454	when	_	
187-4	34455-34468	resting-state	_	
187-5	34469-34481	connectivity	_	
187-6	34482-34490	analyses	_	
187-7	34491-34495	were	_	
187-8	34496-34505	performed	_	
187-9	34506-34508	on	_	
187-10	34509-34513	data	_	
187-11	34514-34523	collected	_	
187-12	34524-34528	from	_	
187-13	34529-34530	2	_	
187-14	34531-34533	to	_	
187-15	34534-34536	11	_	
187-16	34537-34544	minutes	_	
187-17	34544-34545	,	_	
187-18	34546-34549	the	_	
187-19	34550-34557	average	_	
187-20	34558-34569	correlation	_	
187-21	34570-34579	strengths	_	
187-22	34580-34582	of	_	
187-23	34583-34595	time-courses	_	
187-24	34596-34598	in	_	
187-25	34599-34603	data	_	
187-26	34604-34613	collected	_	
187-27	34614-34620	during	_	
187-28	34621-34622	5	_	
187-29	34623-34630	minutes	_	
187-30	34631-34635	were	_	
187-31	34636-34646	comparable	_	
187-32	34647-34651	with	_	
187-33	34652-34655	the	_	
187-34	34656-34667	correlation	_	
187-35	34668-34677	strengths	_	
187-36	34678-34680	in	_	
187-37	34681-34685	data	_	
187-38	34686-34695	collected	_	
187-39	34696-34700	over	_	
187-40	34701-34703	11	_	
187-41	34704-34711	minutes	_	
187-42	34711-34712	.	_	

#Text=Funding
#Text=This work was supported by grants from the National Institute on Drug Abuse (grant no.
188-1	34713-34720	Funding	_	
188-2	34721-34725	This	_	
188-3	34726-34730	work	_	
188-4	34731-34734	was	_	
188-5	34735-34744	supported	_	
188-6	34745-34747	by	_	
188-7	34748-34754	grants	_	
188-8	34755-34759	from	_	
188-9	34760-34763	the	_	
188-10	34764-34772	National	_	
188-11	34773-34782	Institute	_	
188-12	34783-34785	on	_	
188-13	34786-34790	Drug	_	
188-14	34791-34796	Abuse	_	
188-15	34797-34798	(	_	
188-16	34798-34803	grant	_	
188-17	34804-34806	no	_	
188-18	34806-34807	.	_	

#Text=R01DA036487), the Canada Chair in Pharmacogenomics (RFT), a contract with Phillip Morris USA (contract no. 20063287), and endowments from the Thomas P and Katherine K Pike Chair in Addiction Studies and the Majorie M Greene Trust.
189-1	34808-34819	R01DA036487	_	
189-2	34819-34820	)	_	
189-3	34820-34821	,	_	
189-4	34822-34825	the	_	
189-5	34826-34832	Canada	_	
189-6	34833-34838	Chair	_	
189-7	34839-34841	in	_	
189-8	34842-34858	Pharmacogenomics	_	
189-9	34859-34860	(	_	
189-10	34860-34863	RFT	_	
189-11	34863-34864	)	_	
189-12	34864-34865	,	_	
189-13	34866-34867	a	_	
189-14	34868-34876	contract	_	
189-15	34877-34881	with	_	
189-16	34882-34889	Phillip	_	
189-17	34890-34896	Morris	_	
189-18	34897-34900	USA	_	
189-19	34901-34902	(	_	
189-20	34902-34910	contract	_	
189-21	34911-34913	no	_	
189-22	34913-34914	.	_	
189-23	34915-34923	20063287	_	
189-24	34923-34924	)	_	
189-25	34924-34925	,	_	
189-26	34926-34929	and	_	
189-27	34930-34940	endowments	_	
189-28	34941-34945	from	_	
189-29	34946-34949	the	_	
189-30	34950-34956	Thomas	_	
189-31	34957-34958	P	_	
189-32	34959-34962	and	_	
189-33	34963-34972	Katherine	_	
189-34	34973-34974	K	_	
189-35	34975-34979	Pike	_	
189-36	34980-34985	Chair	_	
189-37	34986-34988	in	_	
189-38	34989-34998	Addiction	_	
189-39	34999-35006	Studies	_	
189-40	35007-35010	and	_	
189-41	35011-35014	the	_	
189-42	35015-35022	Majorie	_	
189-43	35023-35024	M	_	
189-44	35025-35031	Greene	_	
189-45	35032-35037	Trust	_	
189-46	35037-35038	.	_	

#Text=As principal investigator of the project, Dr London takes responsibility for the integrity of the data and the accuracy of the data analysis.
190-1	35039-35041	As	_	
190-2	35042-35051	principal	_	
190-3	35052-35064	investigator	_	
190-4	35065-35067	of	_	
190-5	35068-35071	the	_	
190-6	35072-35079	project	_	
190-7	35079-35080	,	_	
190-8	35081-35083	Dr	_	
190-9	35084-35090	London	_	
190-10	35091-35096	takes	_	
190-11	35097-35111	responsibility	_	
190-12	35112-35115	for	_	
190-13	35116-35119	the	_	
190-14	35120-35129	integrity	_	
190-15	35130-35132	of	_	
190-16	35133-35136	the	_	
190-17	35137-35141	data	_	
190-18	35142-35145	and	_	
190-19	35146-35149	the	_	
190-20	35150-35158	accuracy	_	
190-21	35159-35161	of	_	
190-22	35162-35165	the	_	
190-23	35166-35170	data	_	
190-24	35171-35179	analysis	_	
190-25	35179-35180	.	_	

#Text=Supplementary Material
#Text=Supplementary data are available at International Journal of Neuropsychopharmacology online.
191-1	35181-35194	Supplementary	_	
191-2	35195-35203	Material	_	
191-3	35204-35217	Supplementary	_	
191-4	35218-35222	data	_	
191-5	35223-35226	are	_	
191-6	35227-35236	available	_	
191-7	35237-35239	at	_	
191-8	35240-35253	International	_	
191-9	35254-35261	Journal	_	
191-10	35262-35264	of	_	
191-11	35265-35288	Neuropsychopharmacology	_	
191-12	35289-35295	online	_	
191-13	35295-35296	.	_	

#Text=Statement of Interest
#Text=RFT has consulted for Apotex and Avanir on topics unrelated to this study.
192-1	35297-35306	Statement	_	
192-2	35307-35309	of	_	
192-3	35310-35318	Interest	_	
192-4	35319-35322	RFT	_	
192-5	35323-35326	has	_	
192-6	35327-35336	consulted	_	
192-7	35337-35340	for	_	
192-8	35341-35347	Apotex	_	
192-9	35348-35351	and	_	
192-10	35352-35358	Avanir	_	
192-11	35359-35361	on	_	
192-12	35362-35368	topics	_	
192-13	35369-35378	unrelated	_	
192-14	35379-35381	to	_	
192-15	35382-35386	this	_	
192-16	35387-35392	study	_	
192-17	35392-35393	.	_	

#Text=RFT has also received peer-reviewed, arms-length funding from GRAND (unrestricted funding support from Pfizer) as well as University and Hospital speaker honoraria and an associate editor (CPT) honorarium.
193-1	35394-35397	RFT	_	
193-2	35398-35401	has	_	
193-3	35402-35406	also	_	
193-4	35407-35415	received	_	
193-5	35416-35429	peer-reviewed	_	
193-6	35429-35430	,	_	
193-7	35431-35442	arms-length	_	
193-8	35443-35450	funding	_	
193-9	35451-35455	from	_	
193-10	35456-35461	GRAND	_	
193-11	35462-35463	(	_	
193-12	35463-35475	unrestricted	_	
193-13	35476-35483	funding	_	
193-14	35484-35491	support	_	
193-15	35492-35496	from	_	
193-16	35497-35503	Pfizer	_	
193-17	35503-35504	)	_	
193-18	35505-35507	as	_	
193-19	35508-35512	well	_	
193-20	35513-35515	as	_	
193-21	35516-35526	University	_	
193-22	35527-35530	and	_	
193-23	35531-35539	Hospital	_	
193-24	35540-35547	speaker	_	
193-25	35548-35557	honoraria	_	
193-26	35558-35561	and	_	
193-27	35562-35564	an	_	
193-28	35565-35574	associate	_	
193-29	35575-35581	editor	_	
193-30	35582-35583	(	_	
193-31	35583-35586	CPT	_	
193-32	35586-35587	)	_	
193-33	35588-35598	honorarium	_	
193-34	35598-35599	.	_	

#Text=The remaining authors declare no conflicts of interest.
194-1	35600-35603	The	_	
194-2	35604-35613	remaining	_	
194-3	35614-35621	authors	_	
194-4	35622-35629	declare	_	
194-5	35630-35632	no	_	
194-6	35633-35642	conflicts	_	
194-7	35643-35645	of	_	
194-8	35646-35654	interest	_	
194-9	35654-35655	.	_	

#Text=Supplementary Material
#Text=References
#Text=D2-like dopamine receptors depolarize dorsal raphe serotonin neurons through the activation of nonselective cationic conductance
#Text=Non-linear optimisation
#Text=Tobacco craving predicts lapse to smoking among adolescent smokers in cessation treatment
#Text=Functional connectivity of the dorsal and median raphe nuclei at rest
#Text=Establishing a nicotine threshold for addiction.
195-1	35656-35669	Supplementary	_	
195-2	35670-35678	Material	_	
195-3	35679-35689	References	_	
195-4	35690-35692	D2	_	
195-5	35692-35693	-	_	
195-6	35693-35697	like	_	
195-7	35698-35706	dopamine	_	
195-8	35707-35716	receptors	_	
195-9	35717-35727	depolarize	_	
195-10	35728-35734	dorsal	_	
195-11	35735-35740	raphe	_	
195-12	35741-35750	serotonin	_	
195-13	35751-35758	neurons	_	
195-14	35759-35766	through	_	
195-15	35767-35770	the	_	
195-16	35771-35781	activation	_	
195-17	35782-35784	of	_	
195-18	35785-35797	nonselective	_	
195-19	35798-35806	cationic	_	
195-20	35807-35818	conductance	_	
195-21	35819-35829	Non-linear	_	
195-22	35830-35842	optimisation	_	
195-23	35843-35850	Tobacco	_	
195-24	35851-35858	craving	_	
195-25	35859-35867	predicts	_	
195-26	35868-35873	lapse	_	
195-27	35874-35876	to	_	
195-28	35877-35884	smoking	_	
195-29	35885-35890	among	_	
195-30	35891-35901	adolescent	_	
195-31	35902-35909	smokers	_	
195-32	35910-35912	in	_	
195-33	35913-35922	cessation	_	
195-34	35923-35932	treatment	_	
195-35	35933-35943	Functional	_	
195-36	35944-35956	connectivity	_	
195-37	35957-35959	of	_	
195-38	35960-35963	the	_	
195-39	35964-35970	dorsal	_	
195-40	35971-35974	and	_	
195-41	35975-35981	median	_	
195-42	35982-35987	raphe	_	
195-43	35988-35994	nuclei	_	
195-44	35995-35997	at	_	
195-45	35998-36002	rest	_	
195-46	36003-36015	Establishing	_	
195-47	36016-36017	a	_	
195-48	36018-36026	nicotine	_	
195-49	36027-36036	threshold	_	
195-50	36037-36040	for	_	
195-51	36041-36050	addiction	_	
195-52	36050-36051	.	_	

#Text=The implications for tobacco regulation
#Text=Effects of nicotine administration and its withdrawal on plasma corticosterone and brain 5-hydroxyindoles
#Text=Smoking-associated changes in the serotonergic systems of discrete regions of human brain
#Text=Altered resting state functional connectivity of anterior insula in young smokers
#Text=Is there a role for 5-HT1A agonists in the treatment of depression
#Text=The efferent connections of the nucleus raphe centralis superior in the rat as revealed by radioautography
#Text=Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder
#Text=The dorsal raphé nucleus is a crucial structure mediating nicotine’s anxiolytic effects and the development of tolerance and withdrawal responses
#Text=The biochemistry of affective disorders
#Text=Serotonin-1A receptor imaging in recurrent depression: replication and literature review
#Text=Mortality in relation to smoking: 50 years’ observations on male British doctors
#Text=Determinants of tobacco use and renaming the FTND to the fagerstrom test for cigarette dependence
#Text=The role of serotonin in reward, punishment and behavioural inhibition in humans: insights from studies with acute tryptophan depletion
#Text=Reduced-nicotine cigarettes in young smokers: impact of nicotine metabolism on nicotine dose effects
#Text=Sex differences in tobacco withdrawal and responses to smoking reduced nicotine cigarettes in young smokers
#Text=The relationship between reward and punishment processing and the 5-HT1A receptor as shown by PET
#Text=Dopamine D2 receptor-mediated regulation of serotonin extracellular concentration in the dorsal raphe nucleus of freely moving rats
#Text=Serotonin receptors as potential targets for modulation of nicotine use and dependence
#Text=Serotonin and reward-related behavior: focus on 5-HT2C receptors
#Text=Simultaneous detection of indoleamines and dopamine in rat dorsal raphe nuclei using specific antibodies
#Text=Behavioral and neural markers of cigarette-craving regulation in young-adult smokers during abstinence and after smoking
#Text=Patterns of smoking among adolescents in Malaysia and Thailand: findings from the international tobacco control Southeast Asia survey
#Text=Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats
#Text=The early timecourse of smoking withdrawal effects
#Text=The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control
#Text=Antidepressants for smoking cessation
#Text=Improved optimization for the robust and accurate linear registration and motion correction of brain images
#Text=A global optimisation method for robust affine registration of brain images
#Text=Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET
#Text=Projections from the ventral tegmental area and mesencephalic raphe to the dorsal raphe nucleus in the rat.
196-1	36052-36055	The	_	
196-2	36056-36068	implications	_	
196-3	36069-36072	for	_	
196-4	36073-36080	tobacco	_	
196-5	36081-36091	regulation	_	
196-6	36092-36099	Effects	_	
196-7	36100-36102	of	_	
196-8	36103-36111	nicotine	_	
196-9	36112-36126	administration	_	
196-10	36127-36130	and	_	
196-11	36131-36134	its	_	
196-12	36135-36145	withdrawal	_	
196-13	36146-36148	on	_	
196-14	36149-36155	plasma	_	
196-15	36156-36170	corticosterone	_	
196-16	36171-36174	and	_	
196-17	36175-36180	brain	_	
196-18	36181-36182	5	_	
196-19	36182-36183	-	_	
196-20	36183-36197	hydroxyindoles	_	
196-21	36198-36216	Smoking-associated	_	
196-22	36217-36224	changes	_	
196-23	36225-36227	in	_	
196-24	36228-36231	the	_	
196-25	36232-36244	serotonergic	_	
196-26	36245-36252	systems	_	
196-27	36253-36255	of	_	
196-28	36256-36264	discrete	_	
196-29	36265-36272	regions	_	
196-30	36273-36275	of	_	
196-31	36276-36281	human	_	
196-32	36282-36287	brain	_	
196-33	36288-36295	Altered	_	
196-34	36296-36303	resting	_	
196-35	36304-36309	state	_	
196-36	36310-36320	functional	_	
196-37	36321-36333	connectivity	_	
196-38	36334-36336	of	_	
196-39	36337-36345	anterior	_	
196-40	36346-36352	insula	_	
196-41	36353-36355	in	_	
196-42	36356-36361	young	_	
196-43	36362-36369	smokers	_	
196-44	36370-36372	Is	_	
196-45	36373-36378	there	_	
196-46	36379-36380	a	_	
196-47	36381-36385	role	_	
196-48	36386-36389	for	_	
196-49	36390-36391	5	_	
196-50	36391-36392	-	_	
196-51	36392-36396	HT1A	_	
196-52	36397-36405	agonists	_	
196-53	36406-36408	in	_	
196-54	36409-36412	the	_	
196-55	36413-36422	treatment	_	
196-56	36423-36425	of	_	
196-57	36426-36436	depression	_	
196-58	36437-36440	The	_	
196-59	36441-36449	efferent	_	
196-60	36450-36461	connections	_	
196-61	36462-36464	of	_	
196-62	36465-36468	the	_	
196-63	36469-36476	nucleus	_	
196-64	36477-36482	raphe	_	
196-65	36483-36492	centralis	_	
196-66	36493-36501	superior	_	
196-67	36502-36504	in	_	
196-68	36505-36508	the	_	
196-69	36509-36512	rat	_	
196-70	36513-36515	as	_	
196-71	36516-36524	revealed	_	
196-72	36525-36527	by	_	
196-73	36528-36543	radioautography	_	
196-74	36544-36552	Elevated	_	
196-75	36553-36562	serotonin	_	
196-76	36563-36574	transporter	_	
196-77	36575-36582	binding	_	
196-78	36583-36585	in	_	
196-79	36586-36591	major	_	
196-80	36592-36602	depressive	_	
196-81	36603-36611	disorder	_	
196-82	36612-36620	assessed	_	
196-83	36621-36626	using	_	
196-84	36627-36635	positron	_	
196-85	36636-36644	emission	_	
196-86	36645-36655	tomography	_	
196-87	36656-36659	and	_	
196-88	36660-36661	[	_	
196-89	36661-36664	11C	_	
196-90	36664-36665	]	_	
196-91	36665-36669	DASB	_	
196-92	36669-36670	;	_	
196-93	36671-36681	comparison	_	
196-94	36682-36686	with	_	
196-95	36687-36694	bipolar	_	
196-96	36695-36703	disorder	_	
196-97	36704-36707	The	_	
196-98	36708-36714	dorsal	_	
196-99	36715-36720	raphé	_	
196-100	36721-36728	nucleus	_	
196-101	36729-36731	is	_	
196-102	36732-36733	a	_	
196-103	36734-36741	crucial	_	
196-104	36742-36751	structure	_	
196-105	36752-36761	mediating	_	
196-106	36762-36770	nicotine	_	
196-107	36770-36771	’	_	
196-108	36771-36772	s	_	
196-109	36773-36783	anxiolytic	_	
196-110	36784-36791	effects	_	
196-111	36792-36795	and	_	
196-112	36796-36799	the	_	
196-113	36800-36811	development	_	
196-114	36812-36814	of	_	
196-115	36815-36824	tolerance	_	
196-116	36825-36828	and	_	
196-117	36829-36839	withdrawal	_	
196-118	36840-36849	responses	_	
196-119	36850-36853	The	_	
196-120	36854-36866	biochemistry	_	
196-121	36867-36869	of	_	
196-122	36870-36879	affective	_	
196-123	36880-36889	disorders	_	
196-124	36890-36899	Serotonin	_	
196-125	36899-36900	-	_	
196-126	36900-36902	1A	_	
196-127	36903-36911	receptor	_	
196-128	36912-36919	imaging	_	
196-129	36920-36922	in	_	
196-130	36923-36932	recurrent	_	
196-131	36933-36943	depression	_	
196-132	36943-36944	:	_	
196-133	36945-36956	replication	_	
196-134	36957-36960	and	_	
196-135	36961-36971	literature	_	
196-136	36972-36978	review	_	
196-137	36979-36988	Mortality	_	
196-138	36989-36991	in	_	
196-139	36992-37000	relation	_	
196-140	37001-37003	to	_	
196-141	37004-37011	smoking	_	
196-142	37011-37012	:	_	
196-143	37013-37015	50	_	
196-144	37016-37021	years	_	
196-145	37021-37022	’	_	
196-146	37023-37035	observations	_	
196-147	37036-37038	on	_	
196-148	37039-37043	male	_	
196-149	37044-37051	British	_	
196-150	37052-37059	doctors	_	
196-151	37060-37072	Determinants	_	
196-152	37073-37075	of	_	
196-153	37076-37083	tobacco	_	
196-154	37084-37087	use	_	
196-155	37088-37091	and	_	
196-156	37092-37100	renaming	_	
196-157	37101-37104	the	_	
196-158	37105-37109	FTND	_	
196-159	37110-37112	to	_	
196-160	37113-37116	the	_	
196-161	37117-37127	fagerstrom	_	
196-162	37128-37132	test	_	
196-163	37133-37136	for	_	
196-164	37137-37146	cigarette	_	
196-165	37147-37157	dependence	_	
196-166	37158-37161	The	_	
196-167	37162-37166	role	_	
196-168	37167-37169	of	_	
196-169	37170-37179	serotonin	_	
196-170	37180-37182	in	_	
196-171	37183-37189	reward	_	
196-172	37189-37190	,	_	
196-173	37191-37201	punishment	_	
196-174	37202-37205	and	_	
196-175	37206-37217	behavioural	_	
196-176	37218-37228	inhibition	_	
196-177	37229-37231	in	_	
196-178	37232-37238	humans	_	
196-179	37238-37239	:	_	
196-180	37240-37248	insights	_	
196-181	37249-37253	from	_	
196-182	37254-37261	studies	_	
196-183	37262-37266	with	_	
196-184	37267-37272	acute	_	
196-185	37273-37283	tryptophan	_	
196-186	37284-37293	depletion	_	
196-187	37294-37310	Reduced-nicotine	_	
196-188	37311-37321	cigarettes	_	
196-189	37322-37324	in	_	
196-190	37325-37330	young	_	
196-191	37331-37338	smokers	_	
196-192	37338-37339	:	_	
196-193	37340-37346	impact	_	
196-194	37347-37349	of	_	
196-195	37350-37358	nicotine	_	
196-196	37359-37369	metabolism	_	
196-197	37370-37372	on	_	
196-198	37373-37381	nicotine	_	
196-199	37382-37386	dose	_	
196-200	37387-37394	effects	_	
196-201	37395-37398	Sex	_	
196-202	37399-37410	differences	_	
196-203	37411-37413	in	_	
196-204	37414-37421	tobacco	_	
196-205	37422-37432	withdrawal	_	
196-206	37433-37436	and	_	
196-207	37437-37446	responses	_	
196-208	37447-37449	to	_	
196-209	37450-37457	smoking	_	
196-210	37458-37465	reduced	_	
196-211	37466-37474	nicotine	_	
196-212	37475-37485	cigarettes	_	
196-213	37486-37488	in	_	
196-214	37489-37494	young	_	
196-215	37495-37502	smokers	_	
196-216	37503-37506	The	_	
196-217	37507-37519	relationship	_	
196-218	37520-37527	between	_	
196-219	37528-37534	reward	_	
196-220	37535-37538	and	_	
196-221	37539-37549	punishment	_	
196-222	37550-37560	processing	_	
196-223	37561-37564	and	_	
196-224	37565-37568	the	_	
196-225	37569-37570	5	_	
196-226	37570-37571	-	_	
196-227	37571-37575	HT1A	_	
196-228	37576-37584	receptor	_	
196-229	37585-37587	as	_	
196-230	37588-37593	shown	_	
196-231	37594-37596	by	_	
196-232	37597-37600	PET	_	
196-233	37601-37609	Dopamine	_	
196-234	37610-37612	D2	_	
196-235	37613-37630	receptor-mediated	_	
196-236	37631-37641	regulation	_	
196-237	37642-37644	of	_	
196-238	37645-37654	serotonin	_	
196-239	37655-37668	extracellular	_	
196-240	37669-37682	concentration	_	
196-241	37683-37685	in	_	
196-242	37686-37689	the	_	
196-243	37690-37696	dorsal	_	
196-244	37697-37702	raphe	_	
196-245	37703-37710	nucleus	_	
196-246	37711-37713	of	_	
196-247	37714-37720	freely	_	
196-248	37721-37727	moving	_	
196-249	37728-37732	rats	_	
196-250	37733-37742	Serotonin	_	
196-251	37743-37752	receptors	_	
196-252	37753-37755	as	_	
196-253	37756-37765	potential	_	
196-254	37766-37773	targets	_	
196-255	37774-37777	for	_	
196-256	37778-37788	modulation	_	
196-257	37789-37791	of	_	
196-258	37792-37800	nicotine	_	
196-259	37801-37804	use	_	
196-260	37805-37808	and	_	
196-261	37809-37819	dependence	_	
196-262	37820-37829	Serotonin	_	
196-263	37830-37833	and	_	
196-264	37834-37848	reward-related	_	
196-265	37849-37857	behavior	_	
196-266	37857-37858	:	_	
196-267	37859-37864	focus	_	
196-268	37865-37867	on	_	
196-269	37868-37869	5	_	
196-270	37869-37870	-	_	
196-271	37870-37874	HT2C	_	
196-272	37875-37884	receptors	_	
196-273	37885-37897	Simultaneous	_	
196-274	37898-37907	detection	_	
196-275	37908-37910	of	_	
196-276	37911-37923	indoleamines	_	
196-277	37924-37927	and	_	
196-278	37928-37936	dopamine	_	
196-279	37937-37939	in	_	
196-280	37940-37943	rat	_	
196-281	37944-37950	dorsal	_	
196-282	37951-37956	raphe	_	
196-283	37957-37963	nuclei	_	
196-284	37964-37969	using	_	
196-285	37970-37978	specific	_	
196-286	37979-37989	antibodies	_	
196-287	37990-38000	Behavioral	_	
196-288	38001-38004	and	_	
196-289	38005-38011	neural	_	
196-290	38012-38019	markers	_	
196-291	38020-38022	of	_	
196-292	38023-38040	cigarette-craving	_	
196-293	38041-38051	regulation	_	
196-294	38052-38054	in	_	
196-295	38055-38066	young-adult	_	
196-296	38067-38074	smokers	_	
196-297	38075-38081	during	_	
196-298	38082-38092	abstinence	_	
196-299	38093-38096	and	_	
196-300	38097-38102	after	_	
196-301	38103-38110	smoking	_	
196-302	38111-38119	Patterns	_	
196-303	38120-38122	of	_	
196-304	38123-38130	smoking	_	
196-305	38131-38136	among	_	
196-306	38137-38148	adolescents	_	
196-307	38149-38151	in	_	
196-308	38152-38160	Malaysia	_	
196-309	38161-38164	and	_	
196-310	38165-38173	Thailand	_	
196-311	38173-38174	:	_	
196-312	38175-38183	findings	_	
196-313	38184-38188	from	_	
196-314	38189-38192	the	_	
196-315	38193-38206	international	_	
196-316	38207-38214	tobacco	_	
196-317	38215-38222	control	_	
196-318	38223-38232	Southeast	_	
196-319	38233-38237	Asia	_	
196-320	38238-38244	survey	_	
196-321	38245-38255	Fluoxetine	_	
196-322	38256-38264	combined	_	
196-323	38265-38269	with	_	
196-324	38270-38271	a	_	
196-325	38272-38281	serotonin	_	
196-326	38281-38282	-	_	
196-327	38282-38284	1A	_	
196-328	38285-38293	receptor	_	
196-329	38294-38304	antagonist	_	
196-330	38305-38313	reversed	_	
196-331	38314-38320	reward	_	
196-332	38321-38329	deficits	_	
196-333	38330-38338	observed	_	
196-334	38339-38345	during	_	
196-335	38346-38354	nicotine	_	
196-336	38355-38358	and	_	
196-337	38359-38370	amphetamine	_	
196-338	38371-38381	withdrawal	_	
196-339	38382-38384	in	_	
196-340	38385-38389	rats	_	
196-341	38390-38393	The	_	
196-342	38394-38399	early	_	
196-343	38400-38410	timecourse	_	
196-344	38411-38413	of	_	
196-345	38414-38421	smoking	_	
196-346	38422-38432	withdrawal	_	
196-347	38433-38440	effects	_	
196-348	38441-38444	The	_	
196-349	38445-38446	5	_	
196-350	38446-38447	-	_	
196-351	38447-38451	HT2C	_	
196-352	38452-38460	receptor	_	
196-353	38461-38468	agonist	_	
196-354	38469-38479	lorcaserin	_	
196-355	38480-38487	reduces	_	
196-356	38488-38496	nicotine	_	
196-357	38497-38516	self-administration	_	
196-358	38516-38517	,	_	
196-359	38518-38532	discrimination	_	
196-360	38532-38533	,	_	
196-361	38534-38537	and	_	
196-362	38538-38551	reinstatement	_	
196-363	38551-38552	:	_	
196-364	38553-38565	relationship	_	
196-365	38566-38568	to	_	
196-366	38569-38576	feeding	_	
196-367	38577-38585	behavior	_	
196-368	38586-38589	and	_	
196-369	38590-38597	impulse	_	
196-370	38598-38605	control	_	
196-371	38606-38621	Antidepressants	_	
196-372	38622-38625	for	_	
196-373	38626-38633	smoking	_	
196-374	38634-38643	cessation	_	
196-375	38644-38652	Improved	_	
196-376	38653-38665	optimization	_	
196-377	38666-38669	for	_	
196-378	38670-38673	the	_	
196-379	38674-38680	robust	_	
196-380	38681-38684	and	_	
196-381	38685-38693	accurate	_	
196-382	38694-38700	linear	_	
196-383	38701-38713	registration	_	
196-384	38714-38717	and	_	
196-385	38718-38724	motion	_	
196-386	38725-38735	correction	_	
196-387	38736-38738	of	_	
196-388	38739-38744	brain	_	
196-389	38745-38751	images	_	
196-390	38752-38753	A	_	
196-391	38754-38760	global	_	
196-392	38761-38773	optimisation	_	
196-393	38774-38780	method	_	
196-394	38781-38784	for	_	
196-395	38785-38791	robust	_	
196-396	38792-38798	affine	_	
196-397	38799-38811	registration	_	
196-398	38812-38814	of	_	
196-399	38815-38820	brain	_	
196-400	38821-38827	images	_	
196-401	38828-38831	Sex	_	
196-402	38832-38843	differences	_	
196-403	38844-38846	in	_	
196-404	38847-38850	the	_	
196-405	38851-38860	serotonin	_	
196-406	38861-38863	1A	_	
196-407	38864-38872	receptor	_	
196-408	38873-38876	and	_	
196-409	38877-38886	serotonin	_	
196-410	38887-38898	transporter	_	
196-411	38899-38906	binding	_	
196-412	38907-38909	in	_	
196-413	38910-38913	the	_	
196-414	38914-38919	human	_	
196-415	38920-38925	brain	_	
196-416	38926-38934	measured	_	
196-417	38935-38937	by	_	
196-418	38938-38941	PET	_	
196-419	38942-38953	Projections	_	
196-420	38954-38958	from	_	
196-421	38959-38962	the	_	
196-422	38963-38970	ventral	_	
196-423	38971-38980	tegmental	_	
196-424	38981-38985	area	_	
196-425	38986-38989	and	_	
196-426	38990-39003	mesencephalic	_	
196-427	39004-39009	raphe	_	
196-428	39010-39012	to	_	
196-429	39013-39016	the	_	
196-430	39017-39023	dorsal	_	
196-431	39024-39029	raphe	_	
196-432	39030-39037	nucleus	_	
196-433	39038-39040	in	_	
196-434	39041-39044	the	_	
196-435	39045-39048	rat	_	
196-436	39048-39049	.	_	

#Text=Evidence for a minor dopaminergic component
#Text=Evidence for a complex influence of nicotinic acetylcholine receptors on hippocampal serotonin release
#Text=Behavioral impulsivity predicts treatment outcome in a smoking cessation program for adolescent smokers
#Text=Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats
#Text=Reduced frontal cortical thickness and increased caudate volume within fronto-striatal circuits in young adult smokers
#Text=Smoking cessation rates in the United States: a comparison of young adult and older smokers
#Text=Hippocampal innervation by serotonin neurons of the midbrain raphe in the rat
#Text=Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment
#Text=Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635
#Text=Sex differences in nicotine effects and self-administration: Review of human and animal evidence
#Text=Stimulation of serotonin2c receptors blocks the hyperactivation of midbrain dopamine neurons induced by nicotine administration
#Text=First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635
#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
#Text=Steps toward optimizing motion artefact after removal in functional connectivity MRI; A reply to Carp
#Text=Effects of systemic nicotine on serotonin release in rat brain
#Text=An improved framework for confound regression and filtering for control of motion artifact in the preprocessing or resting-state functional connectivity data
#Text=Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study
#Text=Lorcaserin for smoking cessation and associated weight gain: a randomized 12-week clinical trial
#Text=Smoking withdrawal symptoms in two weeks of abstinence
#Text=Negative affect and smoking lapses: a prospective analysis
#Text=Intrinsic functional connectivity as a tool for human connectomics: theory, properties, and optimization
#Text=Temporal autocorrelation in univariate linear modeling of FMRI data
#Text=Gender effects on mood and cigarette craving during early abstinence and resumption of smoking
197-1	39050-39058	Evidence	_	
197-2	39059-39062	for	_	
197-3	39063-39064	a	_	
197-4	39065-39070	minor	_	
197-5	39071-39083	dopaminergic	_	
197-6	39084-39093	component	_	
197-7	39094-39102	Evidence	_	
197-8	39103-39106	for	_	
197-9	39107-39108	a	_	
197-10	39109-39116	complex	_	
197-11	39117-39126	influence	_	
197-12	39127-39129	of	_	
197-13	39130-39139	nicotinic	_	
197-14	39140-39153	acetylcholine	_	
197-15	39154-39163	receptors	_	
197-16	39164-39166	on	_	
197-17	39167-39178	hippocampal	_	
197-18	39179-39188	serotonin	_	
197-19	39189-39196	release	_	
197-20	39197-39207	Behavioral	_	
197-21	39208-39219	impulsivity	_	
197-22	39220-39228	predicts	_	
197-23	39229-39238	treatment	_	
197-24	39239-39246	outcome	_	
197-25	39247-39249	in	_	
197-26	39250-39251	a	_	
197-27	39252-39259	smoking	_	
197-28	39260-39269	cessation	_	
197-29	39270-39277	program	_	
197-30	39278-39281	for	_	
197-31	39282-39292	adolescent	_	
197-32	39293-39300	smokers	_	
197-33	39301-39311	Lorcaserin	_	
197-34	39311-39312	,	_	
197-35	39313-39314	a	_	
197-36	39315-39316	5	_	
197-37	39316-39317	-	_	
197-38	39317-39321	HT2C	_	
197-39	39322-39329	agonist	_	
197-40	39329-39330	,	_	
197-41	39331-39340	decreases	_	
197-42	39341-39349	nicotine	_	
197-43	39350-39369	self-administration	_	
197-44	39370-39372	in	_	
197-45	39373-39379	female	_	
197-46	39380-39384	rats	_	
197-47	39385-39392	Reduced	_	
197-48	39393-39400	frontal	_	
197-49	39401-39409	cortical	_	
197-50	39410-39419	thickness	_	
197-51	39420-39423	and	_	
197-52	39424-39433	increased	_	
197-53	39434-39441	caudate	_	
197-54	39442-39448	volume	_	
197-55	39449-39455	within	_	
197-56	39456-39471	fronto-striatal	_	
197-57	39472-39480	circuits	_	
197-58	39481-39483	in	_	
197-59	39484-39489	young	_	
197-60	39490-39495	adult	_	
197-61	39496-39503	smokers	_	
197-62	39504-39511	Smoking	_	
197-63	39512-39521	cessation	_	
197-64	39522-39527	rates	_	
197-65	39528-39530	in	_	
197-66	39531-39534	the	_	
197-67	39535-39541	United	_	
197-68	39542-39548	States	_	
197-69	39548-39549	:	_	
197-70	39550-39551	a	_	
197-71	39552-39562	comparison	_	
197-72	39563-39565	of	_	
197-73	39566-39571	young	_	
197-74	39572-39577	adult	_	
197-75	39578-39581	and	_	
197-76	39582-39587	older	_	
197-77	39588-39595	smokers	_	
197-78	39596-39607	Hippocampal	_	
197-79	39608-39619	innervation	_	
197-80	39620-39622	by	_	
197-81	39623-39632	serotonin	_	
197-82	39633-39640	neurons	_	
197-83	39641-39643	of	_	
197-84	39644-39647	the	_	
197-85	39648-39656	midbrain	_	
197-86	39657-39662	raphe	_	
197-87	39663-39665	in	_	
197-88	39666-39669	the	_	
197-89	39670-39673	rat	_	
197-90	39674-39685	Multicenter	_	
197-91	39686-39691	trial	_	
197-92	39692-39694	of	_	
197-93	39695-39705	fluoxetine	_	
197-94	39706-39708	as	_	
197-95	39709-39711	an	_	
197-96	39712-39719	adjunct	_	
197-97	39720-39722	to	_	
197-98	39723-39733	behavioral	_	
197-99	39734-39741	smoking	_	
197-100	39742-39751	cessation	_	
197-101	39752-39761	treatment	_	
197-102	39762-39769	Effects	_	
197-103	39770-39772	of	_	
197-104	39773-39776	sex	_	
197-105	39776-39777	,	_	
197-106	39778-39781	age	_	
197-107	39781-39782	,	_	
197-108	39783-39786	and	_	
197-109	39787-39797	aggressive	_	
197-110	39798-39804	traits	_	
197-111	39805-39807	in	_	
197-112	39808-39811	man	_	
197-113	39812-39814	on	_	
197-114	39815-39820	brain	_	
197-115	39821-39830	serotonin	_	
197-116	39831-39832	5	_	
197-117	39832-39833	-	_	
197-118	39833-39837	HT1A	_	
197-119	39838-39846	receptor	_	
197-120	39847-39854	binding	_	
197-121	39855-39864	potential	_	
197-122	39865-39873	measured	_	
197-123	39874-39876	by	_	
197-124	39877-39880	PET	_	
197-125	39881-39886	using	_	
197-126	39887-39888	[	_	
197-127	39888-39889	C	_	
197-128	39889-39890	-	_	
197-129	39890-39892	11	_	
197-130	39892-39893	]	_	
197-131	39893-39896	WAY	_	
197-132	39896-39897	-	_	
197-133	39897-39903	100635	_	
197-134	39904-39907	Sex	_	
197-135	39908-39919	differences	_	
197-136	39920-39922	in	_	
197-137	39923-39931	nicotine	_	
197-138	39932-39939	effects	_	
197-139	39940-39943	and	_	
197-140	39944-39963	self-administration	_	
197-141	39963-39964	:	_	
197-142	39965-39971	Review	_	
197-143	39972-39974	of	_	
197-144	39975-39980	human	_	
197-145	39981-39984	and	_	
197-146	39985-39991	animal	_	
197-147	39992-40000	evidence	_	
197-148	40001-40012	Stimulation	_	
197-149	40013-40015	of	_	
197-150	40016-40027	serotonin2c	_	
197-151	40028-40037	receptors	_	
197-152	40038-40044	blocks	_	
197-153	40045-40048	the	_	
197-154	40049-40064	hyperactivation	_	
197-155	40065-40067	of	_	
197-156	40068-40076	midbrain	_	
197-157	40077-40085	dopamine	_	
197-158	40086-40093	neurons	_	
197-159	40094-40101	induced	_	
197-160	40102-40104	by	_	
197-161	40105-40113	nicotine	_	
197-162	40114-40128	administration	_	
197-163	40129-40134	First	_	
197-164	40135-40146	delineation	_	
197-165	40147-40149	of	_	
197-166	40150-40151	5	_	
197-167	40151-40152	-	_	
197-168	40152-40156	HT1A	_	
197-169	40157-40166	receptors	_	
197-170	40167-40169	in	_	
197-171	40170-40175	human	_	
197-172	40176-40181	brain	_	
197-173	40182-40186	with	_	
197-174	40187-40190	PET	_	
197-175	40191-40194	and	_	
197-176	40195-40196	[	_	
197-177	40196-40199	11C	_	
197-178	40199-40200	]	_	
197-179	40200-40203	WAY	_	
197-180	40203-40204	-	_	
197-181	40204-40210	100635	_	
197-182	40211-40219	Spurious	_	
197-183	40220-40223	but	_	
197-184	40224-40234	systematic	_	
197-185	40235-40247	correlations	_	
197-186	40248-40250	in	_	
197-187	40251-40261	functional	_	
197-188	40262-40274	connectivity	_	
197-189	40275-40278	MRI	_	
197-190	40279-40287	networks	_	
197-191	40288-40293	arise	_	
197-192	40294-40298	from	_	
197-193	40299-40306	subject	_	
197-194	40307-40313	motion	_	
197-195	40314-40319	Steps	_	
197-196	40320-40326	toward	_	
197-197	40327-40337	optimizing	_	
197-198	40338-40344	motion	_	
197-199	40345-40353	artefact	_	
197-200	40354-40359	after	_	
197-201	40360-40367	removal	_	
197-202	40368-40370	in	_	
197-203	40371-40381	functional	_	
197-204	40382-40394	connectivity	_	
197-205	40395-40398	MRI	_	
197-206	40398-40399	;	_	
197-207	40400-40401	A	_	
197-208	40402-40407	reply	_	
197-209	40408-40410	to	_	
197-210	40411-40415	Carp	_	
197-211	40416-40423	Effects	_	
197-212	40424-40426	of	_	
197-213	40427-40435	systemic	_	
197-214	40436-40444	nicotine	_	
197-215	40445-40447	on	_	
197-216	40448-40457	serotonin	_	
197-217	40458-40465	release	_	
197-218	40466-40468	in	_	
197-219	40469-40472	rat	_	
197-220	40473-40478	brain	_	
197-221	40479-40481	An	_	
197-222	40482-40490	improved	_	
197-223	40491-40500	framework	_	
197-224	40501-40504	for	_	
197-225	40505-40513	confound	_	
197-226	40514-40524	regression	_	
197-227	40525-40528	and	_	
197-228	40529-40538	filtering	_	
197-229	40539-40542	for	_	
197-230	40543-40550	control	_	
197-231	40551-40553	of	_	
197-232	40554-40560	motion	_	
197-233	40561-40569	artifact	_	
197-234	40570-40572	in	_	
197-235	40573-40576	the	_	
197-236	40577-40590	preprocessing	_	
197-237	40591-40593	or	_	
197-238	40594-40607	resting-state	_	
197-239	40608-40618	functional	_	
197-240	40619-40631	connectivity	_	
197-241	40632-40636	data	_	
197-242	40637-40646	Measuring	_	
197-243	40647-40657	endogenous	_	
197-244	40658-40665	changes	_	
197-245	40666-40668	in	_	
197-246	40669-40681	serotonergic	_	
197-247	40682-40699	neurotransmission	_	
197-248	40700-40702	in	_	
197-249	40703-40709	humans	_	
197-250	40709-40710	:	_	
197-251	40711-40712	a	_	
197-252	40713-40714	[	_	
197-253	40714-40717	11C	_	
197-254	40717-40718	]	_	
197-255	40718-40722	CUMI	_	
197-256	40722-40723	-	_	
197-257	40723-40726	101	_	
197-258	40727-40730	PET	_	
197-259	40731-40740	challenge	_	
197-260	40741-40746	study	_	
197-261	40747-40757	Lorcaserin	_	
197-262	40758-40761	for	_	
197-263	40762-40769	smoking	_	
197-264	40770-40779	cessation	_	
197-265	40780-40783	and	_	
197-266	40784-40794	associated	_	
197-267	40795-40801	weight	_	
197-268	40802-40806	gain	_	
197-269	40806-40807	:	_	
197-270	40808-40809	a	_	
197-271	40810-40820	randomized	_	
197-272	40821-40823	12	_	
197-273	40823-40824	-	_	
197-274	40824-40828	week	_	
197-275	40829-40837	clinical	_	
197-276	40838-40843	trial	_	
197-277	40844-40851	Smoking	_	
197-278	40852-40862	withdrawal	_	
197-279	40863-40871	symptoms	_	
197-280	40872-40874	in	_	
197-281	40875-40878	two	_	
197-282	40879-40884	weeks	_	
197-283	40885-40887	of	_	
197-284	40888-40898	abstinence	_	
197-285	40899-40907	Negative	_	
197-286	40908-40914	affect	_	
197-287	40915-40918	and	_	
197-288	40919-40926	smoking	_	
197-289	40927-40933	lapses	_	
197-290	40933-40934	:	_	
197-291	40935-40936	a	_	
197-292	40937-40948	prospective	_	
197-293	40949-40957	analysis	_	
197-294	40958-40967	Intrinsic	_	
197-295	40968-40978	functional	_	
197-296	40979-40991	connectivity	_	
197-297	40992-40994	as	_	
197-298	40995-40996	a	_	
197-299	40997-41001	tool	_	
197-300	41002-41005	for	_	
197-301	41006-41011	human	_	
197-302	41012-41024	connectomics	_	
197-303	41024-41025	:	_	
197-304	41026-41032	theory	_	
197-305	41032-41033	,	_	
197-306	41034-41044	properties	_	
197-307	41044-41045	,	_	
197-308	41046-41049	and	_	
197-309	41050-41062	optimization	_	
197-310	41063-41071	Temporal	_	
197-311	41072-41087	autocorrelation	_	
197-312	41088-41090	in	_	
197-313	41091-41101	univariate	_	
197-314	41102-41108	linear	_	
197-315	41109-41117	modeling	_	
197-316	41118-41120	of	_	
197-317	41121-41125	FMRI	_	
197-318	41126-41130	data	_	
197-319	41131-41137	Gender	_	
197-320	41138-41145	effects	_	
197-321	41146-41148	on	_	
197-322	41149-41153	mood	_	
197-323	41154-41157	and	_	
197-324	41158-41167	cigarette	_	
197-325	41168-41175	craving	_	
197-326	41176-41182	during	_	
197-327	41183-41188	early	_	
197-328	41189-41199	abstinence	_	
197-329	41200-41203	and	_	
197-330	41204-41214	resumption	_	
197-331	41215-41217	of	_	
197-332	41218-41225	smoking	_	
